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                                                       “If you can keep your head when all about you 
                                                        Are losing theirs and blaming it on you, 
                                                        If you can trust yourself when all men doubt you, 
                                                        But make allowance for their doubting too; 
                                                        If you can wait and not be tired by waiting, 
                                                        Or being lied about, don't deal in lies, 
                                                        Or being hated, don't give way to hating, 
                                                        And yet don't look too good, nor talk too wise: 
                                                        […] Yours is the Earth and everything that's in it, 
                                                        And - which is more - you'll be a Man, my son!”  
                                                                                                            Rudyard Kipling
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ABSTRACT 
Transporters play a determinant role in creating and maintaining physiological balance 
within the cells. Though, not much information exists on the modulation of transporters, 
especially in terms of polyphenols and other dietary components. 
Initially, a comprehensive database was created, using the high-performance search engine 
Genevestigator. The database summarises the existing knowledge on selected transporters 
(OAT1, OAT3, OATP1A2, OATP1B1, OATP1B3, OATP4C1, MRP2, MRP3, BCRP, 
MCT1, MCT7 and SMCT1). The anatomical distribution of the latters was investigated in 
the human heart, kidney, liver and intestine. Transcriptional modulation was also assessed, 
in response to biological mediators, disease, chemicals and drugs. It was shown that while 
some transporters were modulated from a large number of conditions, others only responded 
to few. Interestingly, not many dietary compounds were tested, highlighting the limited 
knowledge existing in this area.  
Subsequently, expression of a transporter of interest, the organic anion transporter 3 
(OAT3), was assessed in liver HepG2 cells. It was predicted, on the basis of the Ct value, 
that OAT3 was expressed in the cell line at low levels. Modulation of OAT3, in response to 
stressors (hydrogen peroxide, tert-butyl hydroperoxide and ethanol) at various 
concentrations and for different time lengths was assessed. It was shown that none of the 
stressors affected the transporter. 
In the same cell line, uptake of the metabolite kaempferol-3-O-glucuronide was assessed, to 
establish whether uptake occurred in a carrier-mediated manner or through passive diffusion 
mainly. Uptake resulted to be carrier-mediated, although the low Vmax of the transport, 
close to detection limit, did not make possible further studies to identify the transporter(s) 
involved in its uptake.  
Finally, intestine Caco-2 cells were used to assess modulation of the serotonin transporter 
from green tea and coffee. For the first time, it was reported that green tea and coffee acted 
as modulators of serotonin uptake. Whole extracts showed to act in a concentration-
dependent way. Physiological concentrations of individual green tea components showed 
not to have a significant effect on the uptake, however significant effect was observed when 
using supplement concentrations (equivalent to 7 cups). Physiological concentrations of 
several coffee components showed to modulate serotonin uptake. Among them, ferulic acid 
and 5-feruloylquinic acid showed to act in a competitive manner.  
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Ω………………………………………. Ohm 
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Chapter 1  
                                                      Introduction 
 
1.1. Polyphenols  
1.1.1. Chemical features 
Polyphenols are a group of secondary metabolites, abundantly produced in plants, where 
they probably act as defence against pathogens and disease (Visioli and Galli, 1997). More 
than 8,000 polyphenols are currently known (Harborne and Williams, 2000). They are 
generally small molecules with molecular weights between 200 and 800 Da, structurally 
characterized by one or more aromatic phenol rings (C6-OH). Though their chemical 
structure varies considerably from one compound to another (Williamson and Manach, 
2005). Differences in the chemical structure determine the unique biological properties of 
each class and, among the classes, of each compound (Brisdelli et al., 2009).  
Based on their chemical structure, polyphenols can be divided into four classes: flavonoids, 
phenolic acids, lignans and stilbenes (Reboul et al., 2007b) (fig 1-1). Flavonoids can be 
divided into flavonones, proanthocyanidins, anthocyanins, isoflavones, flavones and 
flavonols. Phenolic acids include hydroxybenzoic acids and hydroxycinnamic acids. In the 
human diet, flavonoids are the most abundant and stilbenes the least abundant (Manach et 
al., 2004).  
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Figure 1-1. Chemical structure of the main polyphenol classes. Polyphenols can be 
divided into four classes: flavonoids, stilbenes, phenolic acids and lignans. 
 
1.1.2. Dietary sources 
Each class of polyphenols includes a variety of members widely distributed in commonly 
consumed food and beverages. 
The dominant source of polyphenols in our diet is represented by beverages. Worldwide tea 
is the second most consumed beverage, after water, and is rich in polyphenols. 
Epidemiological studies show that 85 % of the world population regularly drinks tea 
(Beresniak et al., 2012). Coffee is another highly consumed beverage and it is also rich in 
polyphenols. Studies show that 80 % of the world population drinks coffee on a daily basis 
(van Dam, 2008). Another abundant source of polyphenols is fruit, while vegetables contain 
relatively little amount of these compounds (Graham, 1992). 
To give a few quantitative data: one litre of orange juice contains 125-250 mg of the 
flavonone hesperidin, a litre of grapefruit juice contains 145-638 mg of the flavonoid 
naringenin, and a cup of coffee contains about 150 mg of chlorogenic acid (Scalbert and 
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Williamson, 2000). Overall, 1 g/d has been evaluated to be the average intake of 
polyphenols (Beecher, 2003). The relative amount of each polyphenol ingested largely 
depends on consumer preferences and on the alimentary habits linked to the culture. For 
example in some Eastern countries, such as China, a major source of polyphenols is 
represented by soya and the products derived from it. At the contrary soya is barely present 
or not present at all in Western diets (Adlercreutz et al., 1991). 
It must also be considered that the initial abundance of polyphenols in food does not 
necessarily correspond to a high intake, due to food processing. For example, apples contain 
high amount of the flavonol quercetin (1 mg/g of fresh fruit) in the peel, but no quercetin at 
all nor other flavonols in the pulp. Thus, apple peeling eliminates the total flavonol content 
(Lee and Mitchell, 2012). 
A further important factor to be considered when evaluating the actual polyphenol amount 
usable within the human cell is the bioavailability. The bioavailability is the amount of 
compound present in the systemic circulation after oral consumption (Hof et al., 1998). 
Polyphenol bioavailability is quite limited. In fact, a significant part of the ingested amount 
is eliminated from the body. It has been demonstrated that after consumption of 10 to 100 
mg of a single compound, levels of that polyphenol in blood rarely rise above 1 μM, despite 
their local concentrations are certainly much higher than that (Manach et al., 2005). The 
bioavailability mainly depends on the chemical structure of each polyphenol, which 
determines the type and amount of metabolites formed and if they will predominantly be 
absorbed or excreted. 
 
1.1.3. Role in human health 
The human body is constantly exposed to oxidative stress, from both endogenous and 
exogenous sources. The endogenous sources come from our life based on oxygen 
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consumption, which produces the energy necessary for life but also waste products such as 
free radicals (Valko et al., 2006). In the long-term free radicals can damage the cell 
(Tekiner-Gulbas et al., 2013). The exogenous sources include the daily exposure to UV 
light and pollutants such as smoke (Carnevali et al., 2003). 
Oxidative stress is linked to a wide range of degenerative pathologies such as cancer, 
osteoporosis and cardiovascular disease (Simonian and Coyle, 1996). 
Since the endogenous defences of the human body alone are not enough in fighting free 
radicals, it is essential to consume antioxidants through the diet. The main source of 
antioxidants in the human diet is represented by polyphenols. They can play a determinant 
role against oxidative stress, as it has been proved that some of them can help reduce the 
incidence of a variety of degenerative diseases (Middleton et al., 2000, Ding et al., 2013). 
Increasing evidence, showing that polyphenols act as antioxidants, come both from in vitro 
and in vivo studies. As polyphenols are reducing agents, in vitro they give hydrogen atoms 
that can neutralise free radicals and protect the biological membranes. In vivo, they have 
been proven to act as regulatory factors of transcription and as antioxidants. As regulatory 
factors of transcriptions they are connected to many important processes such as cell growth 
and apoptosis, while as antioxidants they are associated with reducing the risk of chronic 
and neurodegenerative disease (Nakatani and Kikuzaki, 1995, Williamson and Carughi, 
2010). 
 
1.2. Metabolism  
The main metabolising organs present in the human body are the stomach, the intestine, the 
liver and the kidneys (fig. 1-2). 
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Figure 1-2. Metabolising organs of the human body. The main sites of metabolism in 
humans are the stomach, the intestine, the liver and the kidneys. All compounds move 
through these organs to be chemically transformed and finally either retained or excreted. 
 
The metabolic reactions occurring after polyphenol ingestion are critical for the final 
bioavailability. The metabolism of xenobiotic compounds consists of two groups of 
reactions, phase I and phase II. Phase I reactions are catalyzed by enzymes such as 
monooxygenases and P450 (Berdikova Bohne et al., 2007). Phase I metabolism results in 
the introduction of functional groups, such as carboxylic and hydroxyl groups. Phase II 
enzymes target the groups introduced during phase I metabolism, triggering in their 
conjugation (Wong et al., 2011c).  
Generally phase I enzymes do not metabolize polyphenols, which are directly conjugated by 
phase II enzymes. Although the organs and the reactions involved are the same for every 
polyphenol (fig. 1-3), the outcome strongly depends on the initial structure of the ingested 
compound.  
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Figure 1-3. Steps of polyphenol metabolism. Polyphenol ingestion is followed by 
chemical transformation through four steps: deglycosylation, conjugation, first pass 
metabolism and entheropatic recirculation. These steps are carried out in the main 
metabolising organs and finally result in absorption or excretion of polyphenol metabolites. 
 
1.2.1. Deglycosylation  
The first step of polyphenol metabolism is the deglycosylation in the gut (Setchell et al., 
2001). Polyphenols predominantly exist in the sugar-conjugated form. The sugar is either 
rhamnose or glucose, but different other sugars can occasionally be found, such as 
arabinose. The number of sugar residues varies from one to three with one being the most 
recurrent number. Also important are the position of the glycosidic group and if the latter is 
or is not further substituted (Liu and Hu, 2007). The presence of glycosidic groups on the 
phenolic compound is critical in inhibiting passage across membranes, because glycosides 
reduce the compound hydrophobicity. Thus initial enzymatic removal of the glycoside 
group is required, for the resulting compound to freely diffuse across membranes. 
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Deglycosilation results in the formation of a polyphenol form, known as aglycone 
(Manevski et al., 2012). 
Different enzymes are involved in the removal of specific sugars. For example the α-
rhamnosidases have activity in cleaving rhamnose residues. Some glycosides are removed 
in the small intestine from endogenously secreted enzymes. Other glycosides are removed 
later in the colon, from enzymes of the intestinal microflora, such as the α-rhamnosidases 
(Avila et al., 2009). 
 
1.2.2. Conjugation 
Aglycones are rarely found free in blood. Immediately after deglycosylation they are 
conjugated through methylation, sulfation, glucuronidation or a combination of the three 
(Liu and Hu, 2002). The hydroxyl groups of the polyphenols are the major target of 
conjugation, resulting mainly in sulfates and sulfo-glucuronides. Glucuronides are a minor 
fraction. The methylated form is the least recurrent (Nardini et al., 2009). 
The amount of polyphenol ingested is critical in determining the conjugation site. When 
moderate doses of polyphenols are ingested the conjugation process happens in the 
intestinal mucosa. If exceptionally high doses of polyphenols are ingested, the main organ 
involved is the liver. This is due to saturation of the conjugating mechanisms in the intestine 
(Scalbert et al., 2002). Conjugates physiologically differ from their aglycone form: 
glucuronidation and sulfation enhance hydrophilicity, whereas methylation enhances lipid 
solubility (Whitley et al., 2005). Conjugates have low propensity for free diffusion through 
biological membranes, thus they need active transport. At the contrary aglycones move 
mainly through passive diffusion.   
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1.2.3. First-pass metabolism 
The liver plays a crucial role in protecting the human body against xenobiotics. Once 
polyphenols have been conjugated in the intestine they are carried into the liver through the 
vein porta, where they undergo first-pass metabolism (Scheepens et al., 2010). First pass 
metabolism consists of further modifications (e.g. sulfation). Subsequently the destiny of the 
resulting metabolites can be either distribution to body tissues, export through the blood 
stream to the kidneys or export through the bile to the gut lumen. In the kidneys polyphenols 
are further modified, consequently they are excreted in the urine. In the gut lumen 
polyphenols are either excreted in the faeces or further metabolised by the intestinal 
microflora (Thill et al., 2012). 
 
1.2.4. Entheropatic recirculation 
The human colon contains about      microorganisms/   . It is estimated that the number 
of bacteria inhabiting the human gut is ten times greater than the total number of cells in the 
body (Bjorksten et al., 2001). The gut microflora is essential in digesting un-utilized energy-
containing substrates produced in the liver (Laparra and Sanz, 2010). 
 
1.3. Transporters  
A determinant role in each of the metabolic steps described above is played by efflux and 
uptake transporters. Transporters are cellular components inserted into either the apical or 
the basolateral side of the epithelium of each organ (Keppler, 2004). They can move 
compounds in or out of the cell. They are called uptake transporters if they move 
compounds from the extracellular space into the cell cytoplasm. At the contrary efflux 
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transporters move compounds out of the cells into either the lumen of the organ or the blood 
stream (fig. 1-4). Efflux transporters were characterized first, whereas uptake transporters 
have seen the focus of relatively recent interest and a lower amount of information is 
available for the latter (Rodrigues et al., 2009). 
 
 
Figure 1-4. Examples of uptake and efflux transport in liver and intestinal cells. 
Transporters can be divided into uptake and efflux, according to whether they mediate 
movement from the extracellular space towards the cytoplasm of the cells or in the opposite 
direction. 
 
Transporters determine whether a particular compound will predominantly be available for 
the body tissues or be eliminated. For this reason, study of the biochemistry of transporters 
is a crucial interest. It is known that transporters can be modulated by a wide range of 
compounds, including dietary molecules, so that our diet is a determining factor for the final 
balance of absorption/excretion (Katragadda et al., 2006). It is essential to identify which 
molecules are responsible for transporter modulation and through what mechanism(s). 
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There are two characterized types of transporter modulation, functional and expressional 
(fig. 1-5).  
Functional modulation applies mainly to efflux transporters and consists of a direct action of 
the modulator on the transporter. This triggers a conformational change that results in  a 
modification of the amount of compound transported (Higashikuni et al., 2010).  
Expressional modulation consists of a change in the amount of mRNA transcribed for a 
certain transporter, due to the interaction of modulating compounds with the promoter of the 
gene of interest (Prasansuklab et al., 2011). Either a modulator interacts directly with the 
gene promoter, acting as a transcriptional factor, or it affects transcription indirectly, by 
triggering the production of secondary mediators interact with the gene promoter (Wetzler 
et al., 2000).  
It is worth mentioning that although a particular molecule may affect the amount of mRNA 
produced, this does not always represents a direct evaluation of the corresponding protein 
levels, which may be modulated by the action of other factors (Zembruski et al., 2011).  
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Figure 1-5. Types of transporter modulation: functional and expressional. Functional 
modulation consists in the direct interaction of modulator with the transporter, resulting in a 
conformational change. Expressional modulation consists in the interaction of modulators 
with the gene promoter of the transporter, resulting into a change in the amount of the 
mRNA transcribed. 
 
Much evidence exists on support of expressional modulation of efflux transporters (Liu et 
al., 1999, Lespine et al., 2008, Gholami et al., 2014), whereas very few data have yet been 
provided on support of the expressional modulation of uptake transporters.  
The first polyphenols described as capable of interacting with uptake transporters were 
coffee and cocoa components, with OATP4C1 and OAT3 respectively uptaking sulfate and 
glucuronide conjugates (Wong et al., 2011b).  
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1.3.1. Main classes of transporters  
1.3.1.1. Efflux transporters 
1.3.1.1.1. ATP-binding cassette proteins (ABCs)  
The major family of efflux transporters is represented by ABC proteins, which directly 
couple the transport of compounds to the hydrolysis of ATP. The ABC is the largest family 
of transmembrane proteins, with members expressed in every existing phyla and members 
specific to certain phyla. Members excreting and uptaking exist in prokaryotes. Eukaryotes 
only express members excreting compounds and certain members which do not uptake or 
excrete but have a role in gene expression modulation and DNA repair (Borst et al., 2006).  
The typical structure of an ABC protein is characterized by the presence of two domains, a 
transmembrane domain (TMD) and a nucleotide-binding domain (NBD). The TMD faces 
the lumen and consists of α-helices inserted into the cell membrane.  
The chemical sequence of the TMD varies greatly according to the substrates transported 
and it undergoes conformational change upon recognizing the substrate and in order to 
transport it. The NBD in contrast faces the cytoplasm of the cell and has a conserved 
sequence, containing the site for ATP binding. Additionally, some ABCs have an 
intracellular domain (ICD) between the TMD and the NBD (Zelcer et al., 2003, Napier et 
al., 2005).  
In the ABCs, the number of TMDs and NBDs varies, with a minimum of two of each 
domain. At gene level it is also not uncommon for an ABC gene to encode for half a 
transporter and for the two halves to subsequently combine as either heterodimers or 
homodimers to form a functional protein (Schinkel and Jonker, 2003). 
The effluxing ABCs expressed in eukaryotes are divided into 7 sub-families (ABCA, 
ABCB, ABCC, ABCD, ABCE, ABCF and ABCG) each with prevalent specificity for 
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certain substrates. Overall the ABCs transport an extremely wide range of chemically 
different substrates (Jones and George, 2004). Efflux transporters are distributed with 
uneven abundance across the biological membranes (fig. 1-6). 
 
 
Figure 1-6. Distribution and localization of the main efflux transporters in mammalian 
liver, intestine and kidney cells (Lubelski et al., 2007, Ganapathy et al., 2008, Pochini et 
al., 2013, Omlin and Weber, 2013).  
 
1.3.1.2. Uptake transporters 
The SLCs (solute carrier transporters) represent the main class of uptake transporters and 
include several families with their members closely related in terms of substrate specificity 
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(DeGorter et al., 2012). Distribution of the SLCs varies across the biological membranes of 
the human organs (fig. 1-7).  
 
 
Figure 1-7. Distribution and localization of the main uptake transporters in 
mammalian liver, intestine and kidney cells (Nigam et al., 2007b, Popovic et al., 2010, 
Mukherjee et al., 2011). 
 
All of the SLCs play a determinant role in drug and nutrient absorption (Scopelliti et al., 
2013). Their understanding is vital for designing effective drugs and functional food and to 
increase the bioavailability of health-promoting food.  
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The major families of uptake transporters are OATPs (organic anion transporting 
polypeptides), OATs (organic anion transporters) and OCTs (organic cation transporters).  
 
1.3.1.2.1. Organic anion transporting polypeptides (OATPs) 
The OATPs are characterized by the presence in their structure of twelve transmembrane 
domains with multiple glycosylation sites. To date 11 members have been identified in 
humans and divided into six subfamilies: OATP1, OATP2, OATP3, OATP4, OATP5 and 
OATP6. All are widely distributed. A few members are ubiquitously expressed, while some 
members are localized in specific organ(s) or tissue(s) (Hagenbuch and Meier, 2004).  
It has been reported that OATP1B1, OATP1B3 and OATP2B1 are only expressed in the 
liver, while OATP4C1 is expressed in the kidney only. Each of them is essential to uptake 
specific compounds in the organ for further metabolism and final elimination through 
bile/urine (Yamaguchi et al., 2008, Vasuri et al., 2011).  
Literature reports that OATP1A2 and OATP2B1 are expressed in the small intestine, where 
they contribute to ion absorption (Glaeser et al., 2007). All other OATPs are mainly 
expressed in peripheral tissues, where they are involved in uptaking hormones (Noe et al., 
2007).  
OATPs mainly transport type II amphiphilic anions and some cation and non-charged 
compounds with molecular weights greater than 400 Da (Kullak-Ublick et al., 2001). 
Although the transport mechanism of OATPs is not yet characterized, it is known that they 
do not directly use ATP. It is also known that they function in a sodium-dependent manner 
(Kalliokoski and Niemi, 2009). It is very likely that anionic uptake depends on its exchange 
with another anion such as glutathione and/or bicarbonate. This hypothesis is consistent 
with observations that all the OATPs (except for OATP1C1) function at their best at low 
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extracellular pHs (Nozawa et al., 2004). Conversion of bicarbonate into carbon dioxide and 
water, triggered by low pH, would determine movement of the bicarbonate ions toward the 
extracellular space. 
 
1.3.1.2.2. Organic anion transporters (OATs) 
The OATs include seven characterized members: OAT1, OAT2, OAT3, OAT4, OAT6, 
OAT7 and OAT10 (Ahlin et al., 2009). They all display extraordinary broad substrate 
specificity. OATs transport mainly type I amphiphilic anions, but also some cation and non-
charged molecules. In either case the compounds transported are generally small molecules 
with molecular weights between 400 and 500 Da (Sekine et al., 2000, Burckhardt and 
Burckhardt, 2003).  
OATs transporters are mainly found in the basolateral membrane of the kidney proximal 
tubules. They work through a sodium-dependent mechanism that relies on two coupled 
proteins, K
+
/Na
+
-ATPase and Na
+
/dicarboxylate co-transporter 3. K
+
/Na
+
-ATPase pumps 
Na
+
 out of the cell using ATP. The Na
+
 electrochemical gradient is subsequently used from 
Na
+
/dicarboxylate co-transporter 3 to intake α-ketoglutarate. Finally the OATs couple the 
uptake of organic ions to the exit of α-ketoglutarate. The mechanism of action of OATs 
gives them the name of active tertiary transporters (Enomoto and Endou, 2005). There are 
exceptions to the above mechanism. OAT2, for example, does not couple transport to α-
ketoglutarate excretion but works in a not yet characterized manner, probably coupling the 
uptake of compounds to ion efflux (Yohannes et al., 2013).  
For the structure of the OATs a model has been proposed, with twelve transmembrane 
domains and multiple glycosylation sites (Burckhardt and Burckhardt, 2003). 
Chapter 1: Introduction 
 
17 
 
OAT1 and OAT3 are found mainly in the human kidneys and in smaller amount in skeletal 
muscle, brain and eye. OAT1 has an extraordinarily broad range of substrates, including a 
wide range of drugs and endogenous compounds, such as some neurotransmitters and 
prostaglandins (Lopez-Nieto et al., 1997).  
OAT3 was firstly identified as a transporter for estrone-3-sulfate but was then discovered to 
transport many other substrates, such as taurocholate (Nigam et al., 2007a).  
OAT2 is mainly expressed in the basolateral membrane of liver and in minor amount in the 
kidney proximal tubules. OAT2 has a much less broad range of substrates compared to 
OAT1 and OAT3. Substrates include steroid hormones (Cha et al., 2001).  
OAT4 is exclusively expressed in humans, where it is found in the placenta and the apical 
membrane of the kidney proximal tubules. OAT4 acts both as an uptake and as an efflux 
transporter towards organic anions. It acts by coupling their movement out of the cell with 
the entrance of other ions such as chloride (Hagos et al., 2008). The substrate specificity of 
OAT4 for effluxed compounds is widely overlapping that of OAT1 and OAT3. For this 
reason it is believed that the three transporters operate in a synchronized manner to 
effectively eliminate organic compounds through the urine (Ekaratanawong et al., 2004). 
 
1.3.1.2.3. Organic cation transporters (OCTs) 
OCTs are mainly expressed in liver, kidney and brain, with varying abundance. OCTs 
mainly transport cations such as monoamine neurotransmitters, but can also transport some 
anions and zwitterions  (Ciarimboli, 2011). So far about 20 members have been discovered 
but for the majority very little is known (Takane et al., 2008). Localization of OCT1, OCT2, 
OCT3 and OCT12 has been assessed. OCT1 is expressed in the human liver and brain (Lee 
et al., 2009). OCT2 is mainly found in the kidneys and in minor amounts in the brain 
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(Kiefer et al., 1998). The prime sites of OCT3 expression are brain and kidney (Wu et al., 
2000). In the kidney OCT3 transports a wide range of solutes including histamine, 
serotonin, norepinephrine and dopamine (Ciarimboli, 2008, Baganz et al., 2008).  
OCT12 is found in the kidney, where deficiency has been linked to hyperuricemia and 
hypouricemia (Motohashi et al., 2013). 
Special importance has to be given to a subclass of OCTs, the OCTNs (organic carnitine 
transporters).  
 
1.3.1.2.3.1. The organic carnitine transporters (OCTNs) 
The OCTNs are responsible for the maintenance of carnitine levels in the body by 
bidirectional transport (Lahjouji et al., 2001). Since carnitine is crucial in the mitochondrial 
utilization of long chain fatty acids, maintenance of carnitine balance plays an important 
role in energy production (Lim et al., 2010). 
Four OCTNs have been discovered: OCTN1, OCTN2, OCTN3 and OCTN4, with varying 
abundance within human organs. OCTN1 is expressed almost ubiquitously, except in adult 
liver. OCTN1 has relatively low substrate affinity. It is thought to act maximally by 
secreting carnitine and short-chain esters at the brush border membrane of kidneys 
(Lamhonwah and Tein, 2006). OCTN2 uptakes carnitine in the majority of human organs 
(Grube et al., 2004).  
In contrast to OCTN1, OCTN2 has high affinity for its substrate and can be quantitatively 
considered the main carnitine uptaking transporter. OCTN2 is highly expressed in skeletal 
muscle, heart, placenta and kidney and weakly expressed in lung, liver and brain (Rodriguez 
et al., 2002). OCTN3 is mainly expressed in the testis, where it uptakes carnitine with 
higher affinity than OCTN1 and OCTN2. Its activity in other organs is not yet fully 
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characterized (Januszewicz et al., 2009). Tissue distribution and mode of action has not yet 
been characterized for OCTN4.  
Interestingly it is not yet known how carnitine is secreted from the human liver, although 
the liver is the main site of carnitine synthesis (Rosenbaum et al., 2013) and thus release 
from this organ is the focus of numerous studies.  
Mechanism of action has only been characterized for two members of the OCTNs, OCTN1 
and OCTN2. OCTN1 works in a pH-dependent manner. OCTN2 works both in a sodium-
dependent and in a sodium-independent manner (Garrett et al., 2008).  
 
1.3.1.2.4. Monoamine transporters (MATs) 
Another important group of transporters are MATs, all indispensable in maintaining the 
intracellular/extracellular balance of monoamine transmitters (Gerevich et al., 2000). There 
are three main members of the MATs: serotonin reuptake transporter (SERT), dopamine 
transporter (DAT) and norepinephrine transporter (NET). SERT, DAT and NET each have a 
specific substrate, serotonin, dopamine and norepinephrine respectively (Gainetdinov and 
Caron, 2003).  
MATs are located in the perisynaptical space, outside the presynaptic cleft. They re-uptake 
transmitter molecules back into the cytoplasm of the presynaptic neuron. Their role is 
crucial for neurotransmitters to be recycled. In fact they terminate one signalling cycle and 
play a determinant role in the start of a new one (Raap and Van de Kar, 1999).  
Certain foods are known to directly increase monoamine neurotransmitter levels, by 
providing their chemical precursors. Other foods indirectly alter serotonin levels (Kim et al., 
2013). A diet rich in milk and eggs, for example, provides tryptophan, precursor of 
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serotonin. Moreover, a diet rich in carbohydrates increases serotonin release through insulin 
secretion (Fernstrom and Fernstrom, 1995).  
SERT can be found primarily in the central nervous system, in the platelets and in the 
gastrointestinal tract (Kish et al., 2005). In recent years evidence has highlighted that 
serotonin is mainly located in the gut (approximately 90 %), where it is synthesized and 
stored. Synthesis and storage occurs in the enterochromaffin cells, lining the intestinal 
lumen. It appears that serotonin must play a fundamental role in regulating the 
gastrointestinal functions (Wheatcroft et al., 2005). In fact, is has been shown that serotonin 
imbalance is the cause of a range of gastrointestinal dysfunctions, such as irritable bowel 
syndrome (Wang et al., 2007). Studies have shown that in patients with irritable bowel 
syndrome the serotonin levels in the gut were much lower than in healthy volunteers 
(Crowell, 2001). The mechanisms through which serotonin affect gut functions and the 
pathophysiology of irritable bowel syndrome are not yet fully characterised, although there 
is evidence that SERT plays a role. SERT removes the serotonin from the post-synaptic 
space. After serotonin binds to its receptors and it initiates a signalling cascade in the post-
synaptic cells, SERT mediate reuptake in the releasing cell. This links to serotonin 
metabolism and recycle (Jafari et al., 2011). Studies have shown that irritable bowel 
syndrome patients had increased expression of SERT in the colon, and therefore, increased 
serotonin reuptake, compared to healthy donors (Coates et al., 2004).   
DAT is primarily found in the substantia nigra of the human brain (Ciliax et al., 1999). 
It has been suggested that DAT plays an important role in maintaining the 
intracellular/extracellular balance of dopamine in the dendrites of the substantia nigra (Liu 
et al., 2007).    
NET expression is restricted to noradrenergic neurons. NET is found in the cell body, 
dendrites and axons (Sager and Torres, 2011). Both NET and DAT can re-uptake 
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norepinephrine (Galli et al., 1995). NET is also essential in maintaining the homeostatic 
balance in the presynaptic neurons (Torres et al., 2003). 
 In terms of protein structure and mechanism of action, the MATs are 12 transmembrane 
domain proteins (Field et al., 2010). They act in a sodium-dependent manner, coupled to the 
Na
+
/K
+
 pump. Three Na
+
 ions bind to the transporter. Subsequently the protonated form of 
the neurotransmitter (serotonin, dopamine or norepinephrine) and Cl
-
 ions also bind to the 
transporter. Binding of chlorine ions is necessary for net transport to happen. The initial 
binding of Na
+
 and Cl
-
 triggers a conformational change of the transporter, which results in 
the uptake of the neurotransmitter and ions into the cell cytoplasm. When the 
neurotransmitter is released and the transporter is unbound, two intracellular K
+ 
ions bind to 
it. This links to the transporter regaining the initial conformation, facing the synaptic cleft 
and ready to undergo the next transport cycle (Kuzelova et al., 2010).  
The MATs expressed in the nervous system are key factors in the treatment of mental illness 
(Min et al., 2009), thus their regulation is the focus of much research. However much less 
research has been so far published concerning the role of MATs outside the nervous system, 
where they probably play equally important functions. 
 
1.3.2.  Interaction of uptake transporters with polyphenols 
Polyphenols interact with uptake transporters in two ways. They either act as substrates or 
as modulators. It is not uncommon for a compound to be both substrate and modulator of a 
specific transporter (Rodriguez-Proteau et al., 2006).   
 
1.2.3.1. Polyphenols as substrates of uptake transporters 
A few reports exist, identifying polyphenols acting as substrates for uptake transporters.  
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A study showed that ellagic acid from berries was taken up from OAT4, expressed in 
oocytes (Whitley et al., 2005).  
It was shown that, in cells expressing OAT1, the uptake of the aglycones morin and silybin 
was 3-fold higher compared to control cells, not expressing OAT1 (Hong et al., 2007). 
Interaction of quercetin and genistein conjugates with OAT1 and OAT3 was assessed. 
Human embryonic kidney cells (293 H) over-expressing OAT1 and OAT3 respectively 
were used. Genistein-4'-O-sulfate and quercetin-3'-O-sulfate were found to be substrates of 
OAT1. Daidzein-7-O-glucuronide, genistein-7-O-glucuronide, glycitein-7-O-glucuronide 
and quercetin-3'-O-glucuronide appeared to be substrates of OAT3 (Wong et al., 2011c). 
Quercetin-3'-O-sulfate was found to be substrate for both OAT4 and OATP4C1. Quercetin-
3’-sulfate uptake was 2.3- and 1.4-fold higher in cells overexpressing OAT4 and OATP4C1 
respectively, than in control cells (Wong et al., 2012). 
It was shown that both EGCG (epigallocatechin gallate) and ECG (epicatechin gallate) were 
substrates of OATP1A2 and OATP1B3, expressed in both enterocytes and hepatocytes 
(Roth et al., 2011). 
 
1.2.3.2. Polyphenols as modulators of uptake transporters 
1.2.3.2.1. Polyphenols as competitive modulators 
Ellagic acid was proven to be a potent inhibitor of OAT1 activity, inhibiting uptake with an 
IC50 of 207 nM (Whitley et al., 2005) 
Silybin and morin were shown to be competitive inhibitors of OAT1 with IC50 values of 25 
and 0.5 µM, respectively. Concentrations up to 400 µM of the two aglycones were also 
tested on OAT3, displaying lower inhibition than on OAT1 (Hong et al., 2007). Consistent 
with these results, a study from the same group demonstrated that following morin 
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administration, renal clearance of the anti-cancer drug methotrexate was decreased by 42 %, 
resulting in improved availability of the drug in the blood stream. Subsequently combined 
effect of morin and methotrexate was assessed in a cell model. In agreement with the 
previous findings, co-incubation of cells with morin and methotrexate resulted in inhibition 
of methotrexate uptake (Hong et al., 2008).    
The effect of the natural phenol curcumin was assessed on a wide range of human 
transporters using human volunteers with cigarette-induced chronic obstructive pulmonary 
disease (COPD). To date corticosteroids are considered the most effective anti-
inflammatory drugs. However people with COPD develop corticosteroid resistance and thus 
chronic inflammation. Curcumin is well known for its antioxidant, anti-cancer and anti-
inflammatory properties (Aggarwal et al., 2013). Patients with COPD were administered 
curcumin (1 % of the daily diet) for several weeks. After curcumin administration, 
inflammation markers showed to decrease by 87 % compared to control patients 
(Moghaddam et al., 2009).  
Quercetin-3'-O-sulfate was shown to be a potent inhibitor of OAT1 (IC50 = 1.22 µM), while 
quercetin-3'-O-glucuronide and quercetin-3-O-sulfate inhibited OAT3, with IC50 of 0.43 μM 
and 1.31 μM respectively (Wong et al., 2012).  
A study demonstrated that the ginkgo flavonoids kaempferol, apigenin and quercetin were 
inhibitors of OATP1A2 and OATP2B1 in HEK 293 cells over-expressing the transporters. 
Quercetin proved to be the most potent inhibitor (Ki on OATP2B1 = 8.7 µM and on 
OATP1A2 = 22 µM on OATP1A2), followed by kaempferol (Ki on OATP1A2 = 25 µM 
and on OATP2B1 = 15 µM) and apigenin (Ki on OATP1A2 = 32 µM and on OATP2B1 = 
21 µM) (Mandery et al., 2010).  
Another research group investigated the effect of naringin and hesperidin from grapefruit 
juice and orange juice on OATP1A2, using transfected HeLa cells. Competitive inhibition 
of the anti-histamine drug fexofenadine, taken up through OATP1A2, was observed after 
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treatment with grapefruit juice or orange juice. IC50 values were 3.6 and 2.7 µM respectively 
(Dresser et al., 2001).  
Modulation of OCT1 and OCT3 from red and white wine components was assessed, using 
1-methyl-4-phenylpyridinium (MPP
+
), a model substrate for OCT1 and OCT3 (Martel et al., 
2001).  
Caco-2 cells, expressing OCT1 and 3, were used to reveal that alcohol-free red wine 
increased uptake of MPP
+ 
in a concentration-dependent manner. Alcohol-free white wine 
only slightly decreased uptake of MPP
+
. In each step of this study, the effect on OCTs was 
confirmed through co-incubation of wine with OCT inhibitors (Monteiro et al., 2005a).  
In another study, the effect of individual wine polyphenols (myricitin, catechin, resveratrol 
and quercetin) was also tested on Caco-2 cells. Myricitin, catechin and quercetin decreased 
MPP
+
 uptake, with quercetin being the strongest inhibitor. Resveratrol displayed no effect 
(Martel et al., 2010).  
The effect of green and black tea on MPP
+ 
uptake
 
was tested in Caco-2 cells. Both teas 
showed to increase MPP
+
 uptake by several fold and in a concentration-dependent manner. 
The highest effect came from treatment with green tea. When tea was co-incubated with 
OCT inhibitors, the effect was attenuated (Monteiro et al., 2005b).  
A study assessed the effect of five procyanidin fractions on uptake of MPP
+
 in Caco-2 cells. 
Extracts with increasing structural complexity were produced using grape seeds and used 
for 60 minutes at a concentration of 600 µg/mL. The work showed that increasing structural 
complexity related to increased apical uptake of MPP
+ 
(Faria et al., 2006). 
Modulation of MATs from polyphenols has been shown. Apigenin and luteolin, extracted 
from the fruit Perilla frutescens, were tested on wild-type dopaminergic cell lines. These 
cell lines had high specificity for dopamine, serotonin and norepinephrine uptake. Treatment 
of the cells with apigenin and luteolin enhanced uptake of the neurotransmitters, with 
luteolin showing greater potency than apigenin (Zhao et al., 2010).  
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Polyphenols have been proven to trigger inhibition of serotonin re-uptake. HEK-293 cells 
were used to stably express SERT and incubated with 50 µ of the following isoflavans from 
liquorice: glabridin, 4′-O-methylglabridin (4′-OMeG), glabrene, resorcinol, 2′-O-
methylglabridin (2′-OMeG), genistein and daidzein. Glabridin, 4′-OMeG and glabrene 
inhibited SERT by 60 %, 53 % and 47 % respectively. The other tested compounds proved 
to have no effect on SERT activity (Ofir et al., 2003). 
 
1.2.3.2.2. Polyphenols as modulators of the mRNA levels 
Expressional modulation of uptake transporters is relatively little investigated to date. The 
first study to show modulation of the mRNA levels of an OAT transporter was carried out 
using nitric oxide (NO). NO is a small lipid-soluble molecule, already known to play a 
significant role in modulating gene expression in many cells (Rossig et al., 2000).  
RT-PCR showed that NO down-regulated the mRNA levels of rOAT2, expressed in rodent 
liver. It was also shown both in vivo and in vitro that compounds inducing NO production 
down-regulated rOAT2 (Cha et al., 2002). For the in vivo experiments, rats were 
intraperitoneally administered lipopolysaccharide, a bacterial component known to induce 
NO production (Shultz and Raij, 1992).  For the in vitro experiments, hepatocytes were 
treated with spermine NONOate, another inducer of NO production (Yin and Dusting, 
1997).   
Curcumin was found to modulate OAT1 and OAT3 in human monocytic cells (U937). 
Cells, expressing OAT1 and OAT3, were treated with the stressing agents hydrogen 
peroxide or cigarette smoke extracts. Both stressors displayed to down-regulate OAT1 and 
OAT3. When, after exposure to the stressing agents, cells were treated with curcumin (1 
µM) for 18 hours, RT-PCR showed up-regulation of OAT1 and OAT3 mRNA levels. Thus 
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curcumin showed to revert the effect of the stressing agents and restore the mRNA levels of 
OAT1 and OAT3 (Meja et al., 2008). 
 
1.4. Aims and objectives 
In this work the main aim was to gain a better understanding of the function, localization 
and modulation of selected transporters.  
In order to achieve that, two different approaches were used: one based on the use of 
bioinformatic resources and another based on the application of classical molecular biology 
techniques, using cultured cell lines.    
The main focus of the present work was to assess the impact of dietary compounds, 
specifically polyphenols, on the expression of selected human transporter genes. Not much 
information yet exists on the impact of food compounds on transporter expression, therefore 
it is necessary to further investigating this field. Understanding the impact of dietary 
compounds on transporters can lead to identifying dietary products and product components 
that positively affect human health. This knowledge is critical for designing food 
supplements and functional food. 
Transporters play a crucial role in every biological process, because they determine 
movement of compounds within cells and organs, thus gaining understanding on the impact 
that modulatory conditions have on them is essential to design drugs and drug-based 
therapies.  
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1.4.1. Creation of a comprehensive database, based on the online application 
Genevestigator, a high performance search engine for gene expression.  
Twelve transporters were initially selected on the base of their known involvement in 
polyphenol transport. They were also selected on the base of the current research interests of 
the research group.   
A database was created, using the bioinformatic tool Genevestigator, in order to have as 
much information as possible on the selected transporters. This information could be used as 
a starting point to further investigate the transporters of interest.  
 
In the database: 
1. The recent information about the anatomical distribution of each transporter was 
extracted. 
2. The available information on how the selected transporters behave in response to 
chemicals, drugs and chemical mediators was summarised.  
3. Information on the expressional modulation of transporters from disease 
(cardiovascular and metabolic diseases and afflictions of the gastrointestinal organs) 
was collected.  
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1.4.2. Assessment of functional and/or transcriptional modulation of selected 
uptake transporters in different cell lines: OAT3 in HepG2 cells and SERT in 
Caco-2 cells.  
Characterisation of kaempferol-3-O-glucuronide uptake in HepG2 cells.  
Two Individual transporters of interest were selected and exposed to a range of compounds. 
Transcriptional and/or functional modulation, in response to the selected compounds  was 
assessed and characterized. 
 OAT3 was the first target to be selected. Recent studies carried out in the research 
group have shown that OAT3 takes up polyphenol conjugates in human cell models 
(Wong et al., 2011a).  
Initially, the mRNA levels of OAT3 (SLC22A8) were evaluated in the human liver 
cell line HepG2. Assessment of transcriptional and functional modulation was 
subsequently carried out. Three stressors (hydrogen peroxide, t-butyl-hydroperoxide 
and ethanol) were selected. These compounds were selected because in vivo they 
interact with the liver. They are both metabolized in this organ, impacting on its 
physiology. 
Assessment of the functional modulation was carried out using the model substrate 
5’-carboxyfluorescein. Effect of the stressing agents was evaluated by quantifying 
through HPLC the amount of intracellular 5’-carboxyfluorescein after pre-
incubation with various concentrations of each stressor. Modulation of the mRNA 
levels was evaluated through RT-PCR, after incubation with each stressor.  
 Kaempferol is the second most abundant flavonol in the human diet, after quercetin. 
Little is known about the cellular uptake of kaempferol-3-O-metabolites in the 
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human body. Kaempferol-3-O-glucuronide was selected. Liver HepG2 cells were 
used to assess whether kaempferol-3-O-glucuronide predominantly occurred via 
active transport, mediated from a carrier, or passive diffusion. If uptake proved to 
be carrier-mediated, the final aim would be to identify the transporter(s) involved 
and to modulate transport using dietary compounds. 
 SERT is a transporter known to play a role in appetite modulation. Recent studies 
have also associated polyphenols with appetite. Of particular interest are green tea 
and coffee, because high consumption of these beverages has been linked to 
appetite suppression. Green tea and coffee whole extracts and individual green tea 
and coffee compounds were tested as functional modulators of SERT in Caco-2 
cells.  
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Chapter 2  
                                        Material and Methods 
 
2.1. Equipment and chemicals 
2.1.1. Equipment 
Below is a list of the equipment used for the experiments (Table 2-1). 
 
Table 2-1. List of equipment used in the experiments. The name of the machine, the 
experimental use and the manufacturing company are reported.  
Equipment Experiment Manufacturer 
   
Cecil CE 201 spectrophotometer  Absorbance 
measurement 
Cecil Instruments Ltd. 
Cambridge, UK 
   
96 well-based Multiskan Ascent plate 
reader  
Absorbance 
measurement 
  Thermo Fisher Scientific, 
Waltham, MA 
   
Agilent 1200 series liquid 
chromatography system, with 
fluorescence detector and diode array 
HPLC    Santa Clara, CA, USA 
 
Zorbax Eclipse XDB-C18 Rapid 
Resolution HT Column  
 
HPLC                               
     
Santa Clara, CA, USA 
 
   
NanoDrop ND-1000 spectrophotometer RNA quantification Agilent technology, UK 
 
Genevac, EZ-2 plus model, was used for 
sample concentration and stock 
preparation  
 
Sample 
concentration and 
stock preparation 
 
 Genevac Ltd. Ipswich, UK 
 
StepOneTM Real-time PCR system  
 
Reverse transcription 
and real-time PCR  
 
Applied Biosystems, Foster 
City, CA 
   
Tri-Carb 1600TR scintillation counter  Radioactivity count    Packard Instruments, UK 
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All the experiments were carried out using ultra-pure water, obtained with a Milli-Q water 
purifying system (Millipore, Milford, MA, USA).  
The Milli-Q system employees a series of successive filtration and deionization steps aimed 
to obtain ultra-pure water. Water purity is related to water resistivity: the highest the 
resistivity the lower the amount of charge-carrying ions. Typically water is considered ultra-
pure when resistivity is ≥ 18.2 MΩ·cm at 25 °C (Huang et al., 1995). 
 
2.1.2 Chemicals  
A list of the chemicals used in the experiments is given below (Table 2-2).  
All the general laboratory consumables not shown in the table were purchased from Fisher 
Scientific (Waltham, MA). 
 
Table 2-2. List of chemicals used in the experiments. For each chemical the origin source 
is given.  
Source Compound 
Sigma-Aldrich (St. Louis, MO) 5’-carboxyfluorescein (5’-CF) 
 
Methylthiazolyldiphenyl-tetrazolium bromide 
(MTT) 
 
Kaempferol-3-O-glucuronide (k-3-O-g) 
 
Ferulic acid (FA) 
 
3,4-dimethoxycinnamic acid (3,4-DMCIN) 
 
Caffeine 
 
Imipramine 
 
Bovine serum albumin (BSA) 
 
Unlabelled serotonin (5-HT) 
 
Egallocatechin gallate (EGCG) 
 
Epigallocatechin (EGC) 
 
Epicatechin gallate (ECG) 
 
Epicatechin (EC) 
Sigma-Aldrich (St. Louis, MO) Fetal bovine serum (FBS) 
 
Dulbecco’s Modified Eagle Medium (DMEM) 
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amphotericin B 
 
 
penicillin-streptomycin 
 
 
Roche Applied Science (West Sussex, UK)  Bradford reagent: Coomassie Brilliant Blue G-250 
  
Cytotoxicity detection kit (LDH) 
Fisher Scientific (Waltham, MA)  Tert-Butyl hydroperoxide (tBOOH) 
  
Hydrogen peroxide (H2O2) 
  
Ethanol (EtOH) 
Applied Biosystems (Carlsbad, California) 
 
Primers for OAT3 (SLC22A8, Hs01056647_m1) 
  
Primers for GAPDH (4326317E) 
  
Primers for SERT (SLC6A4, Hs00984349_m1) 
  
RNAqueous® kit 
  
RNA-to-cDNA Master Mix 
 
PCR Master Mix 
Perkin-Elmer (Boston, MA, USA) 
 
 
Radiolabeled serotonin ([3H]-5-HT), with specific 
activity of 250 μCi/mmol 
Extrasynthese (Genay, France) 
 
 
 
3-caffeoylquinic acid (3-CQA) 
  
5-coffeoylquinic acid (5-CQA) 
  
Caffeic acid (CA) 
Nestlé (Lausanne, Switzerland) 
 
 
Coffee powder (green blend), commercially 
available 
  
Green tea (soluble powder) 
  
3,4-dicaffeoylquinic acid (3,4-diCQA) 
  
3,5-dicaffeoylquinic acid (3,5diCQA) 
Kind gift of Prof. Mike Clifford 
 
5-feruloylquinic acid (5-FQA) 
ATCC (Manassas, VA) 
 
Caco-2 (colorectal adenocarcinoma) cells 
  
HepG2 (hepatocellular carcinoma) cells 
Gentaur (Brussels, Belgium) 
 
 
Enzyme chlorogenate esterase (CES; Aspergillus 
japonicus EC 3.1.1.42) (≥15 U/g) 
National Diagnostics (London, UK) 
 
Ecoscint XR scintillation fluid 
Perkin Elmer, Life Analytical Sciences, 
(Beaconsfield, UK)  
[3H]-5-HT (tritium-labelled serotonin) 
3H Standard 
2.2. Cell line maintenance 
2.2.1. Colorectal adenocarcinoma (Caco-2) cells  
All the plastics used for cell culture were from Corning (Corning Costar Corp., Cambridge, 
MA). 
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Caco-2 (colorectal adenocarcinoma) (HTB-37
TM
) cells were routinely cultured in 75 cm
2
 
flasks in humidified 5 % CO2/O2 atmosphere, at 37 °C. Dulbecco’s Modified Eagle Medium 
(DMEM) was supplemented with 0.25 μg/mL amphotericin B, 100 U/ml penicillin-
streptomycin and 15 % heat inactivated fetal bovine serum (FBS).  
For the experiments, cells were seeded in 6 well plates. Seeding density was 0.283 x 10
6
 
cells/well. Cells were used for the experiments between day 6 and 15 post-confluence. The 
culturing conditions and the medium used for the experiments were the same as when 
culturing in flasks, but FBS percentage was reduced to 10 %.  
All the experimental work was carried out using cells between passage 38 and 50.  
 
2.2.1.1. Optimisation for serotonin uptake experiments 
Optimisation, to determine how many days post-confluence were to be used for serotonin 
uptake experiments was carried out as follows. Expression of the gene encoding for the 
serotonin reuptake transporter, SLC6A4, was assessed between day 5 (day cells reached 
confluence) and 21 post-seeding, through quantitative RT-PCR. After cells reached 
confluence, SLC6A4 mRNA displayed to increase for 5 days. After 5 days from confluence, 
the mRNA levels reached a plateau and remained constant until day 16 post-confluence (fig. 
2-1). On the base of these observations, all the experiment aiming on SERT were carried out 
using Caco-2 cells between day 6 and 15 post-confluence. 
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Figure 2-1. Assessment of SERT (SLC6A4) expression at different days post-
confluence. Caco-2 cells were seeded in 6 well plates and cultured at 37 °C in humidified 5 
% CO2/O2 atmosphere. Total mRNA was extracted and SLC6A4 quantified through 
quantitative RT-PCR for 16 days post-confluence. The results reported are average of 
triplicates, obtained extracting the mRNA from individual wells, ± St. Dev. 
 
2.2.2. Hepatocellular carcinoma (HepG2) cells 
HepG2 (hepatocellular carcinoma) (HB-8065
TM
) cells were routinely cultured in 75 cm
2
 cell 
culture flasks, under a humidified 5 % CO2/O2 atmosphere at 37 °C. The medium, DMEM, 
was supplemented with 10 % fetal bovine serum and 100 U/ml penicillin. When seeding 
cells in 12 well plates, seeding density was of 2 x 10
5
 cells/well. Experiments were 
performed with cells between passages 75 and 85 as soon as cells reached confluence, 
generally 72 h post-seeding. 
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2.2.3. Assessment of cytotoxicity and cellular viability  
Cell viability and cellular integrity were determined using two methods, the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and the lactate 
dehydrogenase (LDH) activity test. These two tests were performed to optimise the 
concentration of each compound to safely be used on the cells. The assays determine the 
percentage of cells that are viable and the percentage of cells which have undergone 
membrane damage, respectively. The MTT and LDH assays can be used as indicators of the 
cytotoxicity of selected compounds. On the basis of the cytotoxicity assays, all the 
experiments were carried out using concentrations of the compounds of interest so that cell 
loss/damage ≤ 15 %. 
 
2.2.3.1. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
assay 
The MTT test is a colorimetric assay. It is based on the measurement of the activity of 
cellular oxidoreductase enzymes. These enzymes reduce the MTT reagent to formazan, 
giving a purple colour. Dye reduction depends on NAD(P)H presence, which is produced in 
high amount in cellular metabolic reactions. Thus, the more viable cells are present the more 
MTT reduction is going to occur (Mbanya et al., 2001).  
For the MTT test, confluent cells grown in 6 well plates were used. Cells were initially 
incubated with a range of concentrations of the compound to be tested for cytotoxicity (50-
1000 µM for t-BOOH, 50-500 µM for H2O2, 0.3-2 mM for EtOH, respectively). The 
incubation conditions (temperature and time of incubation) were selected to be the same as 
in the final experiments.  
Subsequently, cells were washed once with Hank’s balanced salt solution (HBSS) and 
incubated for 4 h, at 37 °C, with 1 mL fresh medium containing 0.5 mg/mL MTT. 
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Incubation medium was removed and cells were incubated for 30 min, at room temperature, 
in the dark and under shaking condition, with 1 mL/well de-staining solution. De-staining 
solution contained 100 mM HCl and 10 % Triton X-100 in isopropanol. All the de-staining 
solution was collected after 30 min. 300 µL of it were diluted 1:2 and used for absorbance 
measurement at 595 nm. A 96 well-based plate reader was used to record absorbance. Fresh 
de-staining solution was used for the blank (fig. 2-2).  
 
 
Figure 2-2. Example of MTT assay. HepG2 cells were incubated with a range of hydrogen 
peroxide (H2O2) concentrations (200-1000 µM) for 12 hours. Subsequently cell viability was 
determined using the MTT assay, as described in this chapter.   
Typical results are displayed. 
 
2.2.3.2. Lactate dehydrogenase (LDH) assay  
The LDH activity test is based on the measurement of the cytosolic enzyme lactate 
dehydrogenase. Presence of the enzyme in the extracellular space is indicative of cell 
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leakage due to cell damage. Thus the more enzyme is measured in the medium the more 
cells have been damaged (Keilhoff and Wolf, 1993).  
For the quantification of the cytosolic LDH, the lactate dehydrogenase activity assay kit 
from Roche Applied Science was used. Catalyst lyophilized powder, provided from the 
manufacturer, was reconstituted in 1 mL H2O. For the cytotoxicity test, the reconstituted 
catalyst and the dye solution were mixed (1:45).  
For the test, cells grown to confluence in 6 well plates were incubated with a range of 
concentrations of the compounds for which cytotoxicity had to be assessed. The incubation 
conditions (temperature and time of incubation) were selected to be the same as in the final 
experiments. The assay was carried out in 96 well-plates as follows. 100 µL cell culture 
medium were collected and mixed with 100 µL catalyst + dye solution.  
Incubation was carried out for 10 sec at RT under shaking condition and subsequently for 10 
min at RT without shaking. 50 µL of stopping solution were added and absorbance was 
measured at 492 nm in a 96 well plate reader (fig. 2-3).  
The following controls were used.  
1. Cell-free cell culture medium. For background values. 
2. Untreated cells, where no stressors had been applied. For spontaneous LDH release 
in the medium. 
3. Lysed cells. Cells were treated with lysing buffer so that total cell lysis was induced 
(100 % LDH release). 
Controls were prepared as shown in the table below (table 2-3). 
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Table 2-3. Preparation of controls used in the LDH activity assay.  
 Ctr 1 Ctr 2 Ctr 3 
Cell-free medium 100 µL 50 µL 50 µL 
Cells - 50 µL 50 µL 
Lysis buffer  - - 5 µL 
 
Cell damage was measured as follows: 
Cell damage (%) = (Experiment value – control 2) / (control 3 – control) x 100 
 
  
Figure 2-3. Example of LDH assay. HepG2 cells were incubated with a range of tert-butyl 
hydroperoxide (t-BOOH) concentrations (50-500 µM) for 8 hours. Subsequently cellular 
damage was determined using the LDH assay, as described in this chapter.   
Typical results are displayed. 
 
2.3. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
Qualitative RT-PCR is a technique used to amplify specific segments of DNA.  
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RNA is initially extracted from the cells. Subsequently complementary DNA (cDNA) is 
transcribed from the RNA. This step is done through reverse transcription, using the enzyme 
Taq DNA polymerase. The cDNA is finally used as a template for amplification of the 
genes of interest. Two primers, short DNA fragments, complementary to the 3’ and 5’ ends 
of the gene of interest are used as starting points for DNA synthesis. 
During synthesis of the cDNA, a reporter dye and a quencher dye are located respectively at 
the 5’ and 3’ end of a short probe. This probe anneals downstream from one of the primers. 
Proximity between the reporter and the quencher prevents significant emission from the 
reporter, due to fluorescence resonance energy transfer (FRET). When the Taq DNA 
polymerase reaches the probe, it acts as endonuclease on the probe. It cleaves it, causing 
separation of the quencher from the reporter. This causes increase in the energy emission of 
the reporter.  
With each PCR cycle a probe is cleaved from the Taq DNA polymerase. This results in an 
increase of the emitted fluorescence proportional to the amount of amplified segments 
(Gelmini et al., 2001). The RT-PCR is used to establish changes in the expression of 
selected genes.  
 
2.3.1 RNA extraction 
Before RNA extraction, cells were washed twice with ice-cold PBS. Total RNA was 
extracted using the RNAqueous® kit according to the protocol supplied from the 
manufacture as follows. 
Cells were harvested through incubation with 250 µL/well lysis buffer for 8 min on ice and 
mixed with an equal volume of 70 % ethanol. Samples were shredded using a syringe in 
order to fragment the DNA. Samples were subsequently filtered using silica filters, allowing 
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the RNA to bind to the filters. A series of washes was performed to purify the RNA. RNA 
was finally eluted and stored at -80 °C until use.  
RNA was quantified using a NanoDrop, measuring absorbance at 260 nm.  
Measurements at 280 and 230 nm were also performed to assess RNA purity. 260/280 and 
260/230 nm ratios were used to assess contamination from proteins, phenols and other 
organic components.  
Values between 2.0 and 2.1 were considered to indicate acceptably pure RNA.  
 
2.3.2. cDNA synthesis 
The High Capacity RNA-to-cDNA Master Mix was used to synthesize cDNA.  
Each reaction tube contained the following components: 
10 μL Buffer Mix + 1 μL Enzyme Mix + 9 μL diluted RNA (= 1 μg) 
The program used for cDNA synthesis was the following:  
60 min at 37 °C, 5 min at 95 °C, with subsequent cooling down to 4 °C. 
 
2.3.3. RT-PCR and gene amplification analysis 
Standard curves for the genes of interest were made using a series of dilutions of the cDNA. 
GAPDH was selected as endogenous control (Fig. 2-4 and 2-5). The gene of interest and the 
endogenous control were labeled with VIC and FAM dyes respectively.  
The optimal cDNA dilution was chosen using the standard curve, so that the threshold cycle 
(Ct) value would be between 15 and 40 cycles.  
The Ct value is the number of PCR cycles necessary for the fluorescence of the report dye to 
exceed the background signal at a given threshold.  
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The Ct value inversely correlates to the amount of target gene in the sample. This value 
gives an overall indication of the amount of target gene in the sample, (McKenney et al., 
2014). 
 
 
Figure 2-4. Standard curve for OAT3 gene expression. Gene expression was evaluated in 
HepG2 cells (see chapter 4). RNA was extracted at day 3 post-seeding, when cells reached 
confluence. RNA was quantified and a range of dilutions were prepared (10-100 ng).  
RT-PCR was carried out for each dilution. GAPDH was used as the endogenous control.  
The results reported represent average of triplicates ± St. Dev.  
 
y = -3.3897x + 24.705 
R² = 0.9992 
y = -2.9725x + 38.848 
R² = 0.9982 
0 
5 
10 
15 
20 
25 
30 
35 
40 
0 0.5 1 1.5 2 2.5 
A
v
er
ag
e 
C
t 
v
al
u
e 
Log cDNA ng 
GAPDH 
OAT3 
Chapter 2: Material and Methods 
 
42 
 
  
Figure 2-5. Standard curves for SERT gene expression. Gene expression was evaluated 
in Caco-2 and HepG2 cells, for comparative analysis (see chapter 5). RNA was extracted 
from Caco-2 cells at day 14 post-confluence and at day 1 post-confluence from HepG2 
cells. RNA was quantified and a range of dilutions were prepared (10-100 ng).  
RT-PCR was carried out for each dilution. GAPDH was used as the endogenous control.  
The results reported represent average of triplicates ± St. Dev.  
 
Each reaction tube contained the following components: 
1 μL GAPDH + 1 μL OAT3 primers + 10 μL Master Mix + 8 μL diluted cDNA. 
The PCR program selected was the following: 
5 min at 50 °C, 10 min at 95 °C for primer annealing, 40 cycles of 15 sec at 95 °C and 1 min 
at 60 °C. 
Results were analyzed using StepOne software 2.1. 
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2.4. Cellular uptake assays 
2.4.1. Functional modulation of transporters 
2.4.1.1. Functional modulation of OAT3 in HepG2 cells 
Assessment of functional modulation of OAT3 was carried out by measuring uptake of a 
selected model substrate for OAT3. The selected model substrate was 5’-carboxyfluorescein 
(5’-CF) (Vallon et al., 2008). The aim was to establish whether pre-incubation with selected 
stressing agents would modulate OAT3, resulting in increase/decrease of 5’-CF uptake. 
The following stressing agents were individually tested: hydrogen peroxide (H2O2), tert-
butyl hydroperoxide (tBOOH) and ethanol (EtOH).  
The protocol used had been optimised in a previous work (Wong et al., 2011c).  
Uptake was carried out in 12 well plates. Transport medium consisted of Hbss, 
supplemented with 1.8 mM CaCl2 for reinforcement of the tight junctions. The pH was 
adjusted to the physiological value of 7.4. 
Cells were washed once with warm transport medium and incubated at 37 °C with each 
stressing agent at a range of concentrations, for either 8 or 12 h.  
Incubation times and concentrations were the following: 8 h with H2O2 (50-200 μM), 12 h 
with H2O2 (25-100 μM), 8 h with t-BOOH (50-100 μM), 12 h with t-BOOH (25 μM), 12 h 
with EtOH (0.5-1 mM).  
The stressing agent concentrations were selected after cytotoxicity assessment of each 
compound, so that cell viability/cellular integrity ≥ 85%.  
After incubation with the stressing agent, the transport medium containing the stressor was 
removed and replaced with fresh transport medium containing 100 µM 5’-CF.  
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5’-CF was prepared by initially dissolving the compound in DMSO to make a stock solution 
(100 mM). The stock solution was subsequently diluted in the transport medium (final 
DMSO ≤ 0.5%) to obtain the wanted concentration (100 μM).  
Cells were incubated for 10 min with 5’-CF and subsequently washed with ice cold 
transport medium. Cell lysis was carried out using 80 % methanol for 1 h in the dark. After 
lysis each well content was collected. Quantification of the intracellular 5’-CF content was 
carried out through HPLC. 
 
2.4.1.2. Modulation of SERT in Caco-2 cells 
For uptake modulation of SERT, the transport medium was prepared in ultra-pure water as 
follows (in mM): 5.4 KCl, 0.44 K2HPO4, 4.2 NaHCO3, 137 NaCl, 0.35 Na2HPO4, 5.5 D-
glucose, 1.8 CaCl2.  
The substrate (serotonin, 5-HT) was present as a mixture of both 5-HT and [
3
H]-5-HT to a 
final concentration of 0.2 µM.  
The protocol was carried out according to previous research (Mendoza et al., 2009).  
A stock solution of 5-HT (1 mM) was prepared by dissolving 5-HT in DMSO. Subsequently 
the stock solution was diluted in the transport medium (final DMSO % ≤ 0.1), to obtain the 
wanted concentrations.    
Cells were pre-incubated with substrate-free transport medium for 30 min at 37°C, to 
reinforce the tight junctions. Cells were quickly washed twice with 1 mL warm substrate-
free transport medium and incubated for 6 min at 37 °C with medium containing the 
substrate and 0.1 % BSA. BSA was used to minimize non-specific transport.  
After 6 min transport was stopped by removing the medium and rinsing the cells twice with 
1 mL ice cold medium containing 0.1 % BSA.  
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Finally, cells were solubilised for 30 min in 1 mL in 1 M NaOH. The whole lysates were 
collected and neutralised using 1 M HCl. Samples were mixed with scintillation fluid before 
measuring the radioactivity (β emission of tritium), using a Tri-Carb 1600TR scintillation 
counter. 
 
2.4.1.2.1. Serotonin uptake optimisation 
Preliminary time-linearity of serotonin uptake was determined. This was done by incubating 
the cells with 0.2 µM of substrate mixture for a time range (1-15 min).  
Concentration-dependence of serotonin uptake was also assessed. This was done by 
incubating cells for 6 min with a range of substrate concentrations (0.1-5 μM).  
Finally, the role of sodium in serotonin uptake was preliminary determined. This was done 
by measuring serotonin uptake in sodium-containing medium in sodium-depleted medium 
respectively. In the sodium-depleted medium, sodium was replaced with potassium. 
 
2.4.1.2.2. Serotonin uptake modulation 
It was assessed whether coffee and green tea whole extracts and individual coffee and green 
tea compounds modulated serotonin uptake through SERT.  
Cells were incubated for 6 min at 37 °C with each compound.  
Coffee and green tea whole extracts were tested at concentrations between 2 and 30 mg/mL. 
Coffee whole extracts were prepared by dissolving soluble coffee powder in warm HBSS. 
pH was adjusted to the physiological value of 7.4. Solution was vigorously vortexed for 2 
min and centrifuged for 5 min at 17,000 g. The supernatant was collected and the pellet 
discarded. Supernatant was filtered and applied to cells.   
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Green tea whole extracts were prepared by dissolving green tea soluble powder in warm 
HBSS. Solution was vigorously vortexed for 3 min and then applied to cells. 
 
2.4.1.2.2.1. Modulation of serotonin uptake using individual coffee compounds  
The following individual coffee compounds were tested: caffeine, caffeic acid (CA), ferulic 
acid (FA), 3, 4-dimethoxycinamic acid (3,4-DMCIN), 5-feruoylquinic acid (5-FQA), 3-
caffeoylquinic acid (3-CQA), 5-affeoylquinic acid (5-CQA), 3,4-dicaffeoylquinic acid (3,4-
diCQA), 3,5-dicaffeoylquinic acid (3,5-diCQA). Initially all compounds, except for 
caffeine, were tested at physiological concentrations (≤ 3 mM). Subsequently the following 
compounds were tested at concentrations equivalent to a strong cup of coffee (15 mg/mL): 
caffeine: 23 mM, CA: 23 μM, FA: 6 μM, 3,4-DMCIN: 02.7 μM, 5-FQA: 400 μM, 3-CQA: 
0.9 mM and 5-CQA: 3.4 mM. Imipramine was used as positive control and tested at 
concentrations between 5 and 15 μM. 
Finally FA and 5-FQA were tested to assess whether they inhibited uptake in a competitive 
manner. They were tested at 1-3 mM and 0.5-2.5 mM respectively, co-incubating with a 
range of serotonin concentrations (between 0.05 and 1 μM).  
 
2.4.1.2.2.2. Modulation using individual green tea compounds  
The following individual green tea components were tested: epigallocatechin gallate 
(EGCG), epicatechin (EC), epigallocatechin (EGC) and epicatechin gallate (ECG). They 
were initially tested at physiological concentrations between 100 and 1000 μM. 
Subsequently EGCG, EC, EGC and ECG were used at supplement concentrations, 
equivalent to 7 cups of green tea (11.6, 2.4, 12 and 2.15 mM, respectively). 
 
Chapter 2: Material and Methods 
 
47 
 
2.4.1.2.3. Radiochemistry 
Intracellular tritium-labeled serotonin ([
3
H]-5-HT) was measured to assess functional 
modulation of SERT, in response to coffee and green tea whole extracts and individual 
compounds. 
The amount of radio-labeled serotonin to be used was calculated on the basis of the 
information provided from the manufacturer (activity amount: 250 µCi, concentration: 
1µCi/µL, specific activity: 82.2 Ci/mmol).  
The final serotonin concentration wanted was chosen as 0.2 µM, according to published 
research (Mendoza et al., 2009). 
  
2.4.1.2.3.1. Radioactive sample preparation and radioactivity measurement 
Samples were prepared for radioactivity measurement as follows.  
1 mL of neutralised cell lysates was mixed with 10 mL of scintillation fluid. Βeta- emissions 
were counted over a period of 10 min in a scintillation counter. Radioactive count was given 
from the counter as count of emission per minute (CPM) and then converted into 
degradation per minute (DPM).  
In every experiment, scintillation counter efficiency was evaluated using a 
3
H standard. 
Comparison between the predicted value (given by the manufacturer) and the obtained value 
was carried out as follows: 
Detector Efficiency = CPM value obtained for the standard/CPM predicted for the standard 
The CPM was converted into DPM using the following formula: 
DPM = (CPMsample – CPMbackground)/Detector Efficiency 
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2.4.2. Cellular uptake of kaempferol-3-O-glucuronide 
The aim was to determine whether kaempferol-3-O-glucuronide (k-3-O-g) uptake in HepG2 
cells mainly occurred in a transporter-mediated manner or it relayed on passive diffusion 
mechanisms.  
The experiment was carried out according to previous published research (Wong et al., 
2012) as follows.  
Uptake was evaluated using 12 well plates. Transport medium was prepared in ultra-pure 
water adding the following components (in mM): 4 KCl, 0.44 K2HPO4, 4.2 NaHCO3, 137 
NaCl, 0.35 Na2HPO4, 5.5 D-glucose and 1.8 CaCl2.  
Cells were washed once with warm transport buffer and incubated with k-3-O-g under the 
conditions described below.  
K-3-O-g uptake was carried out for 10 min at 37 °C using a range of k-3-O-g concentrations 
(50-200 µM) or for 10 min under different temperatures (37°C and 4°C) using 200 μ k-3-O-
g. The aim was to measure concentration- and temperature-dependence of k-3-O-g uptake, 
respectively.  
Time-linearity of the uptake was also evaluated. Cells were incubated for a time range (10-
30 min) with 200 μM k-3-O-g.  
K-3-O-g had initially been dissolved in DMSO to prepare a stock solution (200 mM). The 
stock solution was subsequently diluted in the transport medium to obtain the wanted 
concentrations (final DMSO ≤ 0.5 %).  
After incubation, cells were washed twice with ice cold transport buffer supplemented with 
0.2 % bovine serum albumin (BSA). Cells were washed once with ice cold transport buffer 
without BSA. Cells were scraped in 0.5 mL 50 % methanol and collected for measurement 
of the intracellular k-3-O-g through HPLC. 
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2.4.2.1. Sample deproteination and concentration 
Proteins are large molecules, whose presence in the sample could cause damage to the 
HPLC systems. For this reason samples were deproteinated as follows.  
0.5 mL of each sample (in 50 % methanol) were sonicated for 5 min, in order to complete 
cellular membrane breakage. 1 mL ice cold acetone was added and samples were frozen for 
1 h at -20 °C. Acetone affects the overall protein solubility in water, reducing it and causing 
precipitation of the proteins (Simpson and Beynon, 2010).  
Lysates were thawed and centrifuged for 5 min at 17,000 g. Supernatant and pellet were 
separated. All the supernatant was collected and evaporated under vacuum at 30 °C. 
Subsequently samples were re-dissolved in 100 μL 95 % (v/v) acetonitrile for quantification 
of k-3-O-g, through HPLC analysis. Daidzin (50 μM) was added in the samples, before 
HPLC analysis, and used as internal standard. Optimisation was previously carried out to 
assess the extraction efficiency, which resulted to be ≥ 98 %.  
The pellets, containing the precipitated proteins, were used for total protein quantification, 
using the Bradford assay. 
 
2.4.2.1.1. Protein quantification using the Bradford assay 
The Bradford assay is a colorimetric assay used to quantify the total protein amount in a 
sample. The assay is based on the absorbance shift of the dye Coomassie Brilliant Blue G-
250, commonly known as Bradford reagent. When the dye binds to proteins, it changes from 
the red form to the blue form. The more proteins are present in the sample, the more dye-
protein complexes will be present. The blue form of the dye maximally absorbs at 595 nm, 
thus proteins can be quantified measuring absorbance at 595 nm (Aminian et al., 2013). 
The assay was performed in 96 well plates.  
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For the standard curve, between 0.1 and 1.4 mg BSA were dissolved in 1 mL 0.1 M NaOH. 
For protein quantification in the samples, pellets were dissolved in 0.5 mL 50% NaOH and 
50% HCl. Before absorbance measurement, 5 μL of BSA standard or protein sample were 
mixed with 0.25 mL of Bradford reagent and incubated at room temperature for 15 min. 
Protein quantification was performed at 595 nm, using a Multiskan Ascent 96-well plate 
reader. 
The assay was used to assess protein content variation among wells. Either HepG2 or Caco-
2 cells were seeded in 12 well plates and grown to confluence. Subsequently the cells were 
lysated and the Bradford assay performed for each well. The average protein amount for 
HepG2 cells resulted to be 1.16 mg/ mL, with a standard deviation of 0.04. The average 
protein content for Caco-2 cells resulted to be 0.98 mg/mL, with a standard deviation of 
0.02. The assay showed that the protein content variation among wells was very small, both 
when working with HepG2 and Caco-2 cells. 
An example of BSA standard curve is shown below in figure 2-6. 
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Figure 2.6. Example of Bradford assay standard curve. Between 0.1 and 1.4 mg BSA 
were dissolved in 1 mL 0.1 M NaOH. 5 μL of BSA sample were mixed with 0.25 mL 
Bradford reagent. Protein quantification was made at 595 nm, using a plate reader. 
  
2.5. High-performance liquid chromatography (HPLC) analysis 
HPLC is an analytical chemistry technique, used to quantify compounds in a mixture.  
HPLC is based on a system of under pressure pumps. Selected organic solvents (mobile 
phase) are pumped, along with the mixture sample, through a column (stationary phase) 
packed with solid absorbent material.  
The solvents and the parameters used to perform the elution are chosen mainly according to 
the type of packaging material in the column and the nature of the mixture to analyse. When 
the mixture to be analysed is pumped through the column, each component present in it 
interacts with the packaging material of the column in a different way, according to its 
chemical nature and structure. This results in different compounds eluting from the column 
at different times (retention times).  
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Each compound has its own retention time, strictly associated to the solvent(s), elution 
method and column used in the elution. As long as pure standard compounds are available, 
it is possible to identify the specific retention time for the compound of interest and use it to 
analyse and quantify the same compound in a mixture (Kormany et al., 2013).  
For all my analysis, the stationary phase consisted of a 4.6 x 50 mm column, C18, 1.8 µM 
particle packed. 
 
2.5.1. Quantification of intracellular  5’-carboxyfluorescein 
Intracellular 5’-carboxfluorescein (5’-CF) was quantified using a 10 min isocratic elution 
run. The mobile phase consisted of 20 mM Tris-HCl (pH 8) and 20 % methanol in water. 
The flow rate was 0.5 mL/min. Detection of 5’-CF was carried out at 492 and at 517 nm. 
Quantification was performed based on standard curves, prepared using authentic standards.  
 
2.5.2. Quantification of kaempferol-3-O-glucuronide 
For quantification of the intracellular k-3-O-g a 33 min run was used. Flow rate was 0.5 
mL/min. The mobile phase was made by solvent A and solvent B. A and B were 
respectively 5 % (v/v) acetonitrile in water and 95 % (v/v) acetonitrile in water, each 
containing 0.1 % formic acid. Solvent B gradient was started at 5 %, linearly increased to 10 
% over 5 min. Subsequently B was increased to 40 % in the next 4 min and kept at 90 % for 
2 min. Finally re-equilibration was carried out at 5 % for 4 min. The detection was carried 
out between 250 and 340 nm, based on standard curves prepared using authentic standards. 
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2.5.3. Quantification of chlorogenic acids, after coffee hydrolysis with the 
enzyme chlorogenate esterase 
The aim was to better understand the role that chlorogenic acids present in coffee play in 
modulating serotonin uptake through SERT. In order to do that, coffee whole extracts (15 
mg/mL) were hydrolysed using the enzyme chlorogenate esterase. After hydrolysis, the 
chlorogenic acid content remaining were quantified through HPLC. 
Whole coffee extracts (15 mg/mL) were incubated with the enzyme chlorogenate esterase. 
This was done in order to hydrolyse the majority of the chlorogenic acids present in coffee. 
To determine what percentage of the total amount of chlorogenic acids had been 
hydrolysed, HPLC analysis was performed, quantifying the chlorogenic acids in hydrolysed 
and un-hydrolysed coffee extracts. 
In a subsequent experiment Caco-2 cells were treated with hydrolysed and un-hydrolysed 
coffee respectively and serotonin modulation was assessed. Comparison between the effect 
of coffee containing chlorogenic acids and coffee were the majority of the chlorogenic acids 
had been hydrolysed was carried out.  
Analysis of coffee chlorogenic acids was carried out using a 68 min run with 0.26 mL/min 
flow rate. The solvents were 5 % (v/v) acetonitrile in water (A) and 95 % (v/v) acetonitrile 
in water (B), each containing 0.1 % formic acid. Elution was started with 0 % solvent B, 
maintained at 0 % for 17 min. Percentage of B was subsequently increased to 25 over the 
next 34 min. Percentage of B was immediately increased to 100 and kept at 100 for 5 min. 
Finally column re-equilibration was carried out for 12 min using 0 % solvent B. The 
detection was carried out between 250 and 340 nm, using standard curves prepared with 
authentic standards. 
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2.5.3.1 Coffee hydrolysis with chlorogenate esterase 
2.5.3.1.1. Assessment of Chlorogenate esterase efficacy 
Optimisation was carried out to determine the amount of chlorogenate esterase to be used 
for coffee hydrolysis.  
The aim was to use an amount of chlorogenate esterase, so that the majority of the 
chlorogenic acid content would be hydrolysed.  
The enzyme activity for a selected enzyme represents a measure of the hydrolyzing potency 
of the enzyme. It represents the quantity of active enzyme present. The enzyme activity 
depends on the conditions used to perform the assay (Frei, 1970).  
When an enzyme is purchased, the manufacturer specifies the minimum enzyme activity for 
the product and the conditions under which this measurement was initially made. The 
manufacturer does not provide the exact enzyme activity. This must be calculated from the 
user and re-calculated whenever new experimental conditions are selected.  
Enzyme activity tends to decrease over time. For this reason, it is also important to assess it 
at regular time intervals.  
Assessment of the enzyme activity was carried out based on the guidelines specified from 
the manufacturer. The main steps of the assay are reported below: 
 
5-O-caffeoylquinic acid + H2O + chlorogenate esterase               caffeic acid + quinic acid 
 
 A phosphate buffer (here called reagent A) was prepared mixing 50 mM sodium 
phosphate dibasic (Na2HPO4) and 50 mM potassium phosphate monobasic (KH2PO4). The 
buffer pH was adjusted at pH 6.5.  
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 26 mg of the substrate 5-O-caffeoylquinic acid were dissolved in 0.5 mL methanol. The 5-
O-coffeoylquinic acid solution was diluted using 45.5 mL of reagent A to obtain a 1.5 mM 
solution (here called reagent B).  
 Reagent C (80 % methanol solution) was prepared mixing 20 mL of water and 80 mL 
methanol 100 %.  
 The enzyme solution was prepared immediately before use as follows and kept on ice until 
use. The enzyme was dissolved in ice-cold reagent A, to a final volume activity of 0.3 U, 
equivalent to 20 mg powder (calculated on the base of the information provided by the 
manufacturer, that enzyme activity was ≥ 15 U/g).  
One unit (U) of activity is defined as the enzyme amount that performs hydrolysis of 1 µmol 
5-O-caffeoyl quinic acid per minute at pH 6.5 and temperature of 30 °C. 
The enzyme assay was performed in triplicate as described below: 
a. 0.5 mL of enzyme solution was put in a 15 mL centrifuge tube,  
b. solution was equilibrated at 30 °C in water bath,  
c. 0.03 mL of the solution B was added to the tube. The mixture was briefly vortexed 
and incubated at 30 °C  for further 30 min in water bath,  
d. reaction was stopped by adding 10 mL of solution C to a final volume of 10.53 mL, 
e. measurement of the absorbance was performed using a Cecil CE 201 
spectrophotometer set at 350 nm, using a pair of 1 cm
2
 light path disposable 
cuvettes.  
The blank was prepared using the above protocol but inverting the order of point c. and d.    
The measured absorbance was used to calculate weight activity using the following 
equation: 
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Weight activity (U/g) = Volume activity x  
1
C
 
Where: 
Volume activity =  
                                  
                            
 =                       
with    
  
  
 
Equation 2-1. Calculation of enzyme activity based on enzyme powder (grams). 
In the equation 0.75 is the amount of 5-O-caffeoyl quinic acid in 0.5 mL. 0.62 represents the 
change of absorbance after complete hydrolysis of 0.75 µmol of substrate under 
experimental conditions. Vf and Vi are respectively the final (10.53 mL) and initial (0.5 mL) 
volume of the assay. C is the enzyme concentration (0.02 g/mL).  
 
Calculation resulted in a weight activity of 15.5 U/g. This value was used to calculate the 
amount of enzyme powder required in order to have the wanted enzyme activity of 0.2 U: 
 
Amount of enzyme to be used (mg) = [0.2 (U)] / [15.5 (U/g) / 1000] 
Equation 2-2. Calculation of enzyme powder to be used.  
 
The wanted enzyme activity wanted was selected as 0.2 . In order to obtain this activity, 13 
mg chlorogenate esterase powder were used. 
 
2.6. Statistical analysis 
Unless otherwise stated, all results are expressed as average of triplicates, resulting from 
performing each experiment three times. Dispersion from average is expressed using the 
Standard deviation (St. Dev.).  
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Statistical comparisons were performed by paired t-test, with a significance interval of 95 % 
(P ˂ 0.05). Kinetic analysis of the 5-HT transport values was performed by non-linear 
regression, fitting the results to an equation according to the Michaelis–Menten model.  
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Chapter 3  
A review of transporter distribution and modulation 
 
3.1. Abstract 
Transcription of both uptake and efflux transporters can be modulated from a range of 
conditions. Several publications describe the modulation of individual transporter genes or 
groups of genes. However very few papers are available that summarise the current state of 
knowledge available. 
A comprehensive database for selected genes encoding for human transporters was created 
for the first time. The database was created using the high performance search engine for 
gene expression, Genevestigator. The database summarizes the up to date available 
information on selected human transporters under different conditions: biological mediators, 
disease, chemicals and drugs.  
The following genes were investigated: ABCC2 (MRP2), ABCC3 (MRP3), ABCG2 (BCRP), 
SLOC1A2 (OATP1A2), SLCO1B1 (OATP1B1), SLCO1B3 (OATP1B3), SLCO4C1 
(OATP4C1), SLC22A6 (OAT1), SLC22A8 (OAT3), SLC16A1 (MCT1), SLC16A2 (MCT7), 
SLC5A8 (SMCT1).  
A database containing the available information about anatomical distribution of the 
selected transporters in four human organs (heart, liver, kidney and intestine) was also 
created. 
The present review is based on the comprehensive database created and provides a vital 
starting point for further investigations of selected human transporters. The comprehensive 
database can be found in Appendix I and II. 
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3.2. Introduction 
Transporters can be divided into uptake and efflux, according to the direction of the 
transport they mediate. Uptake occurs when compounds are moved towards the cell 
cytoplasm, while during the efflux compounds are transported out of the cell (Keppler, 
2005). The activity of transporters can be modulated in two ways. In the functional 
modulation, a conformational change of the transporter occurs following interaction with a 
modulator. The conformational change results in either an increase or a decrease in the 
amount of substrate transported (Nunez et al., 2008).  In the expressional modulation, a 
modulator (or compounds produced in response to it into the cell) interacts with the gene 
promoter of the transporter, increasing or decreasing the amount of mRNA transcribed for 
the gene (Zembruski et al., 2011). In the expressional modulation, the modulator acts as a 
transcriptional factor (Ebert et al., 2005). More details about transporter modulation are 
given in Chapter 1.  
The possibility to control the transcription of transporters is the current focus of many 
studies, because it represents a tool to control and modify the cell physiology. The final aim 
of these studies is to optimize the biological processes, maintaining the cell into a healthy 
state (Wood et al., 2000, Pochini et al., 2013). 
There are several methods to assess changes in gene transcription, ranging from techniques 
enabling the analysis of one gene per time to assays allowing the analysis of the whole 
genome in a single experiment (Wasik et al., 2000, Lohr et al., 2012). One method used to 
assess transcriptional changes is microarray analysis. DNA microarrays consist in picomole-
sized DNA spots, called probes, attached to a solid surface. The probes are used to hybridize 
a target cDNA. Subsequently the DNA hybrids are separated and the relative abundance of 
the genes of interest is measured in the DNA sample. Microarray analysis is used when the 
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number of genes to analyse is high, because it allows analysis of a large number of genes at 
once, using customised arrays (Allanach et al., 2008, Esparcia et al., 2011).  
Genevestigator is an online application, developed to provide information about gene 
expression coming from microarray and RNAseq experiments. Data mining systems are 
becoming an increasingly vital tool to collect information for research (Zimmermann et al., 
2005, Zimmermann et al., 2008). As such, Genevestigator has been widely used for 
researchers to collect information on gene expression (Freitas et al., 2011, Mirza et al., 
2012, Han et al., 2012). 
The information provided in Genevestigator is given for a wide range of organisms 
separately, so that gene expression can be investigated in a selected organism individually. 
A range of parameters can be selected to filter the data extraction. For example, by selecting 
the Anatomy tool or the Perturbation tool, the user can look at gene expression in a range of 
tissues or at the expression levels of the gene under a wide range of conditions, respectively.  
A comprehensive database was created extracting data for six uptake and six efflux 
transporters. These transporters were selected as published literature exists, showing that 
they act as active carriers of polyphenols (Table 3-1). The information collected was used to 
design subsequent experiments. 
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Table 3-1. Examples of polyphenols acting as substrates for selected human uptake 
and efflux transporters.  
Transporter  Example of phenolic substrate Reference 
OAT1 Ellagic acid (Whitley et al., 2005) 
OAT3 Naringenin (Hong et al., 2007) 
OAT1A2 Naringin (Bailey et al., 2007) 
OATP1B1 Flavonoid aglycones and glycosides (Wang et al., 2005) 
OATP1B3 Epigallocatechin gallate (Roth et al., 2011) 
OATP4C1 Quercetin-3'-O-sulfate (Wong et al., 2012) 
MRP2 Sulfate conjugates (Brand et al., 2006) 
MRP3 Hesperetin glucuronide (Brand et al., 2008) 
BCRP Hesperetin (Brand et al., 2008) 
MCT1 Ferulic acid (Konishi et al., 2002) 
MCT7 Ferulic acid (Konishi et al., 2002) 
SMCT1 Luteolin (Passamonti et al., 2009) 
 
In the first section of this review, the anatomical distribution of each transporter of interest 
was assessed. In the second part the transporters of interest were investigated for their 
response to different conditions.  
The comprehensive database, can be found in Appendix I and II. All the relevant 
information about the data discussed in this review (e.g. sample type, statistical relevance 
and material used) was extracted from Genevestigator and is provided in the databases. 
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3.3. Methodology 
3.3.1. Tool definition 
The bioinformatic tool Genevestigator (https://www.genevestigator.com/gv/) (Zimmermann 
et al., 2008) was used to extract all the data. Each gene of interest was investigated for 
anatomical distribution and expressional modulation, individually. 
Genevestigator provides information about gene expression in a wide range of organisms. 
For the creation of the present database data mining was performed for Homo sapiens, thus 
all the data discussed in the present review come from experiments carried out using human 
samples or human cell lines.  
 
3.3.1.1. Data normalisation in Genevestigator 
Genevestigator hosts data from multiple platforms. Data come from a variety of different 
experiments which use multiple types of tissues, experimental designs and data integrations. 
In order for all the data provided to be comparable with each other normalisation is 
essential. Genevestigator uses Robust Multi-array Average (RMA) normalisation, which is 
based on the measurement of the probe-level expression of all the arrays in a study to 
estimate expression values (Gentleman et al., 2004). RMA includes also background 
correction.  After normalisation, it is possible to perform meta-analysis across thousands of 
experiments and to integrate data from a variety of different experimental sources. 
For the signal intensity values arbitrary units are used, these are scaled to the total 
abundance of transcripts in a sample. The background range is between 0 and 100, 
depending on the probe set, organism used and type of array. Signal intensity above 100 
means significant presence of a certain transcript, while if values are below 100 transcripts 
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are considered absent, because of the impossibility to clearly discriminate from background 
noise.  
 
3.3.1.2. Evaluation of the anatomical distribution 
The Anatomy tool allows to look at the results of experiments obtained using healthy 
cultured cells and healthy human tissue samples. Cancerous tissues are excluded.   
Each value displayed in Genevestigator represents the mean of all the results obtained using 
a certain tissue/cell type. Details on the number and type of samples used and of the 
standard error values are given in Appendix I. 
 
3.3.1.3. Evaluation of the expressional modulation - choice of modulatory 
conditions 
For the analysis of transporter modulation, results are reported in Genevestigator as the ratio 
between the mRNA values from the treated sample and the mRNA from the control sample, 
untreated.  
For the comprehensive database and for the present review chapter the following 
modulatory conditions were selected: chemicals and drugs, disease (cardiovascular and 
metabolic diseases and afflictions of the gastrointestinal system) and chemical mediators 
(cytokines/growth factors and hormones). These conditions were chosen as they all relate to 
the research interests of the biochemistry group where my PhD project was carried out. The 
main focus of interest of the group was to better understand and characterise the link 
existing between the modulation of human transporters and alterations of the cell 
physiology, resulting from degenerative pathologies. It was also of interest to understand the 
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effect of human dietary compounds on human transporters, with specific focus on 
polyphenols, because of their proved role in protecting against degenerative disease (Botden 
et al., 2011, Mukunda et al., 2012). Chemicals and drugs have high importance in terms of 
cell physiology, members of these two classes strongly impact on the expression of all 
transporters (Rausch-Derra et al., 2001). Cardiovascular and metabolic disease is strictly 
connected to oxidative stress, since it has been shown that oxidative stress is a major cause 
of degenerative disease (Usberti et al., 2002, Khan, 2012). The gastrointestinal system plays 
a crucial role in the metabolism of all the ingested compounds (including polyphenols) and 
is an incredibly rich site of transporters (Chiou et al., 2001). It has been shown that 
gastrointestinal tract disease impact on the distribution of nutrients across all the biological 
organs, due to transporter expression and function alteration (Kovacs et al., 2007). Finally, it 
has been shown that biological mediators greatly impacts on the expression of transporters 
across membranes and on the overall cell physiology (Attali et al., 1997).    
 
3.3.1.4. Choice of probes 
When measuring gene expression using microarrays, different sets of probes are used, 
randomly located on the array and more or less specific for the gene of interest. In general a 
gene is represented by 11-16 probes of 25 nucleotides. Genevestigator presents all the 
available probes for the user to choose. Probes have different specificity, so that the user can 
choose to look at more or less specific results. When investigating gene modulation for this 
review, results were filtered so that the most specific available probes were selected for each 
gene of interest. In a very few cases, probes that were highly specific for a certain gene 
could not be found. In such cases, less specific probes were selected (e.g. probes specific for 
a motif recurrent in multiple genes within the same family).  
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3.3.1.4.1. Types of probes available in Genevestigator 
In Genevestigator all probes carry an extension. The most specific probes, targeting 
nucleotidic sequences unique for a gene of interest, have either _at (anti-sense target) or _st 
(sense target). The _at extension is the most recurrent, while _st is found more rarely. When 
probes carrying _at or _st extensions existed for the genes of interest, they were the ones 
selected for the comprehensive database. 
Below is a list of extensions, representing less specific probes compared to _at and _st 
(specificity decreases from top to bottom): 
 _s_at (or_s_st): probe sets where transcripts from different genes share common probes, 
_a_at (or _a_st): probe sets recognising more than one transcript for a gene, 
_x_at (or _x_st): rules of cross-hybridisation dropped, high risk of cross-hybridisation, 
_g_at (or _g_st): similar genes, 
_f_at (or _f_st): rules of similarity dropped, more than one gene will be recognised, 
_i_at (or _i_st): sequences with less than 11 or 16 unique probes. 
 
3.3.2. Statistical analysis 
Results were considered statistically significant when the p value was < 0.05.  
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3.4. Review 
3.4.1. Tissue distribution 
The tissue distribution of human transporters varies, not only from one family to another, 
but also within families. According to their specific function, transporters are localised on 
the apical or on the basolateral side of the biological membranes. The same transporter can 
have a different localisation depending on the tissue where it is expressed. Variation in the 
distribution of transporters mainly depends on substrate specificity and on the tissues where 
the substrates are metabolised and transported. Having information on the relative 
abundance and distribution of transporters is very useful to predict the function(s) of the 
transported substrates and the biological processes they are involved in. 
 
3.4.1.1. Organic anion transporters - OAT1 and OAT3 
OAT1 and OAT3 showed to be abundantly expressed only in the basolateral membrane of 
the kidney proximal tubules. In this organ, they transport compounds from the blood into 
the proximal tubule cells. In kidney cells, OAT1 was expressed at higher levels compared to 
OAT3 (Fig. 3-1). 
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Figure 3-1. Anatomical distribution of the OAT transporters. Expression is shown for 
OAT1 (a) and OAT3 (b), using the following filling patterns: dots for the renal/urinary 
system, dark vertical for the liver/biliary system, small checker board for the cardiovascular 
system and large grid for the intestine. 
 
 
 
 
 
 
Chapter 3: A review of transporter distribution and modulation 
 
68 
 
a. 
b. 
 
 
70681 
26778 
8064 
913 792 919 740 
0 
10000 
20000 
30000 
40000 
50000 
60000 
70000 
80000 
S
ig
n
al
 in
te
n
si
ty
 
22996 
34987 
13786 
961 1372 1503 954 
0 
10000 
20000 
30000 
40000 
50000 
60000 
70000 
80000 
S
ig
n
al
 in
te
n
si
ty
 
Chapter 3: A review of transporter distribution and modulation 
 
69 
 
3.4.1.2. Organic anion transporting polypeptides - OATP1A2, OATP1B1, 
OATP1B3 and OATP4C1  
Among the OATPs, OATP1A2 was the transporter with the lowest levels of expression 
(signal intensity was below 300 in all the investigated tissues, apart from the cardiovascular 
system where it was slightly above 300). OATP1A2 was the only OATP expressed in the 
cardiovascular system. OATP4C1 was the only OATP expressed in the kidney. Finally, 
OATP1B1 and OATP1B3 were only expressed in the liver, with OATP1B3 being the most 
abundant (Fig. 3-2).  
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Figure 3-2. Anatomical distribution of the OATP transporters. Expression is shown for 
OATP1A2 (a), OATP1B1 (b), OATP1B3 (c) and OATP4C1 (d), using the following filling 
patterns: dots for the renal/urinary system, dark vertical for the liver/biliary system, small 
checker board for the cardiovascular system and large grid for the intestine. 
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3.4.1.3. ATP-binding cassette transporters - MRP2, MRP3 and BCRP 
Among the ABCs, MRP3 displayed to be ubiquitously expressed in the tissues of interest. 
MRP3 was the ABC expressed at the lowest levels: signal intensity was below 500 in the 
kidney, liver and intestine and slightly above 500 in the cardiovascular system. Among the 
ABCs, MRP2 was the transporter expressed in the smallest number of tissues, mainly found 
in liver and kidney. The main site of expression was the liver, followed by the kidney. 
Finally BCRP showed the highest levels of expression in the intestine, followed by the liver, 
which displayed slightly lower abundance compare to the intestine (Fig. 3-3). 
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Figure 3-3. Anatomical distribution of the ABC transporters. Expression is shown for 
MRP2 (a), MRP3 (b) and BCRP (c), using the following filling patterns: dots for the 
renal/urinary system, dark vertical for the liver/biliary system, small checker board for the 
cardiovascular system and large grid for the intestine. 
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3.4.1.4. Monocarboxylate transporters – MCT1, MCT7 and SMCT1 (sodium-
coupled monocarboxylate transporter). 
MCT1 and MCT7 were both ubiquitously expressed in the tissues of interest. The 
expression levels of MCT7 were higher than those of MCT1 in all the tissues investigated, 
except for the heart atrium, where MCT1 was more abundant than MCT7.  
MCT1 displayed the highest levels of expression in the intestine followed by the heart , 
while the richest site of expression for MCT7 was the liver. SMCT1 also was found 
ubiquitously expressed, though expression was lower compared to MCT1 and MCT7. 
SMCT7 was most abundant in the small intestine and in the vascular components of the 
cardiovascular system (Fig. 3-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: A review of transporter distribution and modulation 
 
78 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Anatomical distribution of the MCT transporters. Expression is shown for 
MCT1 (a), MCT7 (b) and SMCT1 (c), using the following filling patterns: dots for the 
renal/urinary system, dark vertical for the liver/biliary system, small checker board for the 
cardiovascular system and large grid for the intestine. 
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3.4.2. Transporter modulation 
3.4.2.1. Modulation of transporters in response to disease, biological mediators, 
chemicals and drugs 
Overall a variety of conditions displayed to modulate the transporters of interest. OAPT1B3 
and BCRP were modulated from the highest number of conditions, among the uptake and 
efflux transporters, respectively. Change in their expression was triggered by 38 and 54 
conditions, respectively. OATP1A2 and SMCT1 were the least affected transporters, among 
the uptake and efflux, respectively. A total of 15 and 25 conditions triggered modulation of 
the expression of these two transporters, respectively.  
Among the transporters of interest, the efflux transporters resulted to be generally more 
responsive to modulation than the uptake transporters.  
All the selected genes of interest belong to the transporter gene clusters. For this reason, 
generally data came from experiments were they were all investigated at once under the 
same modulating conditions. Since the total number of conditions used as modulators were 
the same for each of the transporters included in the database, the overall responsiveness of 
transporters is comparable.  
Table 3-2 reports the number of disease, biological mediators, chemical and drugs 
modulating each transporter. 
In the sessions below, the modulation of each class of transporters is discussed individually. 
The details on the data source and samples used for transporter modulation are given in 
Appendix II. 
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Table 3-2. Number of conditions triggering transcriptional change in the genes of 
interest.  
                      Number of conditions affecting transcription 
Transporter  
Chemicals 
and  
Drugs 
Diseases 
Growth factors and 
cytokines 
Hormones 
 
Total 
OAT1 
 
13 1 3 2  19 
OAT3 
 
14 4 1 1  20 
OATP1A2 
 
9 2 4 0  15 
OATP1B1 
 
15 2 3 0  20 
OATP1B3 
 
26 4 5 3  38 
OATP4C1 
 
15 6 4 5  30 
MRP2 
 
25 3 9 0  37 
MRP3 
 
23 2 7 3  35 
BCRP 
 
31 5 7 11  54 
MCT1 
 
39 3 10 9  61 
MCT7 
 
20 5 14 10  49 
SMCT1 19 2 2 2  25 
 
3.4.2.1.1. Modulation of the OATs (OAT1 and OAT3) 
OAT1 and OAT3 showed to be modulated from a small range of conditions: a total of 19 
and 20 for OAT1 and OAT3, respectively. Both responded mostly to chemicals and drugs. 
Not many food components were found to be used as modulators, highlighting the limited 
knowledge existing to date on the effect of dietary components on transporters. The only 
food compounds tested on OAT1 and OAT3 were apple procyanidin and curcumin. Apple 
procyanidin is a natural phenol, known from previous studies for its anti-inflammatory and 
anti-neoplastic properties (Alaikov et al., 2007, Malik et al., 2009). Both compounds were 
individually used to treat human proximal tubule cells and showed no effect on the 
expression of OAT1 and OAT3 (data not shown). 
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All the chemicals and drugs tested resulted in up-regulation of OAT3. The main up-
regulatory effect was observed after treating DU145 (human prostate cancer) cells with the 
anti-neoplastic R547. Treatment resulted in a 1.38-fold increase in the mRNA levels of 
OAT3.  
OAT1 also responded to a wide range of chemicals, which predominantly triggered up-
regulation. The highest up-regulation was observed following treatment of OPM-1 (human 
myeloma) cells with the anti-myeloma compound zalypsis (1.53-fold change). Down-
regulation of OAT1 was only triggered by treatment of bone marrow stromal cells with the 
phosphatase inhibitor β-glycerophosphate and with the drug AM580, respectively. The 
former treatment triggered a 1.17-fold change, while the latter induced a 1.13-fold change. 
Among the tested biological mediators, OAT3 expression was up-regulated from three 
cytokines: IL-22, IL-24 (interleukin 22 and 24) and G-CSF (granulocyte colony-stimulating 
factor). IL-22 and Il-24 were used to treat neonatal epidermal keratinocytes and showed to 
induce a 1.19- and 1.14-fold change on OAT3, respectively. G-CSF was used on leukocytes  
and induced a 1.20-fold change on OAT3. OAT1 was down-regulated by IL-17 (1.41-fold 
decrease) when treating aortic vascular smooth muscle cells. The hormone 17-β-estradiol 
had opposite effects on OAT3 and OAT1 expressed in MCF-7 (breast cancer) cells, down-
regulating OAT3 and up-regulating OAT1 (1.17- and 1.29-fold change, respectively). 
All the conditions modulating transcription of OAT1 and OAT3 are shown in figure 3-5.
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Figure 3-5. Modulation of the OATs. Modulation is shown for OAT1 (a) and OAT3 (b), 
using the following filling patterns: dots for chemicals and drugs light vertical for biological 
mediators, small checker board for disease.
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a. 
-2 -1.5 -1 -0.5 0 0.5 1 1.5 2 
AM580 
β-glycerofosfate (intermediate) study 2 
β-glycerofosfate (late) study 2 
BPDE study 2 
Echinomycin/Deferoxamine 
PMA study 5 
R547 (6h) 
R547 (24h) study 5 
R547 (6h) study 5 
R547 (1h) study 6 
R547 (24h) study 7 
Sapphyrin PCI-2050 
Sapphyrin PCI-2002 study 2 
Zalypsis study 2 
Hypertrophic cardiomyopathy 
Viral cardiomyopathy 
Ischemic cardiomyopathy  
Ischemic cardiomyopathy (after VAD) 
Il-17 
17-β-estradiol (intermediate) study 10 
Fold change 
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b. 
-1.5 -1 -0.5 0 0.5 1 1.5 2 
BPDE study 2 
Cadmium 
Doxycycline 
Ciclosporin study 2 
Sirolimus 
Calcitriol 
Echinomycin/Deferoxamine 
Lypopolysaccharide 
R547 (4h)-study 4 
R547 (6h)- study 4 
R457 (4h)-study 5 
R547 (4h)-study 6 
Sapphyrin PCI-2050 
Diabetes study 2 
G-CSF 
IL-22 
IL-24 
17-β-estradiol study 10 
17-β-estradiol study 11 
Fold change 
Chapter 3: A review of transporter distribution and modulation 
 
87 
 
3.4.2.1.2. Modulation of the OATPs (OATP1A2, OATP1B1, OATP1B3 and 
OATP4C1) 
Among the OATPs, OATP1A2 was the least responsive to modulation, responding to 15 
conditions. OATP1B1, OATP1B3 and OATP4C1 were modulated from 20, 38 and 30 
conditions respectively.  
Apple procyanidin and curcumin were the only food compounds tested on the OATPs. 
Curcumin tested alone induced a 1.12-fold increase on OATP1A2, expressed in U937 
(human leukemic monocyte lymphoma) cells. Curcumin, used to treat U937 cells, acted as a 
down-regulator of OATP1B1, when it was used after pre-treatment with the stressor 
hydrogen peroxide (H2O2). It is noteworthy to mention that pre-treatment with H2O2 
decreased OATP1B1 expression inducing a 1.23-fold decrease and that subsequent 
treatment with curcumin reverted this effect, inducing a 1.23-fold increase on OAT1B1.  
Among the OATPs, OATP1A2 was the least modulated by chemicals. On the contrary, 
OATP1B3 was the OATP affected by the largest number of chemicals. 
The biggest change triggered from a biological mediator was observed on the expression of 
OATP1B3. When ASPC-1 (metastatic pancreas cancer) cells were treated with the stromal 
cell-derived factor 1 (SDF-1) OATP1B3 showed a 4-fold increase.  
Multiple drugs showed to affect expression of OATP1B3, mainly up-regulating it. 
Significant up-regulation was observed on U251 (astroglioma) cells treated with the 
chelating agent deferoxamine (2.20-fold change). Up-regulation was also triggered form 
treatment with a range of other chemicals, such as 5-aza-2’deoxycitidine (an inhibitor of 
DNA methylation) applied to bronchial epithelial cells and R547, used on DU145O (1.47- 
and 1.42-fold change respectively). On the contrary, OATP4C1 resulted to be 
predominantly down-regulated from chemical compounds. For example, treatment of 
monocytes with PMA (phorbol myristate acetate) triggered a 2.5-fold decrease on 
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OATP4C1. Among the OATPs, OATP1B3 was the most responsive to modulation by 
chemicals.  
Among the biological mediators, none of the tested hormones affected OATP1A2 or 
OATP1B1, while OATP4C1 expressed in MCF-7 cells was down-regulated (1.85-fold 
change) after treatment with 17-β-estradiol. The hormone 17- β-estradiol also down-
regulated OAT1B3, expressed in MCF-7 cells, triggering a 1.19 fold change.  
A small range of cytokines and growth factors affected the expression of the OATPs. 
OATP1A2 underwent a 1.15-fold decrease after treatment with IL-20 in neonatal epidermal 
keratinocytes. OATP1B1, OATP1B3 and OATP4C1 showed to be mainly down-regulated 
form the tested cytokines. The main down-regulatory effect was observed on OATP1B3, 
expressed in metastatic mammary gland cells, following treatment with SDF-1 (4.17-fold 
decrease).  A major effect (2-fold increase) was also observed on OATP4C, after treatment 
of leukocytes with the G-CSF. 
All the conditions modulating transcription of OATP1A2, OATP1B1, OATP1B3 and 
OATP4C1 are shown in figure 3-6. 
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Figure 3-6. Modulation of the OATPs. Modulation is shown for OATP1A2 (a), OATP1B1 
(b), OATP1B3 (c) and OATP4C1 (d) using the following filling patterns: dots for chemicals 
and drugs light vertical for biological mediators, small checker board for disease. 
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b.
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BPDE (intermediate) study 2 
BPDE (late) study 2 
Curcumin/hydrogen peroxide (early) 
Actinomycin D 
Gefitinib 
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Cycloheximide 
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R547 (2 h) study 6  
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BPDE (intermediate) study 2 
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Mifepristone/dexamethasone 
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Calcitriol (early) 
Calcitriol (late) study 2 
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PMA study 2 
R547 (2 h)  
R547 (24 h) study 2 
R547 (2 h) study 3 
R547 (24 h) study 6 
Fold change 
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c.2  
-5 -4 -3 -2 -1 0 1 2 3 
R547 (2 h) study 6 
R568 (early)  
R568 (late) study 2 
Sapphyrin PCI-2050 
Sapphyrin PCI-2050 study 2 
Sapphyrin PCI-2002/ZnOAc2 
Ischemic cardiomyopathy (after VAD) 
Unstable angina (30 d)/unstable angina (7 d) 
Barrett's esophagus (acid) (late) study 2 
Ulcerative colitis study 4 (Inflamm.) 
BMP-2 (late) 
G-CSF 
SDF study 2 
SDF study 4 
TNF-α 
17β-estradiol study 8 
Estrogen (intermediate) 
Fold change 
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d.1 
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5-aza-2'-deoxycitidine/TSA study 5 
Gefitinib 
Peginterferon study 4 
Tibolone 
Lipopolysaccharide study 3 
PMA study 2 
PMA study 2 (shRNA contr.) 
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R547 study 6 (24 h) 
Sapphyrin PCI-5003 
Idiopathic dilated cardiomyopathy 
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d.2 
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Viral cardiomyopathy 
Ischemic cardiomyopathy 
Ischemic cardiomyopathy (after VAD) 
G-CSF 
SDF study 4 
TGF-β3 (intermediate)/ BMP-2 study 2 
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17-betaestradiol (early) study 10 
17-betaestradiol (intermediate) study 10 
17-betaestradiol (late) study 10 
17-betaestradiol study 8 
Estradiol 
Fold change 
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3.4.2.1.3. Modulation of the ABCs (MRP2, MRP3 and BCRP)  
Among the ABCs, MRP3 and BCRP were the least and the most modulated transporter, 
respectively. The total number of conditions affecting expression was 37 for MRP2, 35 for 
MRP3 and 54 for BCRP.  
As for the other transporters discussed so far, apple procyanidin and curcumin were the only 
food compounds tested. Neither apple procyanidins nor curcumin had any effect on MRP2 or 
MRP3 (data not shown). BCRP showed a 1.23-fold decrease when HUVEC (human umbilical 
vein endothelial) cells were treated with apple procyanidin, applied to cells following pre-
incubation with the stressor TNF-α (tumor necrosis factor-α). Pre-incubation with TNF- α up-
regulated BCRP (1.23-fold increase), subsequently incubation with apple procyanidins 
reverted the effect of the tumor necrosis factor. It is noteworthy that treatment of HUVEC 
cells with apple procyanidins alone (without pre-incubation with TNF- α) triggered no change 
in the mRNA levels of BCRP.  
Multiple chemical compounds affected the expression of the ABC transporters. A significant 
effect (64-fold increase) was observed on BCRP when treating ASPC-1 cells with PMA. 
PMA also up-regulated MRP2 in ASPC-1 cells (5-fold change).  
On the contrary, PMA slightly down-regulated MRP3 in monocytic cells, triggering a 1.04-
fold change. The main up-regulatory effect on BCRP was observed when treating MCF-7 
cells with the anti-diabetic drug rosiglitazone (7-fold increase), while the biggest response 
triggered on MRP2 (3.13-fold increase) was observed after treatment of melanoma cells with 
the apoptosis-inducer elesclomol.  
The transcriptional levels of MRP2 were not affected from any of the tested hormones, while 
MRP3 was down-regulated by all the tested hormones. Transcription of BCRP was altered the 
most after treatment with 17 –β-estradiol, resulting in a 2.15-fold increase when MCF-7 cells 
were treated. 
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A range of cytokines and growth factors affected the expression of MRP2, MRP3 and BCRP. 
An example is the TGF- β (transforming growth factor β), that triggered a 9- and a 13-fold 
increase in MRP2 and BCR, respectively, in A549 (adenocarcinomic human alveolar basal 
epithelial) cells.  Overall MRP2 was the ABC affected by the largest number of cytokines and 
growth factors, with an inconsistent pattern of modulation. MRP3 and BCRP mainly resulted 
in up- and down-regulation, respectively, when exposed to growth factors and cytokines. 
All the conditions modulating the transcription of MRP2, MRP3 and BCRP are shown in 
figure 3-7. 
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Figure 3-7. Modulation of ABCs. Modulation is shown for MRP2 (a) MRP3 (b) and BCRP (c), 
using the following filling patterns: dots for chemicals and drugs light vertical for biological 
mediators, small checker board for disease. 
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Sapphyrin PCI-5002 study 2 
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17β-estradiol (early) study 10 
17β-estradiol (intermediate) study 10 
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17β-estradiol study 11 
17β-estradiol study 12 
17β-estradiol study 8 
17β-estradiol study 8 
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Estradiol (late) 
Fold change 
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3.4.2.1.4. Modulation of the MCTs (MCT1, MCT7 and SMCT1)  
Among this group of transporters, MCT1 and SMCT1 showed to  be the members 
responding to the largest and smallest number of conditions, respectively (61 and 25). Of 
the tested food compounds, apple procyanidin tested alone triggered a 1.56-fold increase on 
MCT1, expressed in HUVEC cells. Apple procyanidins affected the transcription of 
SMCT1in lymphatic cells, only when pre-treatment with TNF-α had been carried out. 
Treatment with the tumor necrosis factor resulted in a 1.18-fold decrease of the SMCT1 
mRNA levels and subsequent treatment with apple procyanidins reversed this effect, by 
triggering a 1.18-fold increase on SMCT1.   
A wide range of chemicals affected the mRNA levels of the MCTs. MCT1 resulted 
predominantly down-regulated, while MCT7 and SMCT1 were predominantly up-regulated. 
Of the tested compounds, the major effect was observed on MCT1 and MCT7 expressed in 
astroglioma cells, after co-incubation with the drugs deferoxamine and echinomycin. A 
2.95-fold decrease was observed for MCT1, while a 2.29-fold increase was observed for 
MCT7. Both MCT1 and MCT7, expressed in ASPC-1 cells, were down-regulated by PMA 
(1.94- and 1.52-fold decrease, respectively). 
A wide range of biological mediators modulated the transcription of MCT1 and MCT7, 
while a limited number of biological mediators affected SMCT1. MCT1 and SMCT1 were 
mainly up-regulated from the tested biological mediators, while MCT7 was down-regulated 
from all the tested hormones. The major effect was observed on MCT7, expressed in A549 
cells. When cells were treated with TGF-β a 14.63-fold increase in the mRNA levels of 
MCT7 was observed. All the conditions modulating the transcription of MRP2, MRP3 and 
BCRP are shown in figure 3-8. 
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Figure 3-8. Modulation of the MCTs. Modulation is shown for MCT1 (a) MCT7 (b) and 
SMCT1 (c), using the following filling patterns: dots for chemicals and drugs light vertical 
for biological mediators, small checker board for disease. 
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3.4.2.2. Transporter modulation from disease 
The following disease were considered as modulators for the genes of interest: 
cardiovascular and metabolic disease (such as infarction and diabetes) and affection of the 
gastrointestinal organs (such as ulcerative colitis).  
Overall the transporters of interest were not greatly affected from these conditions (fig. 3-5 
to 3-8). Among the transporters, the one affected by the largest number of disease was 
OATP4C1, which was mainly up-regulated from a range of cardiovascular pathologies. The 
least affected transporter resulted to be OAT3, which only responded to diabetes, with a 
1.34-fold decrease in T-cells. The overall pattern of regulation varies from one transporter to 
another and from one cell line to another when considering affections of the gastrointestinal 
organs. Transporters were mainly up-regulated, when looking at the effect of cardiovascular 
disease. Identifying which transporters are responsible for the inter-membrane transport of 
specific compounds would be a crucial step in improving post infarction treatment.  
 
3.4.3. Discussion and conclusions 
Modulation of transporters impacts on every biological process occurring within the cell. 
Understanding what compounds and how they affect expression of transporters could 
represent a vital tool to control selected cell functions. The final aim would be to enhance 
cellular health, by maximising health-promoting biological processes and minimising 
processes linking to cell damage and death. 
In this review the current knowledge on the anatomical distribution of selected transporters 
(OAT1, OAT3, OATP1A2, OATP1B1, OATP1B3, OATP4C1, MRP2, MRP3, BCRP, 
MCT1, MCT7, SMCT1) was investigated for the human heart, liver, kidney, and intestine. 
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Moreover, the up to date information on the transcriptional modulation of these transporters 
was reviewed. The information reviewed in the present work was obtained using the high-
performance search engine Genevestigator. Genevestigator contains information on the gene 
expression and modulation of a large number of genes and for multiple organisms, 
presented separately. All the data come from microarray experiments. 
The given information is a start point for future studies on transporter modulation and gives 
an overall picture of the sensitivity of each transporter to a range of selected conditions 
(chemicals and drugs, disease, growth factors and cytokines, hormones).   
Abundance of transporters within the organs of interest varies significantly. Some 
transporters, such as SMCT1, were ubiquitously expressed at low levels. Some others were 
localized in specific organs or organ parts, such as OATP1A2, which was only expressed in 
the heart and intestine. 
Certain drugs displayed an opposite effect on uptake and efflux transporters. An example of 
that was given by treatment with zalypsis, an antibiotic with anti-neoplastic activity (Ocio et 
al., 2009, Colado et al., 2011). Zalypsis showed to up-regulate uptake transporters, such as 
OAT1, and down-regulate efflux transporters, such as MCT1.  
It is worth of note the effect of PMA, observed when treating ASPC-1 cells. After treatment 
with PMA, the efflux transporters BCRP and MRP2 showed up-regulation. PMA triggered 
down-regulation of the uptake transporter OATP4C1, expressed in lymphocytic cells. PMA 
is a tumour-promoting agent (Yu et al., 2012), responsible for longevity of the neoplastic 
cells and for the vascularisation of cancerous tissues. In terms of cell physiology, the double 
effect of decreasing uptake and increasing efflux may explain the protective effect that PMA 
has on malignant cells and the resulting failure of anti-neoplastic agents when cells have 
been pre-exposed to PMA (Skinnider et al., 1984). 
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Interestingly, both the efflux transporter MCT1 and MCT7, expressed in ASPC-1 cells, 
were down-regulated by PMA. This apparent contradiction in the effect of PMA could be 
explained with the different roles of the transporters in physiological cell functions and with 
different substrates transported. 
Hormones, cytokines and growth factors are biological mediators known to play a major 
role from the early stages of human development. Therefore, being capable to identify the 
impact they have on transporters would represent a tool to control organ and tissue 
development and to fight a variety of diseases and dysfunctions. Examples of biological 
mediators are the TGF-α and TGF- β, which are involved in the regulation of many 
processes such as cell growth, immunity and cancer development (Kuranami et al., 1989, 
Erbas and Lai, 2000). This review showed that transporters responded differently to 
biological mediators, according to their role in the cell physiology. For example, the uptake 
transporter OATP1B3, expressed in metastatic mammary gland cells, showed down-
regulation following treatment with the SDF-1. The SDF-1 is a cytokine responsible for 
angiogenesis (Zhi et al., 2011), it is a crucial factor in the neovascularisation of cancerous 
tissues and it is believed to be responsible for metastasis formation (Gellmini et al., 2008). 
Major down-regulation of uptake transporters in response to SDF-1 could be associated with 
a decrease in the amount of chemotherapy drugs reaching the cancerous cells and thus with 
the resistance phenomena that lead to therapy ineffectiveness.  
An example of up-regulation was observed on the uptake transporter OATP4C, after 
treatment of leukocytes with the G-CSF, a factor responsible for production of granulocytes 
and stem cells and for the proliferation and differentiation of neutrophils (Rolando et al., 
2000). In terms of cell physiology, such effect agrees with the proliferation of new cells, 
Chapter 3: A review of transporter distribution and modulation 
 
 
117 
 
which is strictly linked to the necessity for more compounds to be transported into the 
dividing cells. 
When looking at the effect of disease, a consistent pattern of regulation was not observed. 
However, transporters were mainly up-regulated from cardiovascular disease. In vivo heart 
failure is linked to increased susceptibility to inflammatory diseases. This links to 
production of high levels of inflammatory molecules and subsequent cell damage (Fuchs 
and Drexler, 2004). It is possible that the physiological changes induced from heart failure 
are associated with an increased production of toxic compounds which is followed by 
increased efflux and transport of pro-inflammatory mediators out of the cell in the blood 
stream. This would finally contribute to promote inflammation. 
The initial aim of creating the present comprehensive database was to identify one or more 
transporters standing out for their response to food compounds. This information would 
have been a starting point in the choice of a target transporter and in testing further food 
compounds. Unfortunately, despite the large amount of data existing about the modulation 
of transporters in response to chemicals, not many food compounds had been tested as gene 
modulators, indicating a lack of knowledge associated with this increasingly important area 
of study. The only food components used were curcumin and apple procyanidin, either used 
alone or after pre-incubation with the stressors H2O2 or TNF-α. In the first study, U937 
cells were used to assess whether curcumin could revert the effect of hydrogen peroxide on 
selected genes. Cells were incubated with hydrogen peroxide for four hours and 
subsequently incubated for four hours with concentrations of curcumin up to 10 µM. Gene 
levels were investigated through microarrays before and after incubation with curcumin. 
Among the genes investigated were the 12 transporters of interest in this review. 
Interestingly only OATP1A2 and OATP1B1 expression was affected by hydrogen peroxide 
Chapter 3: A review of transporter distribution and modulation 
 
 
118 
 
and/or curcumin treatment. In the case of OATP1A2, hydrogen peroxide did not affect the 
expression levels, however treatment with curcumin up-regulated the mRNA levels by 1.12-
fold. In the case of OATP1B1, hydrogen peroxide up-regulated the gene by 1.23-fold, while 
treatment with curcumin completely reverted this effect. In the second study, HUVEC cells 
were incubated with the TNF-α for four hours and subsequently incubated with 10 µg/ mL 
apple procyanidins for four more hours. Microarray analysis was performed to assess the 
response of selected genes to the stressor and subsequently to the polyphenol. Among the 
genes investigated were the 12 transporters of interest in this review. Only three of these 
transporters responded to treatment with apple procyanidins, BCRP, SMCT1 and MCT7. 
The TNF-α up-regulated BCRP by 1.23-fold and down-regulated SMCT1 by 1.18-fold, 
subsequently apple procyanidins completely reverted this effect. In the case of MCT7, the 
stressor did not affect the gene expression, while treatment with apple procyanidins up-
regulated the mRNA by 1.56-fold. It was interesting to note that curcumin and apple 
procyanidins reverted the gene expression of selected uptake and efflux transporters, 
respectively. These two articles confirm the activity of polyphenols as antioxidants. It is 
possible that they have little effect on healthy cells, but major effect when oxidative stress is 
triggered. It is possible that modifications of the cell physiology, triggered by oxidative 
stress, link to activation of protective pathways involving polyphenols, as oxidative stress 
suppressors. A proposed mechanism for the activity of polyphenols is that they bind to 
specific factors, involved in protecting the cell against oxidative stress. This hypothesis 
would be in agreement with the in vivo study from Cao et al. (Cao et al., 2007), assessing 
the effect that phenolic green tea extract have on glucose transporters (Glut1/Slc2a1, 
Glut2/Slc2a2, Glut3/Slc2a3, and Glut4/Slc2a4). In this study rats were fed for 6 weeks 
green tea extracts (1 or 2 g/kg diet) and their diet was supplemented with high levels of 
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fructose levels, a known inducer of oxidative stress (Blond et al., 2011). The liver was then 
dissected and used to investigate the transporters of interest through RT-PCR. Results 
showed that 1 g of green tea/kg diet increased Glut1 and Glut4 expressed in the liver by 110 
% and 160 % respectively, while 2 g of extracts increased Glut4 mRNA levels found in the 
liver by 90 % and Glut2 and Glut4 mRNA levels found in the muscle by 80 % and 40 %, 
respectively.   
Uptake and efflux transporters have gained increasing attention in the last decades (Page et 
al., 2001). Further analysis of transporter function(s) and mechanism(s) of action, in 
response to modulatory conditions, are necessary. This review is a starting point to better 
understand some of these objectives.  
A comprehensive database, reporting anatomical distribution of the selected transporters and 
the conditions modulating the genes of interest can be found in Appendix I and II. 
 
3.5. Conclusions 
The present review aimed to collect information on the anatomical distribution and 
modulation of 12 transporters of interest. Some of the transporters resulted to be 
ubiquitously expressed in the human organs investigated (kidney, liver, heart and intestine), 
such as BCRP. Some others were only significantly expressed in one specific tissue, such as 
OAT1, which was only expressed in the kidney proximal tubules. Transporters responded 
differently to a range of conditions. Interestingly not many food compounds had been tested 
as modulators. The only two food compounds tested were curcumin and apple procyanidins. 
They were both used to revert the effect of stressors (hydrogen peroxide and the tumor 
necrosis factor α, respectively). It was observed that the two polyphenols were able to revert 
the effect of the stressors. This was at the basis of the next chapter, where stressors 
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(hydrogen peroxide, ethanol and tert-butyl-hydroperoxide) would be used as potential 
modulators of the organic anion transporter 3. The aim of the next chapter would be to 
identify stressors acting as modulators of OAT3 and subsequently to identify polyphenols 
able to revert the effect of the stressors.  
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Chapter 4  
Modulation of the Organic Anion transporter 3 and assessment of 
kaempferol- 3-O-glucuronide uptake in liver model HepG2 cells 
 
4.1. Abstract 
The aim of the present work was to assess the effect of selecting stressing agents on the 
organic anion transporter 3 (OAT3) and to characterise the uptake mechanism(s) of 
kaempferol-3-O-glucoronide in the liver model HepG2 cells.  
Expression of OAT3 in the cell model was initial assessed, through RT-PCR. The work 
showed for the first time that OAT3 is expressed in HepG2 cells.  
Subsequently the effect of selected stressors (hydrogen peroxide, tert-butyl-hydroperoxide 
and ethanol) on the expression and function of OAT3 was assessed. Cells were treated with 
the stressing agents for 8-12 h. Subsequently, in order to assess expressional modulation of 
OAT3, RNA extraction was performed and RT-PCR carried out. Alternatively, to assess 
functional modulation, cells were incubated with a model substrate (5’-carboxyfluorescein), 
after the incubation with the stressing agents. Intracellular levels of 5’-carboxyfluorescein 
were measured through HPLC and compared to the levels in control, untreated, cells. None 
of the stressors showed to affect the expression and/or function of OAT3. 
In order to characterise the uptake mechanism(s) of kaempferol-3-O-glucuronide in HepG2 
cell, LC-MS was used to measure the metabolite uptake. Time-, concentration- and 
temperature-dependency of the uptake were assessed. Kaempferol-3-O-glucuronide showed 
to be mainly taken up via active transport (Km and Vmax were 143 µM and 2.2 pmol/min 
respectively). 
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4.2. Chapter summary 
 The first aim of the present work was to determine whether the liver model HepG2 
cells expressed OAT3. RT-PCR was used. The Ct value for OAT3 was 33, while 
the Ct value for the housekeeping gene GAPDH was 16, suggesting a low 
expression profile for OAT3. 
 Subsequently it was investigated whether selected stressing agents modulated 
OAT3 expression and/or function in HepG2 cells. 
The stressing agents selected were hydrogen peroxide, tert-butyl-hydroperoxide and 
ethanol. The stressing agent concentrations to be used were chosen on the basis of 
preliminary cytotoxicity assessments, using two methods: the lactate dehydrogenase 
assay and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.  
RT-PCR was performed to assess expressional modulation. Functional modulation 
was assessed through intracellular quantification of the model substrate 5’-
carboxyfluorescein, through HPLC.  
None of the tested stressing agents were shown to modulate OAT3 expression or 
function. 
 The final aim of the work was characterise the uptake of the metabolite kaempferol-
3-O-glucuronide in HepG2 cells. Time-, concentration- and temperature-
dependence of the uptake were assessed, by measuring the intracellular levels of the 
metabolite through LC-MS. It was shown that kaempferol-3-O-glucuronide was 
taken up in a time-, concentration- and temperature-dependent manner. These 
results suggested that kaempferol-3-O-glucuronide uptake most likely occurred via 
active transport. The Km and the Vmax were 143 µM and 2.2 pmol/min 
respectively. 
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4.3. Introduction 
4.3.1. Role of human liver in detoxification 
The liver is the main organ for detoxification in the body. A large and complex range of 
enzymes present in the liver transforms fat-soluble toxins into water-soluble ones. The latter 
can be eliminated in the urine or bile, according to the specific features of the end-product. 
As a primary site of detoxification, the human liver plays a major role in maintaining cell 
integrity (Ramaccioni et al., 2000, Schmidt et al., 2010).  
It is important to understand what are the modifications triggered by oxidative stress on the 
liver cell physiology and how dietary compounds can be determinant in maintaining the 
balance and ensuring correct functioning of the hepatocytes (fig. 4-1). 
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Figure 4-1. Schematic representation of the human liver, showing its functions and 
role in nutrient and non-nutrient processing and detoxification.   
 
Oxidative agents, such as hydrogen peroxide (H2O2) and tert-butyl-hydroperoxide (t-
BOOH), have been proved to cause cell damage and, in case of prolonged exposition, 
degenerative disease and death (Gutierrez-Ruiz et al., 1999, Van de Bittner et al., 2010, 
Fedotcheva and Mokhova, 2013). It is been hypothesized that oxidative stress impacts on 
cell health in various ways including by affecting transporter expression and/or activity 
(Ikemura et al., 2009).  
A wide range of uptake transporters is expressed in the human hepatocytes. Among them 
are several members of the OATPs and one member of the OATs, OAT2. OAT3 has been 
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shown to be highly expressed in the kidney but does not appear to be expressed in the liver 
(Hilgendorf et al., 2007a).  
4.3.1.1. OAT3 gene structure and gene regulation  
To better understand the biological processes leading to transporter modulation, an analysis 
of gene structure is crucial. The gene structure of OAT3 is not yet fully characterised (fig. 4-
2).  
Previous published work on OATs exist, investigating the gene sequences and their 
regulation. Regulation of the OAT3 gene, SLC22A8, has been previously investigated 
(Ogasawara et al., 2006). Cells from opossum were used to clone the SLC22A8 promoter 
and to perform functional promoter assays. The study showed that both basal and inducible 
activity of the SLC22A8 promoter depended on the activity of the cAMP response element 
(CRE). Two transcription factors were also involved, CREB-1 (cAMP response element 
binding 1), and ATF-1 (activating transcription factor 1). They were shown to act by 
dimerising and binding to CRE.  
PKCs (protein kinase C) are isozymes involved in signal pathways regulating many 
processes, such as cell growth (Hirai and Chida, 2003). Different second messengers are 
required for their activation. On the basis of the second messengers required, the PKCs can 
be divided in three types: classical, novel and atypical.  
A study on gene regulation of organic anion transporters showed that OAT1 and OAT3 
were up-regulated through a pathway involving PKCζ, an atypical PKC (Barros et al., 
2009). The experiment was carried out using two sets of renal cortical tissue slices from rats 
over-expressing OAT3 and OAT1 respectively. When cells were treated with insulin, a 
PKCζ inducer, OAT1- and OAT3-mediated uptake increased. In cells treated with a PKCζ 
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inhibitor, transport of OAT1 and OAT3 substrates was inhibited. This confirmed PKCζ-
dependent activation of OAT1 and OAT3.  
The authors also assessed the role of ATF-1 in gene expression. They showed that ATF-1 
alone did not activate gene expression, despite dimerising with CREB-1. In contrast, gene 
expression was activated when ATF-1 combined with PKA. It was also shown that 
phosphorylation of CREB-1 and ATF-1 by PKA resulted in increased promoter activity and 
gene expression.  
A study published in 2006 (Kikuchi et al., 2006) showed the crucial role of the human 
nuclear factor 1 (HNF1) in regulating the expression of OAT3. HNF1 is a homeodomain-
containing factor, consisting of two isoforms, HNFα and HNFβ. HNF1 is expressed in a 
wide range of organs, including liver and kidney (Saji et al., 2008). In the study, promoters 
were used to identify the functional region of the SLC22A8 promoter. It was shown that the 
region between -308 and +6 is essential for promoter activity. Homology of this region 
between different mammalian (human, rat and mouse) was also investigated, showing that 
almost 70 % homology exists. The authors assessed that the structure of the two isoforms of 
HNF1 enabled, with the same probability, both homodimer and heterodimer formation. 
Both complexes are likely to form in vivo. However, the transactivation potency of HNFα 
was shown to be higher than that of HNFβ. In this study the importance of promoter 
methylation for gene expression was also investigated. The authors analyzed different 
tissues, some expressing OAT3 and some not expressing it, and observed that the gene was 
present in both tissues. However they observed that in the tissues not expressing the 
corresponding protein, the gene promoter was hypermethylated. In contrast, in the tissues 
expressing the protein, the promoter was hypomethylated. Authors concluded that 
methylation is a key mechanism to control tissue-specific gene expression.  
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Figure 4-2. Characterized promoter regions on the OAT3 (SLC22A8) gene promoter.  
 
4.3.2. Kaempferol-3-O-glucuronide uptake in HepG2 cells 
4.3.2.1. Kaempferol: metabolism and impact on human health 
Kaempferol (fig. 4-3) is a flavonoid abundant in a variety of foods. Examples of kaempferol 
sources are tea, broccoli, grapefruit, cabbage and strawberries. The mean intake for 
kaempferol has been determined to be around 4.7 mg/day (Radtke et al., 2002).  
Reports showed that among flavonols, kaempferol is the second biggest contributor to the 
human diet, after quercetin (Sampson et al., 2002). Preclinical studies have suggested that 
kaempferol and its metabolites are associated with a range of pharmacological activities, 
such as anti-cancer, cardio-protective and anti-inflammatory activities (Jeong et al., 2009, 
Sun et al., 2013). An in vivo study showed a significant decrease in pancreatic cancer risk in 
smokers consuming kaempferol, quercetin and myricetin on a daily basis for eight years 
(Nothlings et al., 2007). Kaempferol and quercetin have high structural similarity, the only 
difference is that quercetin has two hydroxyl group substitutions (3 and 4) on the 2’ benzyl 
group, while kaempferol has only one hydroxyl group (4) on the 2’ benzyl group (Fig. 4-3).  
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Figure 4-3. Chemical structure of quercetin and kaempferol. 
 
Whilst numerous studies have focused on understanding the mechanisms of quercetin 
uptake and efflux (Petri et al., 2003, Scalia et al., 2013, Glaeser et al., 2014), little is known 
about kaempferol and kaempferol metabolite transport in and out of cells or about their 
bioavailability (Liu et al., 2006).  
Kaempferol in nature is often found in the form of glycosides. The relative abundance of 
these glycosides varies between members of the pant kingdom (Iwashina et al., 2010). 
After kaempferol ingestion, metabolism of this compound is extensively carried out in the 
liver. Gluco- and sulfo-conjugates are predominantly produced. It has been shown that the 
most abundant kaempferol metabolite to be retrieved from human urine is kaempferol-3-O-
glucorinide (fig. 4-4) (DuPont et al., 2004). 
It has been shown that 1.9-2.5 % of the total ingested kaempferol is excreted in the urine 
(Calderon-Montano et al., 2011). A study carried out on eight volunteers showed that the 
maximum plasma concentration for kaempferol was reached after 5.8 hours from ingestion 
(DuPont et al., 2004). In this study volunteers were provided with a portion of endive, 
containing 8.65 mg kaempferol present as a mixture of 3-glucuronide, 3-glucoside and 3-(6-
malonyl)-glucoside (79 %, 14 % and 7 % respectively). Volunteers were healthy non-
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smokers. In all the volunteers it was observed that the maximum blood concentration of 
kaempferol was 100 nM. 
 
Figure 4-4. Chemical structure of kaempferol and kaempferol-3-O-glucuronide. 
 
Not much is known on how kaempferol metabolites enter the cell and whether they are 
transported actively through carrier proteins or move mainly through mechanisms of passive 
diffusion. It is important to assess the mechanisms behind the cellular uptake of these 
components and what are the biological consequences of decreased/increased levels of these 
putative bioactive compounds. 
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4.4. Results 
4.4.1. Assessment of the expressional modulation of OAT3  
4.4.1.1. Assessment of OAT3 gene expression and modulation in liver HepG2 
cells 
In the present study, RT-PCR was carried out to assess whether the OAT3 gene, SLC22A8, 
was expressed in liver model HepG2 cells. OAT3 gene (SLC22A8) was found in HepG2 
cells. A low expression profile for the gene was predicted, using the Ct value. The Ct value 
for SLC22A8 was 33 (see chapter 2, fig. 2-3), when using 100 ng/µL cDNA. Using the same 
concentration of cDNA, the Ct value for the housekeeping gene GAPDH was 16.   
Cells were treated with different stressing agents for 12 h and subsequently incubated with 
5’-CF, a model substrate for OAT3. RT-PCR was performed to assess whether the stressors 
could act as expressional modulators of SLC22A8. It was shown that none of the stressors 
induced changes in the expression of SLC22A8 when comparing gene expression between 
stressor-treated and untreated cells (fig. 4-5).  
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Figure 4-5. Gene expression modulation of OAT3 (SLC22A8) using different stressing 
agents. HepG2 cells were seeded in 6 well plates and grown until confluent. Cells were 
incubated for 12 h at 37 °C with H2O2 (100 µM), t-BOOH (25 µM) and EtOH (1 mM). 
After incubation, RNA was extracted and RT-PCR performed. Results are expressed as the 
ratio of the expression levels of SLC22A8 from cells treated with each stressor over 
expression levels from control un-treated cells. Results represent average of triplicates ± St. 
Dev. 
The effect of each stressor on OAT3 function was evaluated. Initially the cells were 
incubated with each stressor for 8 or 12 h and subsequently with 5’-CF for 10 min. 
Intracellular 5’-CF content was evaluated through HPLC and compared to un-treated cells. 
No statistically relevant changes were detected (fig. 4-6). 
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c.  
 d. 
 e. 
Figure 4-6. Functional modulation of OAT3 from stressing agents. HepG2 cells were 
seeded in 6-well plates and grown until confluent. Cells were incubated for 8 or 12 h at 37 
°C with H2O2, t-BOOH and EtOH respectively. Subsequently cells were incubated for 10 
min at 37 °C with 100 µM 5’-CF. Cells were lysed and the intracellular content was 
collected. 5’-CF was quantified through HPLC. Results are expressed as ratio of the 
intracellular 5’-CF content from stressor-treated cells over 5’-CF content from un-treated 
control cells. Results represent average of triplicates ± St. Dev.   
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4.4.2 Kaempferol-3-O-glucuronide uptake 
Intracellular k-3-O-g was evaluated, using a k-3-O-g standard curve (fig 4-7). Time-, 
concentration- and temperature-dependence of uptake were evaluated by measuring the 
intracellular k-3-O-g through LC-MS. Uptake was shown to be time- (fig. 4-7), 
concentration- (fig. 4-8) and temperature- (fig. 4-9) dependent. 
 
Figure 4-7. Time-dependent uptake of kaempferol-3-O-glucuronide in HepG2 cells. 
HepG2 cells were seeded in 6-well plates and grown until confluent. Cells were incubated 
with 55 µM k-3-O-g at 37 °C for 10-30 min. Cells were lysed and each well content 
collected separately. Each well content was analysed through LC-MS, to determine the 
metabolite uptake in each well. The intracellular k-3-O-g content for each well was 
calculated in pmol, using a standard curve prepared with k-3-O-g authentic standards. 
Subsequently the calculated amount of intracellular k-3-O-g was divided for the incubation 
time, obtaining the uptake rate per minute (pmol/min). Representative results are displayed.  
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Figure 4-8. Concentration-dependent uptake of kaempferol-3-O-glucuronide in HepG2 
cells. HepG2 cells were seeded in 6-well plates and grown until confluent. Cells were 
incubated with 50-200 µM k-3-O-g at 37 °C for 10 min. K-3-O-g uptake was quantified 
through LC-MS.  Uptake is expressed as pmol/min. Results represent average of triplicates 
± St. Dev.  
  
Figure 4-9. Temperature-dependent uptake of kaempferol-3-O-glucuronide in 
HepG2cells.  HepG2 cells were seeded in 6-well plates and grown until confluent. Cells 
were incubated with 10-100 µM k-3-O-g at 37 °C for 10 min. K-3-O-g uptake was 
quantified through LC-MS. Results represent average of triplicates ± St. Dev.  
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Results from LC-MS analysis were used in the Lineweaver-Burk plot to calculate Km and 
Vmax for k-3-O-g uptake.  Km and Vmax were 143 µM and 0.22 pmol/min respectively 
(fig. 4-9). 
 
 
Figure 4-10. Calculation of Km and Vmax for k-3-O-g uptake in HepG2 cells. The 
Lineweaver-Burk plot was used to calculate Km and Vmax, where S = initial substrate 
concentration and V = uptake/min (pmol/min). From the equation: Km = -1/x intercept = -
1/(-0.4548/64.954) = 143 µM and Vmax = 1/y intercept = 1/0.4548 = 0.22 pmol/min. 
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4.5. Discussion and future prospectives 
4.5.1. Modulation of OAT3 using stressing agents 
 The present study focused on better understanding the uptake mechanisms and the uptake 
modulation in liver model HepG2 cells. Two different aspects of uptake were investigated: 
the expressional and functional modulation of the uptake transporter OAT3, and the uptake 
mechanism(s) for the metabolite kaempferol-3-O-glucuronide.  
The study showed for the first time presence of the OAT3 gene, SLC22A8, in HepG2 cells. 
Low levels of expressions were predicted on the basis of the Ct value. Stressing agents 
(H2O2, t-BOOH and EtOH) were tested as potential modulators of OAT3. The stressing 
agents were tested at ranges of concentrations selected using the LDH and MTT cytotoxicity 
tests. Two different experiments were carried out to assess modulation of OAT3 gene 
(SLC22A8) and of the OAT3 protein respectively. The gene modulation was assessed using 
RT-PCR to assess whether the mRNA levels for SLC22A8 increased/decreases in response 
to long incubation (8-12 h) with each stressor. None of the tested stressors showed to affect 
SLC22A8 amount. Modulation at protein level was assessed by incubating the cells with 
each stressor and subsequently quantifying the uptake of a model substrate for OAT3,  
5’-CF, through HPLC. None of the tested stressors affected OAT3 function, decreasing or 
increasing the amount of 5’-CF taken up in the cell model. 
Multiple studies have been carried out, assessing expression and distribution of OAT3 
(SLC22A8) across human tissues (Sun et al., 2001, Anzai et al., 2006). All the published 
data report that the main site of expression of OAT3 is the proximal tubule of the kidney. A 
study (Hilgendorf et al., 2007a) assessed the expression of 36 transporters in human cell 
lines and tissues. Expression was assessed in cell lines and human tissues, representative of 
intestine, liver and kidney. The study reported a great difference between HepG2 cells and 
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liver tissues, highlighting how these cells may not be the best candidates to select when 
modeling the human liver. The paper also reported a lack of expression of SLC22A8 in both 
liver tissues and HepG2 cells. This is in contrast with the present study that shows low 
expression of OAT3 in HepG2 cells.  
Data differences between different laboratories are not uncommon. Examples exist in the 
literature, showing both qualitative and quantitative discrepancies in the expression of 
transporters (Jennings et al., 2009, Phillips and Castegnaro, 1999). Differences can depend 
on multiple factors, such as the methodology used for mRNA quantification and the 
experimental design (Sun et al., 2002, Landowski et al., 2003). When carrying out 
experiments using cell lines, one of the possible explanations for the inter-laboratory 
discrepancy may be the use of different cell passages for the experiments. Studies have 
shown that different cell stages are linked to different gene expression patterns and different  
cell behaviors, associated with different cellular developmental stages (Kerber and 
Cawthon, 2007, Middleton et al., 2013).  
An important consideration to be made is that in the present study an absolute quantification 
of the SLC22A8 mRNA levels was not made. The Ct value does not represent an absolute 
measure of the target gene, but is rather used to indicate presence or absence of the latter 
(Pornprasert et al., 2010). The Ct calculation is also affected from a wide range of 
conditions, such as the Master Mix used (Sayler et al., 2011). It would have been interesting 
to compare the Ct value for SLC22A8 in HepG2 cells with other cell lines. This would have 
been useful to have an overall picture of the abundance of SLC22A8 in different cell models.  
Another limitation of the present study is the sole use of PCR to look at the expression of 
the gene of interest.  The polymerase chain reaction only gives a relative measure of the 
target gene of interest in the sample. This technique does not give any information on the 
abundance of the corresponding protein (Shen et al., 2007). It would have been useful to 
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quantify the corresponding OAT3 protein in HepG2 cells, for example through Western blot 
analysis. It would also be interesting to compare gene and protein expression of this 
transporter across multiple cell lines.  
When modulation of OAT3 was investigated, none of the tested stressing agents (H2O2, t-
BOOH and EtOH) was shown to act as a modulator. A previous study reported that H2O2 at 
concentrations between 0.01 and 1 mM acted as a powerful down-regulator of hOAT3. 
(Takeda et al., 2000). Proximal tubule cells from mice (S2) were used in this study. Cells 
had been transfected with hOAT3. The study reported a dramatic decrease in the uptake of 
estrone sulfate, a substrate of OAT3, after exposure to hydrogen peroxide. In contrast, the 
present work does not show similar results. The choice of a different cell system may have 
impacted on the outcome of the study.  
Another study reported that t-BOOH acted as a potent modulator of OAT1 uptake in renal 
cortical slides (Roma et al., 2008). The work investigated the effect of t-BOOH on p-
aminohippurate (PAH) transport. It was shown that incubation with the oxidative agent 
permanently reduced uptake of the PAH. In chapter 1, it was discussed how OAT1 and 
OAT3 are closely related in terms of gene structure, mechanism of action and function 
regulation. However, it is possible that the different response of OAT1 and OAT3 to 
modulators could depend on the differences existing in the two gene promoters. For this 
reason, in the future it would be very interesting to fully characterize the two gene 
promoters. A comparison of the functional domains involved in gene up-/down-regulation 
would be interesting.  
Overall these results are inconclusive and would require further investigations to clarify 
their biological meaning and implications. However, from what has been shown so far it is 
possible to hypothesize that OAT3 is not involved in detoxification and this is the reason 
why it is not affected from stressors. It would be interesting to carry out more experiments 
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to identify the main role(s) of OAT3 in human liver and health and to identify possible 
modulators of the transporter. 
 
4.5.2. Characterization of kaempferol-3-O-glucuronide uptake 
After observing that none of the selected stressors affected OAT3 gene levels and/or protein 
function, a change of approach was decided. The work focus was addressed on 
characterizing the uptake mechanisms(s) of a selected metabolite (kaempferol-3-O-
glucuronide) in the liver HepG2 cell model.  
The final aim was to assess transporter modulation in liver HepG2 cells. After having failed 
to identify modulators for the OAT3 gene (SLC22A8), a different aspect of transporter 
modulation was selected. The aim was to assess whether uptake of k-3-O-g mainly occurred 
via carrier-mediated transport or passive diffusion mechanisms. If k-3-O-g uptake resulted 
to be mainly relying on active carriers, the aim of this study would be to identify which 
carriers were involved. This would have been done using a range of strategies, such as 
selective gene knock-down and gene over-expression.  
At the same time, addressing different aspect of gene modulation in HepG2 cells would give 
a better understating of the overall cell model validity for modulation experiments.   
The present work showed for the first time that uptake of k-3-O-g most likely occurs 
through mechanisms of active transport (carrier-mediated transport relying on energy) in the 
liver model cells HepG2. However, it was shown that the uptake rate was very low. This 
made the cell model unsuitable for the assessment of k-3-O-g uptake modulation. The 
reason for that is that with the uptake rate being so close to detection limit, if uptake 
inhibition would be carried out, the intracellular amount of k-3-O-g would decrease to levels 
were it would no longer be detectable.  
Chapter 4: Modulation of the Organic Anion transporter 3 and assessment of kaempferol-3-O-
glucuronide uptake in liver model HepG2 cells 
 
140 
 
When kaempferol is ingested, it undergoes conjugation from phase II enzymes. This process 
results in a decreased ability of the compound to move across the biological membranes via 
free diffusion. Therefore it has been hypothesized that transport mechanisms relying on 
energy may be responsible for the uptake of kaempferol metabolites (Barrington et al., 
2009). Kaempferol is one of the highest contributors to flavonol intake in the human diet. 
Following consumption of kaempferol, glucuronides are among the main metabolites 
(O'Leary et al., 2003, Barrington et al., 2009). The present work showed that k-3-O-g 
uptake in HepG2 cells, at physiological concentrations, is temperature- and time- dependent. 
Moreover results showed that transport was concentration-dependent and saturable, with an 
estimated Km of 143 μM and Vmax of 0.22. pmol/min. The high structural similarity 
between quercetin and kaempferol has been described in the introduction session of this 
chapter. Studies have described that quercetin glucuronides undergo uptake and turnover in 
liver HepG2 cells (O'Leary et al., 2003). Furthermore studies have shown that k-3-O-g is 
transported and further metabolized in hepatocytes by specific UDP-glucuronosyltransferase 
isoforms (Oliveira et al., 2002). However no literature had previously investigated the 
mechanism(s) of uptake of k-3-O-g in liver cells, which was investigated for the first time in 
the present work.  
In the present work it was shown that k-3-O-g uptake is most likely occurring via active 
transport (relying on energy use). Unfortunately inhibition experiments, aimed to identify 
which transporters are responsible for the uptake, were not possible due to the very low 
uptake rate.  
A possible approach to characterize the carrier(s) involved, overcoming the problem of the 
low uptake rate, could be to carry out experiments linking to increased k-3-O-g uptake 
(Hennige et al., 2003). An example would be to identify compounds acting as up-regulators 
of specific transporters expressed in HepG2 cells and to use them to treat the cells. The 
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repercussions on the intracellular levels of k-3-O-g would be assessed in response to cell 
treatment with each of the up-regulators. Once having identified possible transporter or 
transporter families responsible for uptake of the metabolite, overexpression experiments of 
the candidate transporters could be used to confirm that a selected transporter was 
responsible for the uptake.   
Overall these results are important in highlighting a mechanism for kaempferol-3-O-
glucuronide entry into liver cells, following kaempferol metabolism. More studies should be 
carried out to identify the protein(s) responsible for uptake of the metabolite. 
The findings reported in the present wok, its limitation and the plans for future work, based 
on these findings, are further discussed in chapter 6. 
 
4.6. Conclusions 
The present work had three main findings: for the first time expression of the transporter 
OAT3 was shown in liver HepG2 cells, OAT3 did not show to be modulated from any of 
the tested stressors (hydrogen peroxide, tert-butyl-hydroperoxide and ethanol). Finally it 
was shown that the metabolite kaempferol-3-O-glucuronide was taken up in a 
concentration-, time- and temperature-dependant manner in the liver model HepG2 cells. 
However, modulating kaempferol-3-O-glucuronide uptake was not possible due to the low 
Vmax of uptake in the system (0.22 pmol/min).  
Overall the cell line resulted to be a poor model for transporter modulation assessment. 
Therefore in the next chapter a different cell model was used (the intestine model Caco-2 
cells).  
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Chapter 5  
Effect of green tea and coffee on the serotonin reuptake transporter using the 
human intestine Caco-2 cell model   
 
5.1. Abstract  
Imbalance of serotonin levels in the gut is associated with a range of chronic pathologies. In 
this work green tea and coffee were investigated as modulators of serotonin uptake, using 
the human intestinal model Caco-2cells.  
Whole green tea extracts displayed to inhibit uptake in a concentration dependent manner.  
Individual components (epigallocatechin gallate, epigallocatechin, epicatechin gallate, 
epicatechin) also displayed dose-dependent inhibition when tested at supplement 
concentrations (equivalent to 7 cups of green tea).  Among the tested green tea components, 
epigallocatechin showed the most potent inhibition.  
Coffee tested at physiological concentrations showed to be a potent dose-dependent 
inhibitor of serotonin uptake.  
It was shown that among the coffee components the most potent inhibitor of serotonin 
uptake was 5-O-feruloylquinic acid. 5-O-feruoylquinic acid acted as a competitive inhibitor 
(Ki = 340 µM) accounting for over 50 % of the inhibition triggered from coffee.  
Ferulic acid also inhibited uptake in a competitive manner (Ki = 270 µM), whereas caffeine 
was inactive.  
The data predict that strong coffee could be almost as potent as the drug imipramine, used to 
treat patients with gut dysfunctions. The data also provide evidence for a novel caffeine-
independent effect of coffee on gut serotonin-mediated signalling, involving chlorogenic 
acid constituents as well. 
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5.2. Chapter summary 
 The aim of the present work was to investigate whether coffee and green tea could 
modulate serotonin uptake through the serotonin reuptake transporter (SERT) in 
intestinal model Caco-2 cells. The uptake of tritium-labeled serotonin was evaluated 
with and without the compounds of interest, using a scintillation counter. 
 Coffee and green tea inhibited serotonin uptake in a concentration-dependent 
manner, with IC50 of 8.45 mg/mL and 10.9 mg/mL respectively. 
 Individual green tea compounds were tested at physiological concentrations ≤ 1 
mM. Epigallocatechin gallate (EGCG) did not affect serotonin uptake. 
Concentration-dependent inhibition was associated with epigallocatechin (EGC), 
epicatechin gallate (ECG) and epicatechin (EC).  
 Supplement concentrations (equivalent to 7 cups of green tea) of EGCG, EGC, 
ECG and EC inhibited uptake by 30, 54, 43 and 23 % respectively.  
 Individual coffee components were tested at 1 mM. Caffeic acid (CA), ferulic acid 
FA), 3,4-dimethoxycinnamic acid (3,4-DMCIN), 5-O-feruoylquinic acid (5-CQA) 
and 3-O-caffeoylquinic acid (3-CQA) inhibited uptake by 17.4, 25, 26, 33 and 9 % 
respectively. 5-FQA and FA inhibited uptake in a competitive manner, with Ki = 
340 and 270 µM respectively 
 Caffeine, 3,4-dicaffeoylquinic acid (3,4-diCQA), 3,5-dicaffeoylquinic acid (3,5-
diCQA) and 5-O-caffeoylquinic acid (5-CQA) had no effect on serotonin uptake 
 Individual compounds from coffee and green tea could be used to create drugs 
modulating serotonin uptake in the gut. These drugs could be used to fight 
pathologies caused by serotonin imbalance. 
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5.3. Introduction  
5.3.1. Synthesis and importance of serotonin for human health 
The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) is synthesized from the amino 
acid tryptophan (Fig. 5-1). About 90 % of the total serotonin is synthesised in the 
enterochromaffin cells of the gut (Best et al., 2010). In the gut serotonin is involved in a 
range of processes such as nutrient absorption (Ellis et al., 2013, Coates et al., 2004), 
nociception (Maneepak et al., 2009) and appetite modulation (Lima et al., 2004, Gill et al., 
2008). Altered balance of serotonin in the gut is associated with a range of chronic 
gastrointestinal pathologies, such as irritable bowel syndrome and inflammatory bowel 
disease (Wheatcroft et al., 2005, Wang et al., 2008). In addition, imbalance of serotonin in 
the gastrointestinal tract has been linked to colorectal cancer (Chubak et al., 2009, Ataee et 
al., 2010) and celiac disease (Coleman et al., 2006).    
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Figure 5-1. Steps of serotonin synthesis. Serotonin is synthesized from the amino acid L-
tryptophan in two steps. Initial hydroxylation is catalysed by tryptophan-5-hydroxylase, 
producing 5-hydroxytryptophan. Subsequently 5-hydroxytryptophan is decarboxylated by 
the aromatic-L-amino acid decarboxylase, producing serotonin.  
 
The role of serotonin has been best investigated in the central nervous system (Williams et 
al., 2001), while less is known about the function(s) of serotonin in the human gut. It has 
been shown that the appetite suppressor fenfluramine partly acted by stimulating release of 
serotonin in the gut and that subsequently serotonin acted at brain level, reducing appetite 
(McCann et al., 1995). Studies have also shown that alteration of tryptophan and serotonin 
balance at brain level were determinants in the development of food disorders such an 
anorexia nervosa (Curzon, 1990). 
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Serotonin action starts with release in the extracellular space. From here the 
neurotransmitter reaches target cells and activates the receptors exposed on the cell surface, 
initiating a cascade response. When serotonin dissociates from its receptors, action is 
terminated and serotonin is re-uptaken in the cell cytoplasm (Isaac et al., 2013). Here the 
neurotransmitter is metabolised and recycled (fig. 5-2). 
 
 
Figure 5-2. Metabolism of serotonin. After serotonin re-uptake in the releasing cell, the 
neurotransmitter is metabolised by the enzymes monoamine oxidase and aldehyde 
dehydrogenase into 5-hydroxyindoleacetic acid. 
The sodium-dependent serotonin reuptake transporter (SERT) (fig. 5-3) contributes to 
serotonin re-uptake (Field et al., 2010, Giannaccini et al., 2011).  
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Figure 5-3. Structure of the serotonin reuptake transporter. SERT is a 12 
transmembrane domain protein encoded by 630 amino acids. Domain 3 is crucial for 
serotonin translocation (Horschitz et al., 2001).  
 
Serotonin is released from the pre-synaptic cell in the synaptic space, where it reaches the 
receptors expressed on the surface of the post-synaptic cell. Serotonin binding to receptors 
initiate a response cascade in the cell. As soon as the response cascade is initiated, serotonin 
dissociates from the receptors and is taken back up into the releasing cell through SERT 
(Koldso et al., 2011). Therefore SERT plays a determinant role in the 
intracellular/extracellular balance of serotonin. In pathologies caused by low serotonin 
release, such as certain forms of depression and irritable bowel syndrome, selective 
serotonin reuptake inhibitors are used to decrease the amount of serotonin taken back into 
the releasing cell (fig. 5-4). Selective inhibition of SERT results in increased levels of 
extracellular serotonin and higher amount of ligand-receptor complex formation (Pollier et 
al., 2000). For these reasons the discovery of new SERT modulators is the focus of a 
number of studies with the aim of controlling symptoms of pathologies associated with 
altered serotonin levels (Warden et al., 2008, MacGillivray et al., 2011). 
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Figure 5-4. Scheme of the role of the serotonin reuptake transporter in the 
intracellular/extracellular serotonin balance. a. SERT reuptake serotonin in the releasing 
cell for it to be recycled. b. When a selective inhibitor of SERT is present, SERT is blocked 
and unable to reuptake serotonin effectively, resulting in increased amount of serotonin 
present in the synaptic space and subsequently more receptor-ligand complex formation.  
 
An example of drug acting via SERT inhibition is imipramine. Imipramine is widely used in 
the fight against depression and anxiety (Russell et al., 2001). Among the tricyclic 
antidepressants imipramine has the second highest affinity for SERT, after clomipramine. 
Studies have linked SERT modulation to appetite suppression and have indicated SERT as a 
potentially valid target for the treatment of obesity and food-linked dysfunctions (de 
Magalhaes-Nunes et al., 2007, Talbot et al., 2010). Imipramine is also used to control 
gastrointestinal dysfunctions (Talley et al., 2008, Abdul-Baki et al., 2009b). Studies have 
shown that low doses of imipramine are effective in reducing the symptoms of irritable 
bowel syndrome. For example, one study assessed the effect of imipramine on 56 patients 
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suffering from the syndrome, observing that 80.6% of the patients showed significant 
improvement of the symptoms after 12 weeks of treatment with 25 mg/ day of the drug 
(Abdul-Baki et al., 2009a).  However, using imipramine to control irritable bowel syndrome 
commonly causes a series of side effects, such as dizziness and extreme fatigue 
(Mavissakalian and Perel, 2000). The main limitation of the currently existing medications 
for irritable bowel syndrome is that they can only alleviate the discomfort caused by it but 
cannot completely eliminate the symptoms, nor cure the dysfunction (Mavissakalian et al., 
2002). A number of studies currently focus on finding new treatments for irritable bowel 
syndrome (Labus, 2007).  
 
5.3.2. Green tea role in human health 
Green tea is the most consumed beverage in the world, after water (Cabrera et al., 2006a). 
Both whole extracts and individual components are long known for their health beneficial 
effects. Studies associate regular green tea intake with a wide range of benefits for human 
health, such as chemopreventive effects (Gao et al., 1994, Cooper et al., 2005, Lee, 2007), 
antiviral activity (Song et al., 2005) and diabetes prevention (Waltner-Law et al., 2002). 
Green tea is a rich source of the polyphenols, catechins and epicatechins (fig. 5-5).  
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Figure 5-5. Chemical structure of the most abundant polyphenols present in green tea: 
epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG) 
and epicatechin (EC). 
 
The relative amounts of bioactive components in green tea may vary, according to the origin 
of the leaves and the processing conditions. An average commercially-available green tea 
blend contains 3-10 times more catechins than black tea (Henning et al., 2003), with 
catechins accounting for 60-80 % of the total polyphenol content (Cabrera et al., 2006b). 
Green tea components have been associated with weight loss, enhancing daily energy 
expenditure and fat oxidation (Dulloo et al., 1999). Epigallocatechin gallate (EGCG) from 
green tea has also been associated with weight loss. Animal studies showed that rats daily 
injected with EGCG for one week consumed up to 60 % less food (Kao et al., 2000) 
compared to control.  
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Further studies suggested that green tea itself is a potent modulator of appetite and 
facilitates weight loss, by enhancing fat burning and increasing the turnover of serotonin 
and dopamine (Mirza et al., 2013). In order to achieve significant effects on human health 
the recommended dose is at least 2-3 cups of the beverage per day (equivalent to 240-320 
mg catechins). The  maximum recommended amount is 10 cups per day (Fujiki et al., 
2002). Despite the known health beneficial effects, green tea is still very little consumed in 
Western countries (Graham, 1992) and often supplements are used as a replacement or in 
addition to beverage consumption.  
In the present study whole extracts and individual green tea compounds were used as 
potential modulators of SERT, using the Caco-2 cell model. Caco-2 cells were used as they 
constitutively express the human SERT (Martel et al., 2003b).   
The table below shows the composition of the green tea blend used in the present work 
(table 5-1). 
 
Table 5-1. Green tea composition. Values are given as compound percentage in the 
extracts. The values result from unpublished carried out previously carried out in the 
research group. 
 
Green tea compound % 
(-)- epigallocatechin gallate 17.8
3 
(-)- epigallocatechin 12.3
9 
(-)- epicatechin gallate 3.15 
(-)- epicatechin 2.2 
(+)- catechin 1.62 
(+)- gallocatechin 9.45 
(-)- catechin gallate 0.15 
(-)- gallocatechin gallate 0.14 
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5.3.3. Coffee and role in human health 
Coffee is also long known for its beneficial effects on human health (van Dam, 2008, 
George et al., 2008, Shin et al., 2010). However, a number of side effects have been 
associated with high coffee consumption, mainly ascribable to caffeine (Leviton and 
Cowan, 2002, Cornelis and El-Sohemy, 2007). The increasing availability of decaffeinated 
beverages raises the question of whether the positive effects derived from coffee are 
caffeine-dependent and whether caffeine-free products would still result in improved health 
(Skerrett, 2012). 
To date, no studies have reported the effect of coffee and coffee components on serotonin 
balance within the gut. In the present work the effect of whole coffee extracts and individual 
components was assessed on SERT, expressed in Caco-2 cells.  
 
5.4. Results 
5.4.1. Experimental design validation 
Validation of the method was carried out. Expression of the SERT gene (SLC6A4) was 
evaluated in Caco-2 cells through RT-PCR. Liver HepG2 cells were used as comparative 
cell model to evaluate SLC6A4 expression. Serotonin uptake was also evaluated in the cell 
model, assessing concentration- and time-dependency of the transport, using tritium-labelled 
serotonin. Finally Sodium-dependency of serotonin uptake was evaluated, comparing uptake 
between sodium-containing medium and sodium-depleted medium. Details on the methods 
used are given in chapter 2.  
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When 100 ng cDNA were used, Ct value in Caco-2 was found to be 28 for SLC6A and 21 
for the housekeeping gene, GAPDH. In HepG2 cells, when 100 ng cDNA were used, the Ct 
value was found to be 32 for SLC6A4 and 18 for GAPDH (fig. 2-2).  
Serotonin uptake proved to be linear for the time interval considered: 1-15 min (fig. 5-6). 
Concentration-dependent uptake was also observed for the range of concentrations used, 
0.1-2.5 µM (fig. 5-7) and the Km calculated to be 0.9 µM. 
 
  
Figure 5-6. Time-dependent uptake of serotonin in Caco-2 cells. Cells were incubated 
with 0.2 µM tritium-labelled serotonin for 1-15 min at 37 °C. Cells were lysed and the 
content of each well collected separately, to determine the intracellular serotonin in each 
well. The amount of serotonin taken up in each well  was measured based on the β 
emissions of tritium using a scintillation counter, as counts per minute (CPM) and converted 
into decays per minute (DPM). For each incubation time, the percentage of uptake is 
reported (e.g. the graph shows that after an incubation of 10 minutes almost 1.5 % of the 
initial 0.2 µM serotonin is taken up). Representative results are shown.  
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Figure 5-7. Concentration-dependent uptake of serotonin in Caco-2 cells. Cells were 
incubated for 6 min with 0.1-2.5 μM tritium-labelled serotonin. Intracellular uptake was 
measured based on the β emissions of tritium using a scintillation counter. Results shown 
represent average of triplicates ± St. Dev.  
Among the preliminary experiments, sodium-dependence of serotonin uptake was assessed. 
When serotonin uptake was carried out in sodium-free medium, uptake was decreased by  
40 % (fig 5-8). 
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Figure 5-8. Sodium-dependent uptake of serotonin in Caco-2 cells. Cells were incubated 
for 6 minutes with 0.2 μM tritium-labelled serotonin in either standard transport medium 
(containing sodium, Na
+
) or sodium-depleted medium (where sodium had been replaced 
with potassium, K
+
). Intracellular serotonin was measured based on the β emissions of 
tritium using a scintillation counter. The intracellular serotonin amount was normalized to 1. 
Results represent the average of triplicates ± St. Dev. 
 
5.4.2. Modulation of SERT using whole green tea extracts and individual 
compounds at physiological concentrations 
Whole green tea extracts were tested on Caco-2 cells at concentrations between 2 and 30 
mg/mL as potential modulators of SERT. Green tea inhibited serotonin uptake in a 
concentration-dependent manner (fig. 5-9). IC50 was calculated resulting to be 8.45 mg/mL.  
At physiological concentrations ≤ 1 mM, none of the tested concentrations of EGCG 
affected serotonin uptake. EGC, ECG and EC inhibited uptake in a concentration-dependent 
way. EGC triggered a 9, 18 and 21 % inhibition of the serotonin uptake at 0.1, 0.5 and 1 
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mM respectively. ECG inhibited uptake at 0.5 and 1 mM by 12 and 16 % respectively. The 
effect of EC was only significant at 1 mM, when a 15 % inhibition was observed (fig. 5-10).  
 
 a. 
 b. 
Figure 5-9. Effect of whole green tea extracts on serotonin uptake. (a) Whole extracts 
were prepared at concentrations between 2 and 30 mg/mL and co-incubated for 6 minutes 
with tritium-labeled serotonin. The intracellular amount of serotonin was calculated on the 
basis of the β emissions of tritium, using a scintillation counter.  
Results are expressed as the ratio of the intracellular serotonin from cells treated with green 
tea over control cells, untreated. Results represent average of triplicates ± St. Dev.  
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(b) The IC50 was calculated by plotting the percentage of inhibition against the 
corresponding green tea concentration (mg/mL) used. The predicted polynomial was used, 
where x = IC 50. 
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 c. 
 d. 
Figure 5-10. Effect of physiological concentrations of individual green tea components 
on serotonin uptake in Caco-2 cells. Cells were co-incubated for 6 min at 37 °C with 
tritium-labelled serotonin and EGCG (a), EGC (b), ECG (c) or EC (d) at concentrations ≤ 1 
mM. Intracellular levels of serotonin were measured using a scintillation counter, based on 
the β emissions of tritium. Results are expressed as the ratio of intracellular serotonin from 
cells treated with green tea components over control cells, untreated.  
Results represent the average of triplicates ± St. Dev.  
* = P ˂ 0.05 and ** = P ≤  0.01. 
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5.4.3. Modulation of SERT using supplement concentrations of green tea 
Supplement concentrations equivalent to 7 cups of green tea were used as modulators of 
serotonin uptake. Concentrations of 11.6 mM EGCG, 12 mM EGC, 2.15 mM ECG and 2.4 
mM EC were used, resulting in decrease in intracellular serotonin of 30, 54, 43 and 23 % 
respectively (fig 5-11). 
 
 
Figure 5-11. Effect of supplement concentrations of green tea components on serotonin 
uptake in Caco-2 cells. Cells were incubated with EGCG, EGC, ECG and EC at 11.6, 12, 
2.15 and 2.4 mM respectively, corresponding to 7 cups of green tea. 
Results are expressed as ratio of the intracellular serotonin in cells treated with the green tea 
compounds over untreated cells.  
Results represent the average of triplicates ± St. Dev.  
* = P ˂ 0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001. 
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5.4.4. Inhibition of 5-HT uptake using whole coffee extracts 
Whole coffee extracts were initially tested. They showed to inhibit 5-HT uptake in a 
concentration-dependent manner (fig. 5-12). The IC50 for coffee extracts was calculated to 
be 10.9 mg/mL.  
 
 a. 
 b. 
Figure 5-12. Coffee inhibition of serotonin uptake. (a) Whole extracts were prepared at 
concentrations between 2 and 30 mg/mL and co-incubated for 6 minutes with tritium-
labeled serotonin. Results are expressed as the ration of intracellular serotonin from cells 
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treated with coffee over control cells, untreated. Results represent the average of triplicates 
± St. Dev.  
(b) The IC50 was calculated by plotting the percentage of inhibition against the 
corresponding coffee concentration (mg/mL) used. The predicted polynomial was used, 
where x = IC 50. 
Individual coffee compounds were selected for testing, starting with caffeine. Caffeine was 
tested at 2.3 mM, a concentration equivalent to 15 mg/mL coffee (strong coffee). At this 
concentration, no effect on serotonin uptake was observed (fig. 5-13).  
 
 
Figure 5-13. Effect of caffeine on serotonin uptake in Caco-2 cells. Cells were incubated 
for 6 min at 37 °C with 2.3 mM caffeine and tritium-labelled serotonin. Intracellular 
serotonin was measured using a scintillation counter, on the basis of the β emissions of 
tritium. Results are expressed as ratio of intracellular serotonin in cells treated with caffeine 
over control cells, untreated. Results represent the average of triplicates ± St. Dev.  
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5-CQA and 3-CQA are chlorogenic acids, they are among the most abundant compounds in 
the selected coffee blend (table 5-2). 
 
Table 5-2. Coffee composition. Values are given as mg of compound per grams of coffee 
powder (Hoelzl et al., 2010).  
Coffee compound Amount (mg/g solid) 
 
5-caffeoylquinic acid 41 
4-caffeoylquinic acid 12.4 
3-caffeoylquinic acid 10.5 
5-feruoylquinic acid 7.9 
4,5-di-caffeoylquinic acid 5.8 
3,4-di-caffeoylquinic acid 5.7 
3,5-di-caffeoylquinic acid 4 
4-feruoylquinic acid 2.2 
caffeic acid 0.279 
Ferulic acid 0.077 
3,4-dimethoxycinnamic acid 0.037 
caffeine 29 
 
3-CQA and 5-CQA were tested at 3.4 and 0.9 mM respectively, corresponding to 15 mg/mL 
coffee. 3-CQA inhibited serotonin uptake by 4 %, while 5-CQA had no effect (see fig. 5-
16). 
3,4-diCQA, 3,5diCQA, CA, FA, 3,4-DMCIN and 5-FQA were tested at physiological 
concentrations ≤ 3 mM. 3,4-diCQA and 3,5-diCQA had no effect (fig. 5-15). CA, FA, 5-
FQA and 3,4-DMCIN acted as concentration-dependent inhibitors (fig. 5-14-fig. 5-16). The 
IC50 values for FA and 5-FQA were calculated to be 3 and 1.6 mM respectively.  
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Figure 5-14. Effect of physiological concentrations of individual coffee components on 
serotonin uptake. Cells were incubated at for 6 min at 37 °C with physiological 
concentrations ≤ 3 mM of CA, FA, 5-FQA or 3,4-DMCIN and 0.2 µM tritium-labelled. 
Intracellular serotonin was measured based on the β emissions of tritium using a scintillation 
counter. Results are expressed as ratio of the intracellular serotonin from treated cells over 
untreated cells.  
Results represent the average of triplicates ± St. Dev.  
* = P ˂ 0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001. 
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Figure 5-15. Chemical structures of bioactive compounds and caffeine from coffee 
tested for ability to inhibit SERT.  
 
Having identified potential inhibitors, the predicted inhibition values for the active 
compounds were calculated for concentrations equivalent to 15 mg/mL coffee. CA (23 µM), 
FA (6 µM), 3,4-DMCIN (2.7 µM) and 5-FQA (0.4 mM) would inhibit 5-HT uptake by  
0.4 %, 0.15 %, 0.0 7 % and 26 % respectively. Subsequently the predicted inhibitory effects 
were individually validated in the cell system. Results were in agreement with the predicted 
values, showing 26 % inhibition for 0.4 mM 5-FQA and no observable effect for the other 
compounds (fig. 5-16). Imipramine was used as positive control as a known down-regulator 
of SERT. 75 % inhibition was observed when treating cells with 5 µM imipramine (fig. 5-
16).  
 
3-caffeoylquinnic acid 5-feruloylquinic acid Caffeic acid
Ferulic acid 3,4-dimethoxycinnamic acid Caffeineferuli  acid
Chapter 5: Effect of green tea and coffee on the serotonin reuptake transporter using the human 
intestine model Caco-2 cells 
 
165 
 
 
Figure 5-16. Effect of selected coffee components on serotonin uptake in Caco-2 cells. 
Cells were incubated for 6 min with 0.2 µM tritium-labelled serotonin and caffeine, 3,4-
diCQA, 3,5-diCQA, 5-FQA, 3-CQA, 5-CQA, CA, FA or 3,4-DMCIN at concentrations 
equivalent to 15 mg/mL coffee. Intracellular serotonin was measured based on the β 
emissions of tritium using a scintillation counter. Results are expressed as ratio of 
intracellular serotonin from treated cells over control cells, untreated.  
Results represent the average of triplicates ± St. Dev.  
* = P ˂ 0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001. 
 
These results highlight the difference between absolute and relative potency of the tested 
compounds. When considering 1 mM of 5-FQA, FA, CA and 3,4-DMCIN uptake was 
inhibited by 34, 25, 17.4 and 26 % respectively.  
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Whole coffee extracts tested at a concentration of 15 mg/mL inhibited 5-HT uptake by 53 
%. Overall, individual coffee compounds accounted for 32 % inhibition, over half of the 
observable inhibition (fig. 5-17 and table 5-3).  
 
 
Figure 5-17. Contribution of individual coffee compounds to the observed inhibition of 
serotonin uptake in Caco-2 cells. Over half of the observable inhibition triggered by coffee 
was characterized and associated with specific compounds. 5-FQA alone accounted for 49 
% of the inhibitory effect. 
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Table 5-3. Absolute and relative potency of individual coffee compounds on serotonin 
uptake. Coffee components are listed in order of their abundance in the coffee blend. 
Absolute potency of each compound is reported at a concentration of 1 mM. The 
contribution to the overall inhibition is shown at concentrations equivalent to 15 mg/mL 
coffee.   
Compound  
 
Amount in 
coffee  
(mg/g solid) 
Inhibition  
by  
1 mM (%) 
Inhibition by 
concentrations 
equivalent to 15 
mg coffee/ mL (%) 
5-CQA 40.6 0 0 
3-CQA 10.5 9 4 
 5-FQA 7.9 34 26 
3,4-diCQA 5.7 0 0 
3,5-diCQA 4 0 0 
CA 0.279 17.4 0.4 
FA 0.077 25 0.15 
 3,4-DMCIN 0.037 26 0.07 
Caffeine 29 0 0 
 
 
FA and 5-FQA were tested at physiological concentrations (1-3 mM and 0.5-2.5 mM 
respectively), co-incubating with a range of serotonin concentrations (0.05-1 µM). The aim 
was to assess whether FA and 5-FQA acted as competitive inhibitors of serotonin uptake. 
Both compounds were shown to be competitive inhibitors (fig. 5-18 and 5-19).  
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Figure 5-18. Competitive inhibition of ferulic acid on serotonin uptake in Caco-2 cells. 
Cells were incubated with a range of concentrations of FA in combination with a range of 
tritium-labelled serotonin concentrations. Intracellular 5-HT was measured based on the β 
emissions of tritium using a scintillation counter. Results are expressed as ratio of the 
intracellular 5-HT from treated cells over untreated cells.   
The results represent the average of triplicates ± St. Dev. 
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Figure 5-19. Competitive inhibition of 5-O-feruoylquinic acid on serotonin uptake in 
Caco-2 cells. Cells were incubated with a range of concentrations of 5-FQA in combination 
with a range of tritium-labelled serotonin concentrations. Intracellular 5-HT was measured 
based on the β emissions of tritium using a scintillation counter. Results are expressed as 
ratio of the intracellular 5-HT from treated cells over untreated cells.  Typical results are 
shown. 
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The inhibition constants (Ki) for FA and 5-FQA were calculated using the Dixon plot and 
resulted to be 270 µM and 340 µM respectively (fig. 5-20).  
 
 a. 
 b. 
Figure 5-20. Calculation of the inhibition constants (Ki) for ferulic acid and 5-O-
feruoylquinic acid, using the Dixon plot. The Ki was calculated for FA (a) and 5-FQA (b) 
using the Dixon plot. In the equation x = Ki  
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Hydrolysis of whole coffee extracts with the enzyme chlorogenate esterase was carried out, 
in order to assess if and in which measure chlorogenic acids contributed to inhibit serotonin 
uptake. HPLC analysis showed that 84 % of the total chlorogenic acid content was 
hydrolysed after treatment with the enzyme (fig. 5-21). When using hydrolysed coffee for 
cell treatment, the inhibition potency of the whole coffee extracts drastically decreased, 
compared to non-hydrolysed coffee.  Serotonin uptake was inhibited by 28 % and 47 % 
using hydrolysed and non-hydrolysed coffee respectively (fig. 5-22). 
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a. 
 b. 
Figure 5-21. HPLC analysis of coffee hydrolysed with chlorogenate esterase. Whole 
coffee extracts, prepared using 15 mg soluble coffee/ mL water, were incubated for 30 min 
at  
37 °C with the enzyme chlorogenate esterase. Hydrolysed samples (b) were analysed 
through HPLC and compared to control non-hydrolysed extracts (a). Analysis was carried 
out based on the retention time for chlorogenic acid, which resulted to be 1.11 minute, under 
the method conditions. Typical chromatograms are shown. 
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Figure 5-22. Effect of hydrolysed and non-hydrolysed coffee on serotonin uptake. 
Caco-2 cells were incubate for 6 min at 37 °C with 15 mg/mL hydrolysed or non-
hydrolysed coffee extracts and 0.2 µM tritium-labelled serotonin. Intracellular serotonin was 
measured based on the β emissions of tritium using a scintillation counter. Results are 
expressed as ratio of the intracellular serotonin from cells treated with hydrolysed coffee 
over serotonin from control cells, treated with non-hydrolysed coffee extracts.  
Results represent the average of triplicates ± St. Dev. 
  
5.5. Discussion 
5.5.1. Understanding the mechanisms of serotonin uptake in intestinal cells 
Multiple mechanisms exist to re-uptake serotonin in the intestinal cells (Freeman et al., 
2004). It is known that one of the ways serotonin is taken back up in the releasing cells is 
through SERT, a sodium-dependent protein (Huot et al., 2011).  When serotonin transport 
was carried out in sodium-free medium, uptake was dramatically decreased. This proved the 
determinant role of the sodium-dependent SERT and highlighting, according to 
expectations, the existence of multiple mechanisms responsible for 5-HT uptake. The results 
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also showed that Caco-2 cells are a representative model for intestinal cells, displaying 
molecular pathways comparable to in vivo intestine cells. Serotonin imbalance in the gut is 
associated with a range of pathologies, such as irritable bowel syndrome. So far no 
treatments exist capable of completely eliminate the symptoms and discomfort coming from 
this syndrome. Also, the existing drugs used often cause a range of unpleasant side effects. 
The current work showed that selected polyphenols, from coffee and green tea, acted as 
modulators of serotonin uptake, inhibiting reuptake through SERT. The possibility of using 
food compounds to treat irritable bowel syndrome and other gut dysfunctions associated 
with serotonin imbalance is extremely interesting. In fact, if natural products could be used 
to treat these pathologies, it would be possible to eliminate the side effects, caused by long-
term treatment with synthetic drugs, such as imipramine.    
 
5.5.2. Effect of green tea on serotonin uptake 
Studies have associated green tea consumption with appetite suppression and weight loss, 
via a range of mechanisms including alteration of serotonin levels (Hursel et al., 2009). 
However only a limited number of studies have investigated the molecular mechanisms 
involved in green tea effects on appetite suppression and weight loss (Jurgens et al., 2012). 
No studies so far exist on the role of green tea on serotonin re-uptake via SERT. 
 
5.5.2.1. Effect of green tea whole extracts and individual components tested at 
physiological concentrations 
The present work reports for the first time a role for green tea whole extracts and individual 
components in inhibiting serotonin re-uptake via SERT. The intestinal model Caco-2 cells 
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were used, as they constitutively express SERT (Martel et al., 2003a). Whole green tea 
extracts showed concentration-dependent inhibition of serotonin uptake. Concentrations as 
low as 2 mg/mL, corresponding to a weak cup of green tea, triggered serotonin uptake 
inhibition. Physiological concentrations ≤ 1 mM of individual green tea components 
(EGCG, EGC, ECG and EC) showed to have a limited effect on serotonin re-uptake. The 
compound triggering highest inhibition of serotonin uptake was EGC, which displayed to 
inhibit uptake in a concentration-dependent manner at all the tested concentrations. EGC 
inhibited uptake up to 21 % (when tested at 1 mM). Interestingly EGCG was the least 
effective inhibitor. In fact none of the tested physiological concentrations of EGCG 
produced any effect on serotonin uptake. It is noteworthy that EGCG was the most abundant 
component in the green tea blend used for the work, while EGC was the second most 
abundant compound. The results obtained testing selected green tea components showed 
that initial abundance of certain compounds in the green tea blend did not necessarily 
correlate with a high effect of the compound on biological processes, such as serotonin 
uptake. An important step to do would be to test other green tea components, present in 
green tea at small levels. They could be tested both individually and in combination with 
each other, to assess whether they have any effect on serotonin uptake.  
It would also be interesting to assess whether the four compounds initially selected (EGCG, 
EGC, ECG and EC) could trigger more/less inhibition of serotonin uptake when tested in 
combination with each other.  
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5.5.2.2. Effect of individual green tea components tested at supplement 
concentrations  
Supplement concentrations of the individual green tea compounds EGCG, EGC, ECG and 
EC were subsequently tested. Concentrations equivalent to 7 cups of green tea used. 
According to published literature 10 cups of green tea per day is the maximum 
recommended intake (Halegoua-De Marzio et al., 2012), thus 7 cups would be a safe 
amount. Studies have shown that, despite the limited bioavailability of polyphenols, local 
concentration of these compounds in the colon can reach much higher concentrations 
compared to the systemic circulation. A study from Duthie et al. showed that after ingestion 
of 500 mg of polyphenols, the plasma concentration reached by these compounds was 50 
μM. However, their concentration in the colon was 3 mM, 60 times higher than in the 
plasma (Duthie et al., 1998). According to these findings, if 7 cups of green tea were drunk 
each day, they would provide the colon with polyphenol concentrations high enough to 
modulate serotonin uptake.  
However the final concentrations in the colon would still be diluted compared to the initial 
intake, due to progressing through the gastrointestinal tract. An approach to overcome 
dilution could be designing drugs containing the equivalent amount of 7 cups of green tea. 
These drugs would have to be designed so that, once ingested, they would not be affected by 
movement through the gastrointestinal tract, but they would release their intact content once 
they reach the colon.     
When using these concentrations, a high inhibition of serotonin re-uptake was observed, 
with consequent increase of the neurotransmitter availability in the extracellular space. 
Among the tested green tea compounds, the most powerful effect on serotonin re-uptake 
was observed when incubating the cells with EGC, both at physiological and at supplement 
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concentrations. A correlation between EGCG supplement consumption and weight 
maintenance in patients who were previously obese has been reported (Westerterp-
Plantenga et al., 2005). In this study male and female volunteers were given 45 mg EGCG 
before meals and displayed reduced weight re-gain compared to the volunteers administered 
placebo tablets. The study did not investigate the mechanism of action of EGCG but 
supports evidence for the health beneficial effects of green tea components at supplement 
concentrations. It is interesting to note that, among the compounds tested at supplement 
concentrations in the present work, EGCG was the second least effective inhibitor of 
serotonin uptake, after EC. It would be interesting to assess the effect of EGC using human 
volunteers and compare the results obtained with those published from Westerterp-Plantega 
et al.  
Other interesting results were observed in a study from 2007 (Nagao et al., 2007). 240 obese 
patients were given green tea extracts, rich in catechins, over a period of 12 weeks. 
Volunteers displayed reduced hip circumference, body fat ratio and body mass index, 
compared to placebo treated patients.  
Further studies could be designed to assess the biological repercussions of serotonin 
modulation, associated with incubation of the cells with individual green tea components. It 
would be also interesting to assess the effect of whole green tea extracts, tested on Caco-2 
cells at supplement concentrations and compare serotonin uptake to uptake obtained 
incubating the cells with the same extracts selectively depleted of one component per time. 
This experimental design could clarify the contribution of each green tea components while 
assessing the overall effect of green tea extracts when individual compounds are allowed to 
interact with each other.  
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5.5.3. Effect of coffee on serotonin uptake 
Coffee is long known to have beneficial effects on the human health (Harries-Rees, 2005, 
Taylor, 2008), although the mechanisms of actions are not fully known (Rogers et al., 
1995). Studies have associated a wide range of coffee effects to the presence of caffeine, an 
alkaloid compound acting on the central nervous system as stimulator (Chou and Benowitz, 
1994). Consumption of caffeine-containing products has repercussions on the serotonin 
levels in various neurological ways, for example increasing the levels of the hormone 
cortisol (Griffiths and Chausmer, 2000, Cummings et al., 2013). Though not much is known 
about the effects of coffee on serotonin re-uptake within the gastrointestinal tract (Higdon 
and Frei, 2006). The present work reported a caffeine-independent effect of coffee on 
inhibition of intestinal serotonin re-uptake. Previous studies agree with these findings, 
having demonstrated that both caffeinated and decaffeinated drinks link to intestinal 
stimulation and increased bowel movements (Brown et al., 1990, Rao et al., 1998). These 
results could be crucial to develop health-promoting caffeine-free drinks. These drinks 
could be used as enhancers of the extracellular serotonin levels in target organs, such as the 
gut.  
The inhibitory effect of whole coffee extracts and individual polyphenols on SERT activity 
were assessed for the first time in the present work.  
Whole coffee extracts proved to inhibit uptake in a concentration-dependent manner. This 
result is in agreement with previously published results, showing that coffee administered to 
rats altered the serotonin levels found in the brain (Yamato et al., 2002). Several coffee 
components showed to inhibit serotonin uptake in a concentration-dependent manner, when 
tested at physiological concentration ≤ 3 mM. 1 mM of 5-FQA, FA, CA and 3,4-DMCIN 
inhibited uptake by 33, 25, 17.4 and 26 % respectively. Though the amounts of FA, CA and 
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3,4-DMCIN in coffee are many fold lower than 1 mM, therefore when assessing the effect 
of these compounds related to their effective concentrations, contribution to the overall 
serotonin inhibition resulted limited. When testing these compounds at concentrations 
equivalent to a strong cup of coffee (15 mg/mL) the majority of compounds did not show 
any effect on the uptake of serotonin. 5-FQA and 3-CQA were the only compounds to 
display significantly inhibition of SERT when tested at concentrations equivalent to a strong 
cup of coffee. They inhibited uptake by 4 and 26 % respectively. These results highlighted 
the difference between absolute and relative potency of the tested phenolic compounds.  
Previous literature has reported that phenolic compounds can inhibit SERT-mediated 
serotonin uptake using a cell model (Ofir et al., 2003). The liquorice components, glabridin, 
4′-O-methylglabridin and glabrene, inhibited serotonin uptake by 60, 53 and 47 % 
respectively.  
The drug imipramine, which is used to cure depression and gut dysfunctions, was used as 
positive control, for its known role as a SERT inhibitor. According to published literature 
(Ofir et al., 2003), imipramine proved to be a potent modulator of SERT. Inhibition 
triggered by imipramine was compared to the inhibition triggered by whole coffee extracts. 
The data presented suggested that strong coffee modulated SERT with a potency 
comparable to the drug imipramine in the intestine model Caco-2 cells.  
 
5.5.4. Role of chlorogenic acids on serotonin re-uptake inhibition 
Chlorogenic acids are esters of hydroxycinnamic acids (caffeic acid, p-coumaric acid or 
ferulic acid) with (-)-quinic acid (Kwon et al., 2010) . Multiple compounds belong to this 
family and their relative abundance varies in food (Dupas et al., 2006). Coffee contains a 
range of chlorogenic acids (Moon et al., 2009). The blend used in the present work was rich 
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in chlorogenic acids (table 5-2). However authentic standards were not available for all the 
compounds present in the blend and therefore they could not all be individually tested on the 
cells.   
Treatment of coffee with the enzyme chlorogenate esterase was carried out in order to 
assess if and in which measure the total content of chlorogenic acids contributed to inhibit 
serotonin uptake. When using hydrolysed coffee for cell treatment, the inhibition potency 
drastically decreased, compared to non-hydrolysed coffee. This result highlighted a role for 
chlorogenic acids in the inhibition of serotonin re-uptake.  
 
5.5.5. Work limitations and prospectives for future work  
In the present work Caco-2 cells were used as a model for the human intestine. Despite 
literature showing that Ccao-2 cells are representative of the in vivo intestine (Hilgendorf et 
al., 2007b), cell lines in general offer a limited amount of information. In vivo, every tissue 
is part of an organ, which in turn is part of a system (Bassingthwaighte, 2002). The main 
limitation of using a cell model is that, in this case, the cells will be exposed to selected 
compounds/environments, while in vivo cells are simultaneously exposed to a much larger 
variety of compounds. In vivo human intestinal cells are simultaneously exposed to an 
enormous variety of compounds, from a multitude of dietary and non-dietary sources, while 
in the cell model one individual food/food compound is used on the cells. It is most likely 
that in vivo all the food compounds present in the gastrointestinal tract at a specific time 
interact with each other and with the cells, possibly resulting in a different physiological 
response compared to the cell model. It would be interesting to carry out a human study to 
compare the in vitro results with findings obtained using human volunteers.  
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More studies will have to be carried out to assess the biological repercussions of altered 
serotonin balance within intestinal cells and on the mechanisms through which coffee and 
coffee compounds interact with serotonin uptake, resulting in inhibition.  
Nevertheless this study represents a significant step into better understating the effect of 
coffee on serotonin levels within the human gut, demonstrating that coffee and individual 
coffee compounds inhibit serotonin reuptake in a dose-dependent manner and that caffeine 
does not affect the process. 
The present work showed that chlorogenic acids play a crucial role in inhibiting serotonin 
uptake in the Caco-2 cells. However it is not clear whether individual compounds are 
responsible for inhibiting uptake alone or if they interact with each other. It would be 
interesting to test these compounds individually in the cell model. It would also be 
interesting to test various compounds combined with each other, to assess whether the 
inhibition of serotonin uptake, which has not yet been fully characterised, is the result of 
single compounds acting independently on SERT or whether these compounds interact with 
each other to give the final inhibition. 
The limitations of the present work and the prospectives for future work are further 
discussed in chapter 6. 
5.6. Conclusions 
The present work showed that coffee and green tea whole extracts and individual 
compounds acted as inhibitors of serotonin reuptake in the intestine model Caco-2 cells. 
Green tea individual compounds had limited effect at physiological concentrations, although 
their effect was high at supplement concentrations, equivalent to 7 cups of green tea. 
Among the individual coffee compounds tested, caffeine did not affect serotonin reuptake, 
while 5-FQA resulted to inhibit uptake in the most powerful way at concentrations 
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equivalent to a strong cup of coffee (26 % inhibition). It would be interesting to assess the 
effect of the identified inhibitors in vivo. If these compounds proved effective in inhibiting 
serotonin reupkae in vivo, they could be used to design drugs to treat serotonin-dependent 
gut dysfunctions such as irritable bowel syndrome.  
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Chapter 6  
General discussion and suggestions for future work 
6.1. Potential use of coffee and greet tea polyphenols to treat gut dysfunctions 
The present study showed that selected coffee and green tea polyphenols acted as 
modulators of serotonin uptake in the intestinal model Caco-2 cells. This finding is 
interesting and should be further investigated since it highlights the possibility of treating 
serotonin-dependant gut dysfunctions, such as irritable bowel syndrome, using natural 
compounds from food. Further studies will have to be carried out to assess if and to what 
extend the selected polyphenols act as modulators of the serotonin reuptake transporter in 
vivo.  
 
6.1. Polyphenol absorption in the gastrointestinal system and the role of 
transporters 
Polyphenols have received increasing interest in the last few decades, for their properties as 
antioxidants (Reboul et al., 2007a).  
They have high structural diversity and are found in all plants and certain fungi (Mahbub et 
al., 2013). Animals, including humans, cannot synthesize polyphenols, thus the only route 
of entrance of these compounds in the human body is ingestion through the diet (Pereira et 
al., 2013). Over 8,000 polyphenols have been identified so far (Perez-Ternero et al., 2013), 
however polyphenols most often are found in plants as biologically unavailable glycosides 
or polymers, that need chemical modification in order to become available. Degradation 
occurs extensively in the intestine and gives origin to different products (Silberberg et al., 
2006). The nature of the products depends largely on the type of food initially ingested 
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(Lambert et al., 2003), the initial amount of polyphenol present in the meal, the chemical 
structure of the latter (Johnson, 1998) and the composition of the surrounding food matrix 
ingested from the host. The latter is important because the chemical interactions between 
molecules does impact on the effect they have on the human health (Roura et al., 2008, 
D'Agostino et al., 2012). A crucial role is also played by the unique set of enzymes found in 
each individual (Larrosa et al., 2006, D'Archivio et al., 2010).  
Each step of polyphenol metabolism within the human body is determinant for the resulting 
bioavailability. In the mouth, during mastication, polyphenols are partially released from the 
food matrix (Ginsburg et al., 2013). They interact with salivary proteins, rich in the amino 
acid proline, either through hydrophobic interactions or hydrogen bonds (Ginsburg et al., 
2012). It is very interesting to note that different polyphenols have different affinity for the 
salivary proteins. Proanthocyanidins and flavanols interact the most with the salivary 
proteins (Obreque-Slier et al., 2012). Great differences in affinity also exist among these 
two classes of polyphenols. For example, studies have shown that proanthocyanidin dimers, 
containing a bond between a C-4 and a C-8, had higher affinity for the salivary proteins than 
dimers containing a bond between a C-4 and a C-6. It was also shown that (+)-catechin 
interacted with the proline residues with much greater affinity than (-)-epicatechin (Spencer, 
2003).  
As a result of the binding between the salivary proteins and the polyphenols, soluble 
aggregates are formed. The described interaction is crucial for the resulting chemical 
activity of the proteins, since it impacts on the tertiary structure of the latter, modifying it 
due to the disruption of existing bonds and the formation of new ones (Bennick, 2002). 
Multiple protein-polyphenol complexes can join together resulting in large aggregates, 
which precipitate out of the solution (Soares et al., 2011). Interestingly it was observed that 
presence of these complexes did not impact greatly on the absorption and final availability 
of polyphenols (Tagliazucchi et al., 2010). There is evidence that it is likely that a part of 
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the ingested polyphenols could be absorbed directly in the mouth. One example is the case 
of resveratrol (Walle et al., 2004). However not many publications exist on this topic and 
nothing is known on the transporters which could be responsible of such movements across 
membranes. Buccal and gingival absorption has been proved for a variety of compounds 
and drugs and is currently used to deliver certain drugs (Darwish et al., 2007, De Caro et al., 
2008, Sakata and Onishi, 2013). It would be interesting to carry out studies to identify such 
transporters. A first step would be to select simple foods, rich in polyphenols and assess the 
percentage of oral absorption for each of them, using human volunteers or using human 
gingival epithelium cell lines as an initial model (Calenic et al., 2013). 
Recent studies have shown that polyphenol exposure to saliva increases the oxidant 
scavenging activity (OSA) of these molecules and thus it highlights a further relevant role 
for mastication (Ginsburg et al., 2012). 
When food progresses through the gastrointestinal tract the compounds present in it, 
including the polyphenolic content, undergo dramatic changes, in terms of the pHs they are 
exposed to. The stomach is characterized by a high acidic environment, with pH that can be 
as low as 1-2 and that in normal healthy conditions does not exceed 4-5 (Fisher et al., 1994). 
Individual studies were carried out using various compounds (malvidin-3-glucoside, 
resveratrol, catechins, proanthocyanidins) and demonstrated that polyphenols are incredibly 
tolerant to these pH changes. In contrast to what would be expected, they did not undergo 
any damage or structural change when exposed to different pHs (Lewandowska et al., 
2013). 
Deglycosilation occurs in the small intestine, mainly via the activity of two endogenous β-
glucosidase enzymes: the β-D-glucosidase and the lactase. Β-D-glucosidase targets β1-4 
bonds with broad substrate specificity, mainly acting on cleaving sugar complexes with 
glucose substitutes. Lactase is abundantly present at the brush board membrane of the 
enterocytes covering the intestinal villi and it is mainly involved in the breakdown of the 
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simple sugar lactose, found in milk, making possible its complete digestion (Teng et al., 
2012). After this step, the aglycones enter the epithelial cells through passive diffusion 
(Almon et al., 2011). In the small intestine polyphenols undergo extensive glucuronidation, 
from uridine diphosphate glucuronosyltransferases (UGT).  The UGTs catalyse covalent 
addition of glucuronic acid, recognised at the carboxyl-terminal end of the protein, to 
multiple lipophilic substrates and have a determinant role in detoxification by producing 
more polar compounds that are easily eliminated from the body. The amino-terminal half of 
these enzymes is the site of aglycone binding, thus its structure greatly changes between 
isoforms, while the carboxyl-terminal end is more conserved. Among the UGTs, UGT1A8 
and UGT1A10 are the isoforms involved the most with glucuronidation of polyphenols, 
targeting the C5 and C7 of the A ring (Meech and MacKenzie, 1997). The human small 
intestine is also an important site for O-methylation and O-methylation of flavanol 
glucuronides (Daniel et al., 2006). From the enterocytes, polyphenols are transported to the 
liver, which has the main role of increasing the overall solubility of compounds for their 
easier elimination from the body as xenobiotics (Forrester et al., 1992, Wen and Walle, 
2006). Thus polyphenolic compounds are mainly sulfated and methylated (Okushio et al., 
1999, De Santi et al., 2000), resulting the almost complete conjugation of these compounds 
which, with exception of epicatechin gallate and epigallocatechin gallate, are found in blood 
as aglycones at extremely low concentrations (Selma et al., 2009).  
The main site of polyphenol absorption in the human body is the large intestine (Borges et 
al., 2013). Polyphenols are initially modified by the intestinal microflora (Corona et al., 
2006) and then the products are absorbed, eliminated from the body or transported to the 
liver where they are transformed to monosulfates or monoglucuronides to be transported in 
the blood and subsequently excreted through the activity of the kidneys (Yang et al., 2013).  
In recent years, it has become evident that transporters play a major role in each of the 
metabolic steps of drug and xenobiotic transformation and transport across the various part 
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of the body. Polyphenols and their metabolites have gained attention for their promising 
health beneficial effects. It is known that they are highly absorbed, and therefore they must 
interact with transporters, due to the observation that after oral consumption of these 
compounds, they are all found into the blood circulation (Clifford et al., 2013), although 
different absorption dynamics are expected according to the ingested compound(s). The 
relationship between polyphenols and transporters remains fascinating, both in terms of 
compound transport and in terms of transporter modulation from these compounds 
(Rodriguez-Proteau et al., 2006). In fact many studies have been carried out assessing the 
effect that selected polyphenols have on specific transporters. However it is difficult to draw 
general conclusions, because the chemical structure of polyphenols varies considerably from 
one compound to another.  
 
6.2. Limitations of in vitro studies 
So far many studies have aimed to better understand the interactions between polyphenols 
and transporters. Though the majority of these studies are in vitro and only a limited number 
has been carried out both in vitro and in vivo, allowing a comparison of the results.  
Chapter 4 highlights the differences existing between cell lines and in vivo cells. In fact, 
while chapter 3 showed that OAT3 is only significantly expressed in the human kidney, 
chapter 4 showed for the first time expression of the transporter in the liver cell line HepG2. 
This existing discrepancy further highlights the limitation of using cell lines. Although using 
cells is a powerful tool to model specific cellular activities, such as the mechanism of 
selected transporters, the use of cells does not offer a true representation of what happens in 
vivo. In a recent study, four polyphenols with different chemical structures were selected 
(emodin, chrysophanol, apigenin and resveratrol) to better understand their interaction with 
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transporters, both in vitro and in vivo (Teng et al., 2012). The authors used the Caco-2 cell 
model for the in vitro assessment and blood samples from human donors for the in vivo 
assessment, identifying which transporters may be involved in the movement of the selected 
compounds. This study highlights the importance of using both in vitro and in vivo methods 
in order to obtain a more complete understating on the molecular mechanisms involved.  
It is noteworthy that this study did not identify significant differences between the results 
obtained using the in vitro and the in vivo models.   
A different example of such a comparison between in vivo and in vitro studies involved the 
assessment of the potential effect of orange juice polyphenols on decreasing the risk of 
cardiovascular disease (Vinson et al., 2002). Interestingly this work highlights big 
differences between the results obtained using in vitro and in vivo measurements. A model 
of heart disease, based on measuring the inhibition of lower density lipoproteins promoted 
by cupric ion, and a hamster model of atherosclerosis were used for the in vivo and in vitro 
measurements respectively. The orange juice polyphenols showed promising protective 
effects in vivo but not in vitro.  
In chapter 5, the effect of whole green tea and coffee was assessed, testing both whole 
extracts and individual compounds as down-regulators of the serotonin reuptake transporter. 
In the case of both whole extracts, time- and concentration-dependent down-regulation was 
observed. For certain individual coffee compounds it was shown that at physiological 
concentrations they were powerful down-regulators of SERT. In contrast, none of the tested 
individual compounds from green tea at physiological concentrations displayed a high 
modulatory effect on SERT. In both cases, experiments were carried out using a model, 
Caco-2 intestinal cells. There are multiple limitations in using such a cell model. First of all, 
when using cell lines, the cell model is created using cancerous cells. These cells show 
physiological and morphological differences compared to healthy cells and often present a 
very altered gene expression profile (Richmond and Su, 2008). Although experimental 
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technologies have been developed to assess the differences between immortalised cell lines 
and primary cells from the same tissue, these technologies are often extremely difficult to 
perform and only take into account specific aspects of the cell physiology (Tong et al., 
2009). For this purpose, bioinformatic tools could be extremely useful, since they are 
relatively cheap to use and give comprehensive information on the most different aspects of 
gene expression and cell physiology. For example, a bioinformatic comparison between 
hepatoma cell line Hepa1–6 with primary hepatocytes showed that the cell lines were 
deficient in mitochondria, as a result of re-arrangements occurring in the metabolic 
pathways. The cell lines also showed high up-regulation of the functions associated with 
cell cycle and great under-expression of drug metabolizing enzymes, which were typically 
highly expressed in primary liver cells (Pan et al., 2009). Knowing these changes could be 
very important in order to predict the in vivo situation, on the basis of results obtained using 
cell lines. It would be interesting to perform a comparative analysis between Caco-2 cells 
and primary intestine cells, comparing the serotonin transport in the two models, to predict 
more in vivo representative effects for green tea and coffee.  
Another limitation of using cells, both cell lines and primary cells, is the extreme 
simplification of the cell model compared to the in vivo situation. When cells are used as 
part of a tissue or a whole organism, the amount of interactions they have with other 
structures/organs is enormous, impacting on the molecular processes happening within 
individual cells.  
Moreover, when assessing the effect of compounds on selected cellular functions, it is 
important to consider that cultured cells are only exposed to the selected compound(s). At 
the contrary, in the in vivo situation, cells are generally exposed to complex matrixes. These 
matrixes greatly vary, especially in the case of the gastrointestinal tract, for the complexity 
and diversity of the food and beverages ingested at ones (Spahn-Langguth et al., 1998, Nieto 
et al., 2013). It would be interesting to design a human study, based on the results obtained 
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using coffee and green tea on SERT, to compare the effects of these beverages obtained 
using Caco-2 cells and human volunteers. 
 
6.3. The effect of white tea, green tea and black tea could be assessed on the 
cells 
It is noteworthy that three main teas exist, all produced from Camellia sinensis. They are 
white, green and black tea. The flavour, colour and nutritional properties of each tea are the 
result of different processes involved to prepare them (Sereshti et al., 2013). The white tea 
is the least processed and it is not oxidized, thus it is the one with mildest flavour and lower 
amount of caffeine. It is also the one with the highest polyphenol content (Ji et al., 2002, 
Tenore et al., 2013). To produce green tea, leaves undergo several steaming or roasting 
steps (Xu et al., 2012). This results in a reduction of the polyphenol content and in the 
development of more caffeine (Manning and Roberts, 2003). Finally black tea is a fully 
fermented beverage. This causes darkening of the leaves, due to tannin development, high 
caffeine levels and minimal amount of remaining polyphenols, compared to white and green 
teas (Yang et al., 2000, Di Lorenzo et al., 2013). 
It would be interesting to test the effect of white tea and black tea whole extracts 
respectively on Caco-2 cells and compare the results obtained to those obtained using green 
tea. This would give useful information on the effect of different caffeine levels on 
serotonin uptake and on the effect of different food processing methods in terms of 
serotonin uptake modulation and human health.  
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6.3. The importance of better investigating dietary food supplements 
An interesting area is represented by dietary supplements, which are becoming more and 
more popular (Umhau et al., 2012). It is very important to investigate and better understand 
the overall effect of these supplements, in order to ensure concrete health benefits and to 
limit adverse effects and negative health effects.  
A first step in this direction was made in 1994 with the approval of the Dietary Supplement 
and Health and Education Act (Young and Bass, 1995, Umhau et al., 2012), that stated the 
need to carry out rigorous studies and trials to assess the beneficial effects and the safe 
doses of new food ingredients and dietary food supplements. In Europe, the studies on food 
and supplements and their relationship with human health are regulated from the EFSA 
(European Food Safety Authority). The main responsibility of the EFSA is to evaluate the 
scientific validity of health claims coming from food and /or supplement consumption 
(Birchard, 1999). EU-countries provide the Commission with National lists of health claims. 
These claims are subsequently evaluated by the EFSA.  
The EFSA draws up lists of health beneficial compounds, dividing them in botanical 
compounds and non-botanical ones. The EFSA also provides a list of all the food 
compounds for which health claims were rejected. A different list if used for risk reducing 
compounds and compounds associated with children development. Certain food 
supplements have dramatically impacted on improving life conditions and are used 
nowadays routinely administered. An example is folic acid, or vitamin B12, which in many 
countries is routinely given during pregnancy. Folic acid has helped to reduce the incidence 
of neural tube defects, such as spina bifida (Scholl and Johnson, 2000). It is noteworthy that 
many drugs which are commonly nowadays would have been classified as supplements in 
the past. An example is aspirin, which was first discovered and administered after extracting 
it from the bark of the willow tree (Girstenbrey, 1983). Thus it would not be surprising if 
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one day the supplements daily taken today would become part of future pharmaceutical 
plans. In chapter 5, the effect that supplement concentrations of green tea and green tea 
individual compounds have on SERT in Caco-2 cell monolayers was described. A human 
study, based on these results would be very interesting, especially considering the 
controversial results from various studies. It has been shown that green tea supplements 
vary highly in their content of health-beneficial components. Moreover claims on the label 
of these supplements often do not correlate with the actual polyphenol content of an 
equivalent amount of dry green tea leaves. Finally caffeine content is often overlooked and 
in many cases data are not reported for this compound. A study carried out in America 
showed that out of 19 analysed green tea supplements, only 7 labels displayed caffeine 
content, 11 gave EGCG content and only 5 specified the overall polyphenol content 
(Seeram et al., 2006). In this study caffeine, EGCG and total polyphenol content was 
measured to vary from 20 to 183 %, from 12 to 143 % and from 14 to 36 %, respectively.  
The data reported highlight the need for more standardized procedures used to prepare green 
tea supplements and for more accurate information to be provided on the label. The need to 
do long term clinical trials to assess the effects of green tea supplements on human health, 
based on standardized administered doses, also seems evident. In fact, it is likely that 
despite the predicted health beneficial effects of green tea supplements or daily green tea 
consumption, their actual interaction with other dietary components would modify the 
overall outcomes. 
There are several considerations to make about human studies designed to test dietary 
supplements. The introduction of the Dietary Supplement and Health and Education Act has 
meant the introduction of stricter laws to be applied to even natural ingredients, which in the 
past could be sold without undergoing long trials (Ashar, 2010). The set of laws approved 
shorten the distance, in terms of health and safety assessment, between pharmaceutical 
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drugs and natural products, even though the clinical safety assessment for the 
pharmaceutical is still more complex and is more time-consuming.  
This increase in the time, costs and ethical implications for testing natural ingredients, such 
as green tea, has meant that many companies have abandoned the idea of carrying out 
assessment of a range of compounds (Avenell et al., 2005). However, it vital to to invest 
more in such trials for the impact that, in the longer term, they could have on improving the 
average health conditions and to reduce the costs of public health care. In fact, it has been 
shown that malnutrition and  lack of certain health-beneficial compounds are often at the 
base of many degenerative pathologies linked to oxidative stress, such as cancer (Russell, 
2007). In chapter 5, it was shown how multiple compounds from coffee significantly down-
regulated SERT, especially 5-FQA which was shown to be a very powerful modulator, at 
concentrations equivalent to these present in a strong cup of coffee. This results could 
represent a first step to further assess the potency of 5-FQA, selected coffee components and 
whole coffee extracts in vivo. For example a study based on human volunteers could be 
designed, having volunteers consuming coffee or coffee components in the form of 
supplements as part of their normal diet.    
 
6.4. Importance of bioinformatic tools 
In chapter 3 the high performance search engine Genevestigator was used to collect 
information on the anatomical distribution and transcriptional modulation of selected 
transporters of interest. The work was useful to collect comprehensive information on the 
transporters. The initial aim of the work was to obtain as much information as possible on 
the modulation of the genes of interest from food compounds. Using Genevestigator  
highlighted the lack of information available on polyphenols as transporter modulators. In 
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fact, only two compounds had been tested, curcumin and apple procyanidins. Using 
Genevestigator provided a large number of information which are useful to create a 
comprehensive profile on the responsiveness of the genes of interest to a range of 
conditions.  Bioinformatic tools provide a cheap way to carry out preliminary work on 
selected genes. Filters can be applied in order to refine the results to better match the 
research interests.  
6.5. Functional foods - the importance of better characterizing their impact on 
human health  
Another area of interest is represented by functional food. Similar considerations to those 
made for dietary food supplements can be made about functional food. Functional food 
offers food companies growing opportunities. It represents, at the same time, the possibility 
for consumers to buy quality food that would target specific health end-points and enhance 
the beneficial effects coming from consumption. Many foods currently sold on the market 
contain added elements and are reinforced in health-beneficial components. For example, 
the majority of breakfast cereals are fortified with iron (Whittaker et al., 2001).  
An example of the growing interest in functional food is given by the Swiss food company, 
Nestlé, which in the last decades has invested over £300 million towards research into 
functional food and beverages (Adriaanse, 2010). For this purpose the company has created 
two new units. These new units have the purpose of investigating and developing foods and 
drinks which may help prevent and/or treat chronic diseases, such a Alzheimer’s and 
diabetes. Many studies are currently carried out to better understand how to connect 
functional ingredients/compounds and foods. The main aim is to determine which 
food/health promoting compound combinations result in a more appealing product for the 
consumer to buy (van Kleef et al., 2005, Horska and Sparke, 2007, Vergari et al., 2010). 
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However, these studies are mainly marketing-oriented and they do not consider a 
determinant point: the interaction between the functional compound(s) added and the other 
components already present in the product. Dietary components are always inserted into a 
very complex matrix, moreover humans often consume multiple food ingredients at once 
(Frank et al., 2012). Cell-based studies exist that look at the impact of functional food 
ingredients on human health (Glei et al., 2003). Cell models are a very useful preliminary 
tool, to predict the effect of individual compounds or simple foods on certain processes. 
However the cells are not representative of the in vivo situation and often result in 
observations that are not confirmed by studies involving complex food matrixes or human 
studies (Yin and Chen, 2008). An example is given from studies carried out on carotenoids, 
which are compounds proven to correlate with a reduced risk of developing certain chronic 
pathologies. Since carotenoids are not endogenously produced in humans, they have to be 
introduced through the diet (Michaud et al., 2000, Osganian et al., 2003). In vitro studies 
initially resulted in identification of very high absorption of carotenoids, linked to high 
presence in the blood stream and therefore to potential for great beneficial health effects 
(Rauscher et al., 1998). However when comprehensive studies were carried out, considering 
the interaction between carotenoids and other food compounds, the results showed that the 
many other food compounds affected their absorption. For example it was shown that fibre 
significantly reduced the absorption of these compounds (Riedl et al., 1999). This result is 
extremely interesting, since carotenoids are compounds found in vegetables and thus their 
consumption is always linked to that of fibre. Taking these considerations into account, it 
would be interesting to test the green tea and coffee effect on SERT, using a range of food 
matrices, in a human study. This would help to assess the impact of other ingredients on the 
overall effect of green tea and coffee on serotonin uptake.  
In chapter 5, over 30% of the observed coffee effect on SERT was attributed to specific 
individual coffee compounds, although the rest of the effect was not explained. It would be 
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interesting to carry out further studies to characterise the rest of the down-regulatory effect 
observed on Caco-2 monolayers. There are mainly two possibilities to explain the remaining 
observable effect on SERT. One is the involvement of other coffee components that have 
not been tested in this work. Another possibility is the interaction between different 
compounds: it is possible that the overall observed effect is the result of the different 
compounds interacting with each other and that the observed result of an individual 
compound is not necessarily representative of the effect that the same compounds would 
have if tested in combination with other components.  
 
6.6. The impact of genetic variations on transporter modulation 
An important consideration to be made, when evaluating polyphenol absorption, is that 
transporter expression varies among human beings and it is strictly related to individual 
genetics (Benet, 2012). Thus, it is important to remember that, when predicting the impact 
of transporter modulators on human health, the initial genetic of the host plays a determinant 
role. Each individual represents a unique situation to be considered when designing drugs 
and therapies.  
Awareness of the genetic variation should be the object of more interest when predicting the 
pharmacological kinetics and the effects of drugs. General and reliable predictions can be 
made only for biological processes which are based on transporters and enzymes with 
limited genetic variation. It would be interesting to determine the genetic variation of 
transporters which are crucial for specific processes, such as serotonin uptake. This would 
be useful to determine the impact of this variation on pathologies such as depression and 
eating disorders, linked to poor serotonin presence. This could be done, for example, using 
tissue samples from a range of donors presenting symptoms of these pathologies and 
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relating the results of gene quantification in these samples to the analysis of tissues from 
healthy individuals.  
Nowadays the most used therapeutic approach to the cure of pathologies such as depression 
and eating disorders is based on the use of drugs targeting serotonin and other dopaminergic 
neurotransmitters. Many of these drugs target re-uptake transporters, such as SERT (Hatta et 
al., 2013). Though, prescription of these drugs does not take into account the individual 
variation. Administration of these drugs has often shown to cause problems, such as bone 
resorption, which may increase the risk of bone fractures (Diem et al., 2007, Shea et al., 
2013). It has been hypothesized that the effect of these drugs on bone health is due, at least 
to an extent, to the presence of a dopaminergic pathway in bone formation (Warden et al., 
2005). In fact studies carried out in rats showed that rats expressing a null mutation in the 
gene encoding for 5-HT had a dysfunctional bone formation (Nandhu et al., 2011).  
The general doses of drugs for depression and eating disorders are standardised mainly 
according to the age and the gender of the patient and do not consider other factors, such as 
the genetic variation (Rozzini et al., 2008). It could be very useful to introduce a test 
evaluating the gene levels, as one of the preliminary criteria for patient assessment. This 
could give more details on the specific situation of an individual and allow adjustment of the 
pharmacological does. Another important reason to know the genetic variation would be the 
possibility to introduce natural dietary supplements as an aid to the drug therapy.  
For example, in the case of serotonin-dependent eating disorders, the case scenario would be 
considerably different if the patient displayed abnormally high levels of SERT or normal 
levels of SERT but abnormally low levels of serotonin synthesis. In the second case the 
traditional antidepressants, that act by inhibiting SERT and therefore reducing the re-uptake 
of serotonin, would only represent a very limited part of the therapy. Dietary supplements 
containing serotonin or serotonin precursors would contribute to restoring normal serotonin 
levels.  
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A similar example is given by OAT3. Literature typically describes OAT3 as only 
significantly expressed in the kidney, as discussed in chapter 3. Studies have identified ten 
different coding-region variants for SLC22A8, resulting in an a slightly different amino acid 
sequence for OAT3, in DNA samples taken from 270 donors (80 African-Americans, 80 
European-Americans, 60 Asian-Americans, and 50 Mexican-Americans) (Erdman et al., 
2006). The interesting result of this work is that, among the ten SLC22A8 forms, only three 
of them had allele frequency >1 % in a particular ethnic group. However 3.5% of the Asian-
American donors expressed an SLC22A8 form which is associated with reduced ability of 
OAT3 to transport estrone sulfate. The same form does not affect OAT3 ability to transport 
cimetidine. Both estrone sulfate and cimetidine are model substrates for OAT3 (Aslamkhan 
et al., 2006). These findings suggest that OAT3 does not vary a lot among individuals of the 
same ethnic group and highlights the existence of gene variations between different ethnic 
groups. Estrone sulfate is an important marker in certain cancers, such as prostate and breast 
cancer (Purohit et al., 1999, Giton et al., 2008). Increase of estrone sulfate is displayed from 
patients with these pathologies. It could be interesting to consider that there is only little 
variability of the gene OAT3, among particular ethnic groups, when designing cancer 
therapies and predicting anti-cancer pharmacokinetics.   
 
6.7. Conclusions 
It is important to investigate the role that our diet has on human transporters, due to the 
important role that these compounds have in controlling a variety of physiological processes 
(Srimaroeng et al., 2008, Markadieu and Delpire, 2014). The present work sheds light on 
some of the aspects of transporter expression and modulation. There are still many grey 
areas on the topic and much more work will need to be carried out to clarify multiple aspect 
of transporter modulation, in response to dietary compounds such as polyphenols.  
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This work summarises the existing knowledge on the anatomical distribution and the 
modulation of selected transporters. This information could be very useful as a starting point 
to design comprehensive modulation studies. The work also predicts that the liver HepG2 
cell line is an unsuitable model, to assess transporter modulation. In fact the expression 
patterns of this cell line is very different from human hepatocytes. When investigating the 
modulation of the organic anion transporter 3, none of the stressors tested showed to have 
any effect on the transporter. Moreover, uptake of the metabolite kaempferol-3-O-
glucuronide was investigated in the cell line: despite an energy-dependent uptake 
mechanism has been predicted further studies to characterise this mechanism were 
unsuitable due to the poor uptake rate in the cell model. 
Finally the present work showed for the first time that green tea and coffee act as 
modulators of serotonin re-uptake in the intestine model Caco-2 cells. Both whole extracts 
and selected individual components acted as concentration-dependent modulators and could 
be further investigated as potentially useful to treat gut dysfunctions, such as irritable bowel 
syndrome.  
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Appendix I 
Anatomical distribution of transporters 
Transporter Tissue
Signal 
Intensity 
(IQR)
Standard 
error
N°of 
samples
OAT3 (SLC22A8 )
Kidney 22996 1472 100
Cortex 34987 4189 8
Medulla 13786 4938 8
Liver 961 43 75
Cardiovascular system 1372 23 137
Small intestine 1503 67 5
Large intestine 954 103 146
OAT1 (SLC22A6 )
Kidney 70681 4665 100
Cortex 26778 4964 8
Medulla 8064 2517 8
Liver 913 44 75
Cardiovascular system 792 17 137
Small intestine 919 52 5
Large intestine 740 47 146
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Transporter Tissue
Signal 
Intensity 
(IQR)
Standard 
error
N°of 
samples
OATP1A2 (SLCO1A2 )
Renal/Urinary system 256 4 111
Liver 292 40 75
Cardiovascular system 314 7 137
Small intestine 252 17 5
Large intestine 205 5 146
OATP1B1 (SLCO1B1 )
Renal/Urinary system 356 9 111
Liver 37477 1559 75
Cardiovascular system 370 4 137
Small intestine 363 8 5
Large intestine 281 4 146
OATP1B3 (SLCO1B3 )
Renal/Urinary system 340 5 111
Liver 45681 2519 75
Cardiovascular system 258 6 137
Small intestine 365 8 5
Large intestine 370 20 146
OATP4C1 (SLCO4C1 )
Kidney 21498 1122 100
Cortex 3255 458 8
Medulla 3536 379 8
Liver 1332 121 75
Cardiovascular system 186 4 137
Small intestine 204 4 5
Large intestine 526 38 146
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Transporter Tissue
Signal 
Intensity 
(IQR)
Standard 
error
N°of 
samples
MRP2 (ABCC2 )
Kidney 2715 207 100
Cortex 1169 77 8
Medulla 726 60 8
Liver 13174 792 75
Cardiovascular system 767 21 137
Small intestine 763 91 5
Large intestine 400 24 146
MRP3 (ABCC3 ) 
Kidney 353 8 100
Cortex 497 19 8
Medulla 452 17 8
Liver 426 19 75
Arterial system 522 24 10
Aorta 481 22 4
Coronary artery 549 33 6
Heart 327 7 121
Heart atrium 419 19 17
Heart ventricle 312 7 104
Small intestine 455 16 5
Large intestine 418 8 146
BCRP (ABCG2 )
Kidney 2778 206 100
Cortex 908 58 8
Medulla 909 75 8
Liver 13374 835 75
Cardiovascular system 1292 47 137
Small intestine 2109 1017 5
Large intestine 13620 1101 146
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Transporter Tissue
Signal 
Intensity 
(IQR)
Standard 
error
N°of 
samples
MCT1 (SLC16A1 )
Kidney 2113 228 100
Cortex 442 52 8
Medulla 318 19 8
Liver 2639 177 75
Arterial system 644 96 10
Aorta 841 198 4
Coronary artery 513 28 6
Heart 2001 108 121
Heart atrium 2791 494 17
Heart ventricle 1872 90 104
Small intestine 1283 439 5
Large intestine 3671 277 146
MCT7 (SLC16A2 )
Kidney 2455 85 100
Cortex 2217 117 8
Medulla 2005 69 8
Liver 12024 594 75
Arterial system 2562 284 10
Aorta 1714 153 4
Coronary artery 3128 283 6
Heart 2174 52 121
Heart atrium 1838 161 17
Heart ventricle 2229 53 104
Small intestine 1602 173 5
Large intestine 820 28 146
SMCT1 (SLC5A8)
Kidney 412 31 100
Cortex 1163 24 8
Medulla 1078 19 8
Liver 1004 37 75
Arterial system 1348 45 10
Aorta 1365 35 4
Coronary artery 1337 77 6
Heart 867 20 121
Heart atrium 1033 35 17
Heart ventricle 839 21 104
Small intestine 1419 109 5
Large intestine 986 27 146
Appendix II- Transcriptional modulation of transporters  
 
V 
 
Appendix II 
Transcriptional modulation of transporters 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
OAT1               
  Chemicals and Drugs             
  
 
AM580 -0.18 -1.13 0.034 
Vehicle (DMSO/EtOH) IL-4/ 
GM-CSF treated cells 
Tuomisto et al., 
2008 
  
 
Beta-glycerofosfate 
(intermediate) study 
2 
-0.23 -1.17 0.050 
Diff. Medium exposed bone 
marrow stomal cells 
Stockwin et al., 
2008 
  
 
Beta-glycerofosfate 
(late) study 2 
-0.56 -1.47 0.002 
Diff. Medium exposed bone 
marrow stomal cells 
Stockwin et al., 
2008 
  
 
BPDE study 2 0.51 1.44 0.027 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
  
 
Echinomycin/Defero
xamine 
0.48 1.39 0.007 
Astroglia cells stimulated with 
deferoxamine 
Bourdeau et al., 
2007 
  
 
PMA study 5 0.39 1.31 0.047 ASPC-1 cells Murphy et al., 2010 
  
 
R547 (6h) 0.41 1.34 0.034 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24h) study 5 0.23 1.17 0.029 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (6h) study 5 0.39 1.32 0.020 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (1h) study 6 0.31 1.23 0.028 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24h) study 7 0.38 1.29 0.004 Vehicle (DMSO) treated Fridgway and 
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VI 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
DU145 cells Conlon, 2011 
  
 
Sapphyrin PCI-2050 0.32 1.25 0.047 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
    
Sapphyrin PCI-2002 
study 2 
0.16 1.12 0.031 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Zalypsis study 2 0.61 1.53 0.007 Untreated OPM1 cells 
Sarasin-Filipowicz 
et al., 2008 
  Disease             
  
 
Hypertrophic 
cardiomyopathy 
-0.28 -1.22 0.014 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Viral cardiomyopathy -0.25 -1.20 0.012 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Ischemic 
cardiomyopathy  
-0.19 -1.14 0.008 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Ischemic 
cardiomyopathy 
(after VAD) 
-0.40 -1.34 0.029 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
Growth factors and 
cytokines 
            
  
 
Il-17 -0.49 -1.41 0.024 
Untreated aortic vascular 
smooth muscle cells 
Tallides and Eid, 
2008 
  Hormones             
  
 
17-betaestradiol 
(intermediate) study 
10 
0.37 1.29 0.005 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
OAT3               
  Chemicals and Drugs             
  
 
BPDE study 2 0.34 1.26 0.016 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
  
 
Cadmium 0.27 1.21 0.014 Untreated, 72h starved NPrEC Bakshi et al., 2008 
Appendix II- Transcriptional modulation of transporters  
 
VII 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
cells 
  
 
Doxycycline 0.18 1.13 0.040 
Untreated, stably transfected 
SW480 cells 
Gerin et al., 2007 
  
 
Ciclosporin study 2 0.23 1.17 0.006 Normal PBMC sample 
Grundberg et al., 
2008 
  
 
Sirolimus 0.23 1.17 0.006 Normal PBMC sample 
Brouard et al., 
2010 
  
 
Calcitriol 0.22 1.16 0.007 Untread breast cancer cells Murphy, 2010 
  
 
Echinomycin/Defero
xamine 
0.43 1.35 0.004 
Astroglia cells stimulated with 
deferoxamine 
Roth, 2007 
  
 
Lypopolysaccharide 0.38 1.30 0.007 
Vehicle DTT/ polym.B treated 
monocytes 
Fulcher, 2006 
  
 
R547 (4h)-study 4 0.25 1.18 0.044 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (6h)- study 4 0.37 1.29 0.017 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R457 (4h)-study 5 0.46 1.38 0.032 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (4h)-study 6 0.35 1.28 0.001 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
Sapphyrin PCI-2050 0.23 1.17 0.014 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
   Disease             
  
 
Diabetes study 2 -0.41 -1.34 0.040 Normal regulatory T-cells Lu et al., 2009 
  
Growth factors and 
cytokines 
            
  
 
G-CSF 0.27 1.20 0.025 Untreated leukocytes Buzzeo et al., 2007 
  
 
IL-22 0.26 1.19 0.003 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
IL-24 0.18 1.14 0.013 Untreated neonatal epidermal Sarasin-Filipowicz 
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VIII 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
keratinocytes et al., 2008 
  Hormones             
  
 
17-beta estradiol 
study 10 
-0.16 -1.12 0.019 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17-beta estradiol 
study 11 
-0.23 -1.17 0.002 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
OATP1A2               
  Chemicals and Drugs             
  
 
Curcumin (late) 0.16 1.12 0.032 
Untreated PMA diff. U937 
cells 
Mishra et al., 2008 
  
 
Paricalcitol 
(itermediate) 
0.20 1.14 0.026 Coronary smooth muscle cells 
Stockwin et al., 
2009 
  
 
Paricalcitol 
(itermediate) study 2 
0.18 1.13 0.042 Coronary smooth muscle cells 
Stockwin et al., 
2009 
  
 
Propiconazole 
(itermediate) 
0.22 1.17 0.024 DMSO treated hepatocytes 
Goetz and Dix, 
2008 
  
 
Triadimefon (high) 0.26 1.20 0.003 DMSO treated hepatocytes 
Goetz and Dix, 
2008 
  
 
Triadimefon (low) 0.14 1.10 0.006 DMSO treated hepatocytes 
Goetz and Dix, 
2008 
  
 
R547 (4 h) study 4 0.22 1.17 0.018 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R568 (intermediate) 
study 2 
0.29 1.22 0.024 Coronary smooth muscle cells Rosinski, 2009 
  
 
Sangivamycin 0.28 1.21 0.042 MCF-7 cells Rosinski, 2009 
  Disease             
  
 
Dilated 
cardiomyopathy 
(after VAD) 
-0.13 -1.09 0.017 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Hypertrophic 0.30 1.21 0.028 Myocardial sample (left Schinke et al., 2004 
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IX 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
cardiomyopathy ventricle biopsy) 
  
Growth factors and 
cytokines 
            
  
 
IL-20  -0.20 -1.15 0.027 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
TGF-β (intermediate) 
study 5 
-0.13 -1.10 0.043 Untreated A549 cells 
Shalhoub et al., 
2010 
  
 
TGF-β3 
(intermediate)  
-0.14 -1.10 0.026 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
  
 
TGF-β3 (late)  -0.13 -1.09 0.038 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
OATP1B1               
  Chemicals and Drugs             
  
 
BPDE (intermediate) 
study 2 
-0.18 -1.13 0.043 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
  
 
BPDE (late) study 2 0.09 1.06 0.029 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
  
 
Curcumin/hydrogen 
peroxide (early) 
0.30 1.23 0.025 
Exposed (H2O2)/PMA diff. 
U937 cells 
Mishra et al., 2008 
  
 
Actinomycin D -0.14 -1.10 0.045 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Gefitinib -0.44 -1.36 0.027 Wild type A431 cells Guix et al., 2008 
  
 
Hydrochloric acid -0.20 -1.16 0.023 
Breast epithelial cells exposed 
to acidosis 
Chen et al., 2010 
  
 
Vitamin D3 0.09 1.07 0.009 
Vehicle (EtOH) treated 
bronchial smooth muscle cells 
Bossé et al., 2007 
  
 
Cycloheximide 0.14 1.10 0.034 
Vehicle (DMSO) treated 
MCF-7 cells 
Johnson et al., 
2006 
  
 
Lipopolysaccharide 0.10 1.07 0.049 
Vehicle DTT/ polym.B treated 
monocytes 
Fulcher et al., 2006 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
PMA study 4 0.21 1.16 0.014 ASPC-1 cells 
Osaba et al., 2008 
(a) 
  
 
R547 (6 h) 0.19 1.14 0.017 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (2 h) study 6  0.14 1.10 0.022 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
Sapphyrin PCI-2050 0.41 1.34 0.010 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Sapphyrin PCI-2050 
study 2 
0.38 1.31 0.017 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Sapphyrin PCI-
2002/ZnOAc2 
0.09 1.06 0.023 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  Disease             
  
 
Viral cardiomyopathy 0.20 1.14 0.005 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Ischemic 
cardiomyopathy 
0.13 1.09 0.005 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
Growth factors and 
cytokines 
            
  
 
Angiopoietin-1 0.16 1.11 0.040 
Sparse human umbelical vein 
cells 
Fukuhara et al., 
2008 
  
 
G-CSF 0.35 1.28 0.006 Untreated leukocytes Buzzeo et al., 2007 
  
 
IL-4/anti CD40 -0.13 -1.09 0.019 Normal resting B-cells Nickols et al., 2007 
OATP1B3               
  Chemicals and Drugs             
  
 
Beta-
glycerophosphate 
(intermediate) 
0.29 1.22 0.022 
Diff. Medium exposed bone 
marrow stomal cells 
Stockwin et al., 
2008 
  
 
BPDE (intermediate) 
study 2 
-0.89 -1.85 0.000 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
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XI 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
  
 
  
 
    
  
 
5-aza-2'-
deoxycitidine/TSA 
study 4 
0.55 1.47 0.006 
Mock treated bronchial 
epithelial cells 
Milani et al., 2011 
  
 
Actinomycin D 0.51 1.43 0.001 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Gefitinib -0.93 -1.91 0.000 Wild type A431 cells Guix et al., 2008 
  
 
Dexamethasome 
study 4 
0.14 1.10 0.004 Vehicle treated HOb514 cells Guix et al., 2008 
  
 
Mifepristone/dexame
thasone 
0.12 1.09 0.018 A549 cells Olsen et al., 2009 
  
 
Mifepristone 0.26 1.20 0.002 A549 cells Olsen et al., 2009 
  
 
Deferoxamine 1.13 2.20 0.001 
Untreated U251 astroglioma 
cells 
Bourdeau et al., 
2007 
  
 
Tibolone 0.11 1.08 0.038 
Untreated endometrium 
sample 
Hanifi-
Moghaddam et al., 
2007 
  
 
Calcitriol (early) 0.18 1.13 0.016 Untread breast cancer cells 
Wermuth et al., 
2010 
  
 
Calcitriol (late) study 
2 
-0.16 -1.12 0.037 Untread breast cancer cells 
Wermuth et al., 
2010 
  
 
Paricalcitol (late) -0.13 -1.10 0.037 Coronary smooth muscle cells 
Stockwin et al., 
2009 
  
 
Cycloheximide 0.19 1.14 0.032 
Vehicle (DMSO) treated 
MCF-7 cells 
Johnson et al., 
2006 
  
 
PMA study 2 0.20 1.15 0.005 
Mock treated transduced 
MONO-MAC-6 (shRNA 
contr.) 
Osaba et al., 2008 
(b) 
  
 
PMA study 4 -6.76 -108.44 0.000 
Vehicle (DMSO) tretaed 
ASPC-1 cells 
Murphy, 2010 
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XII 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
R547 (2 h)  0.50 1.42 0.007 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24 h) study 2 0.70 1.61 0.012 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (2 h) study 3 0.35 1.28 0.040 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24 h) study 6 -0.50 -1.43 0.028 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (2 h) study 6 -0.30 -1.23 0.046 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R568 (early)  0.13 1.09 0.046 Coronary smooth muscle cells 
Stockwin et al., 
2009 
  
 
R568 (late) study 2 -0.20 -1.15 0.014 Coronary smooth muscle cells 
Stockwin et al., 
2009 
  
 
Sapphyrin PCI-2050 0.59 1.51 0.006 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Sapphyrin PCI-2050 
study 2 
0.39 1.31 0.011 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Sapphyrin PCI-
2002/ZnOAc2 
0.29 1.22 0.034 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  Disease             
  
 
ischemic 
cardiomyopathy 
(after VAD) 
0.12 1.09 0.042 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Unstable angina (30 
d)/unstable angina (7 
d) 
0.15 1.11 0.033 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Barrett's esophagus 
(acid) (late) study 2 
-0.46 -1.38 0.043 CP-A hTERT cells 
Donnellan and 
Hardie, 2007 
  
 
Ulcerative colitis 0.92 2.19 0.048 Colonic mucosal endoscopic Sa et al., 2007 
Appendix II- Transcriptional modulation of transporters  
 
XIII 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
study 4 (Inflamm.) pinch biopsies 
  
Growth factors and 
cytokines 
            
  
 
G-CSF 0.18 1.13 0.032 Untreated leukocytes Buzzeo et al., 2007 
  
 
SDF study 2 -0.42 -1.34 0.017 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
SDF study 4 -1.99 -4.17 0.000 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
TNF-α -0.24 -1.18 0.024 
Normal lymphatic endotelial 
cells biopsies 
Kirshner et al., 
2008 
  Hormones             
  
 
17beta-estradiol 
study 8 
-0.25 -1.19 0.008 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
Estrogen 
(intermediate) 
-0.23 -1.17 0.029 MCF-7 cells Carroll et al., 2006 
  
 
Estrogen (late) -0.31 -1.24 0.011 MCF-7 cells Carroll et al., 2006 
OATP4C1               
  Chemicals and Drugs             
  
 
5-aza-2'-
deoxycitidine/TSA 
study 5 
1.04 2.07 0.004 
Mock treated bronchial 
epithelial cells 
Milani et al., 2011 
  
 
Gefitinib -0.22 -1.17 0.041 Wild type A431 cells Guix et al., 2008 
  
 
Peginterferon study 4 0.49 1.48 0.011 PBMC cells Sartor et al., 2009 
  
 
Tibolone -0.08 -1.06 0.012 
Untreated endometrium 
sample 
Hanifi-
Moghaddam et al., 
2007 
  
 
Lipopolysaccharide 
study 3 
-0.23 -1.17 0.015 Untreated THp-1  cells Fulcher et al., 2006 
  
 
PMA study 2 -1.30 -2.47 0.001 
Mock treated transduced 
MONO-MAC-6 (shRNA 
contr.) 
Osaba et al., 2008 
(b) 
  
 
PMA study 2 -0.71 -1.65 0.033 Mock treated transduced Osaba et al., 2008 
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XIV 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
(shRNA contr.) MONO-MAC-6 (shRNA 
contr.) 
(b) 
  
 
R547 study 3 (24 h) -0.23 -1.18 0.021 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 6 (24 h) 0.10 1.07 0.030 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
Sapphyrin PCI-5003 -0.13 -1.09 0.046 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  Disease             
  
 
Idiopathic dilated 
cardiomyopathy 
0.12 1.09 0.005 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Familial 
cardiomyopathy 
0.15 1.10 0.029 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Postpartum 
cardiomyopathy 
0.18 1.13 0.037 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Viral cardiomyopathy 0.21 1.15 0.002 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Ischemic 
cardiomyopathy 
0.21 1.16 0.001 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Ischemic 
cardiomyopathy 
(after VAD) 
-0.13 -1.09 0.025 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
Growth factors and 
cytokines 
            
  
 
G-CSF 1.08 2.04 0.003 Untreated leukocytes Buzzeo et al., 2007 
  
 
SDF study 4 -0.43 -1.34 0.001 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
TGF-β3 
(intermediate)/ BMP-
2 study 2 
(intermediate) 
-0.15 -1.11 0.014 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
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XV 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  Hormones             
  
 
17-betaestradiol 
(early) study 10 
-0.25 -1.19 0.047 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17-betaestradiol 
(intermediate) study 
10 
-0.51 -1.42 0.004 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17-betaestradiol (late) 
study 10 
-0.89 -1.85 0.001 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17-betaestradiol 
study 8 
0.20 1.15 0.049 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
Estradiol -0.14 -1.10 0.003 
Untreated endometrium 
sample 
Meja et al., 2008 
MRP2               
  Chemicals             
  
 
beta-
glycerophosphate 
(short) 
0.78 1.75 0.012 
Diff. Medium exposed bone 
marrow stomal cells 
Stockwin et al., 
2008 
  
 
BPDE (intermediate) 
study 2 
-0.59 -1.49 0.010 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
  
 
Rosiglitazone/IL-
4/GM-CSF 
0.47 1.38 0.021 
Vehicle (DMSO/EtOH) IL-4/ 
GM-CSF treated cells 
Tuomisto et al., 
2008 
  
 
Lactic acid/hypoxia 0.27 1.20 0.013 
Untreated breast epithelial 
cells 
Donnellan and 
Hardie, 2007 
  
 
5-aza-2'-
deoxycitidine/TSA 
study 4 
0.27 1.21 0.014 
Mock treated bronchial 
epithelial cells 
Milani et al., 2011 
  
 
Elesclomol/paclitaxel 1.17 2.26 0.015 
Vehicle (DMSO) treated Hs 
294 T cells 
Lu et al., 2009 
  
 
Dexamethasone 
(early) study 3 
0.55 1.46 0.011 Vehicle treated HOb514 cells Guix et al., 2008 
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XVI 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
Dexamethasone (late) 
study 3 
-0.62 -1.54 0.007 Vehicle treated HOb514 cells Guix et al., 2008 
  
 
Dexamethasone study 
4 
-0.52 -1.43 0.000 Vehicle treated HOb514 cells Guix et al., 2008 
  
 
Mifepristone/dexame
thasone study 4 
0.46 1.38 0.000 A549 cells Olsen et al., 2009 
  
 
Tibolone 0.13 1.09 0.019 
Untreated endometrium 
sample 
Hanifi-
Moghaddam et al., 
2007 
  
 
Echinomycin/deferox
amine 
0.92 1.87 0.004 
Astroglia cells stimulated with 
deferoxamine 
Bourdeau et al., 
2007 
  
 
Elesclomol  0.93 1.90 0.003 
Vehicle (DMSO) treated Hs 
294 T cells 
Lu et al., 2009 
  
 
Elesclomol study 4 1.64 3.13 0.012 
Vehicle (DMSO) treated Hs 
294 T cells 
Lu et al., 2009 
  
 
GW7647 (24 h) -0.52 -1.44 0.001 
Vehicle (DMSO) treated 
HepG2 cells 
 Wang (Z) et al., 
2007 
  
 
GW7647 (6 h) -0.28 -1.22 0.004 
Vehicle (DMSO) treated 
HepG2 cells 
 Wang (Z) et al., 
2007 
  
 
PMA study 2 -0.29 -1.22 0.050 
Mock treated transduced 
MONO-MAC-6 (shRNA 
contr.) 
Osaba et al., 2008 
(b) 
  
 
PMA study 4 2.13 4.61 0.003 
Vehicle (DMSO) tretaed 
ASPC-1 cells 
Murphy, 2010 
  
 
R547 (24 h) study 3 0.83 1.77 0.001 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (2 h) study 3 -0.26 -1.20 0.003 
Vehicle (DMSO) treated 
DU145 cells 
Murphy, 2010 
  
 
R547 (6 h) study 3 0.72 1.67 0.042 
Vehicle (DMSO) treated 
DU145 cells 
Murphy, 2010 
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XVII 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
Sapphyrin PCI-5020  -0.55 -1.47 0.001 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Sapphyrin PCI-5020 
study 2 
-0.30 -1.23 0.034 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Sapphyrin PCI-5002 
study 2 
-0.32 -1.24 0.009 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
UO126 (late) -0.31 -1.24 0.028 Untreated MCF-7 cells Roth, 2007 
  Disease             
  
 
Ischemic 
cardiomyopathy 
-0.16 -1.12 0.023 
Myocardial sample (left 
ventricle biopsy) 
Schinke  et al., 
2004 
  
 
Ulcerative colitis 
study 4 (Inflamm.) 
0.23 1.18 0.002 
Colonic mucosal endoscopic 
pinch biopsies 
Sa et al., 2007 
  
 
Ulcerative colitis 
study 4 (Inflamm.) 
0.20 1.15 0.018 
Colonic mucosal endoscopic 
pinch biopsies 
Sarasin-Filipowicz 
et al., 2008 
  
Growth factors and 
cytokines 
            
  
 
Angiopoietin-1 
(sparse)/angiopoietin-
1 (conf) 
-0.06 -1.04 0.039 
Sparse human umbelical vein 
cells 
Fukuhara et al., 
2008 
  
 
BMP-2 (early) 0.34 1.26 0.038 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
  
 
G-CSF 1.08 2.11 0.000 Untreated leukocytes 
Bvuzzeo et al., 
2007 
  
 
IL-20 -0.47 -1.39 0.007   
Sarasin-Filipowicz 
et al., 2008 
  
 
KGF -1.03 -2.05 0.004 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
TGF-β (intermediate) 
study 5 
-3.17 -8.28 0.002 Untreated A549 cells 
Shalhoub et al., 
2010 
  
 
TGF-β (late) study 5 -3.17 -8.88 0.009 Untreated A549 cells Shalhoub et al., 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
2010 
  
 
TGF-β3 
(intermediate) study 
5/BMP-2 
(intermediate) study 
2 
0.34 1.27 0.005 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
  
 
TGF-β3 
(intermediate)  
0.31 1.24 0.047 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
MRP3               
  Chemicals             
  
 
AG1478 (late) 0.32 1.24 0.028 Untreated MCF-7 cells Roth, 2007 
  
 
beta-glycerophospahe 
(late) study 2 
-0.18 -1.13 0.027 
Diff. Medium exposed bone 
marrow stomal cells 
Stockwin, 2008 
  
 
curcumin (early) -0.18 -1.13 0.007 
Untreated PMA diff. U937 
cells 
Mishra et al., 2008 
  
 
Rosiglitazone/IL-
4/GM-CSF 
0.02 1.02 0.025 
Vehicle (DMSO/EtOH) IL-4/ 
GM-CSF treated cells 
Tuomisto et al., 
2008 
  
 
5-azacytidine -0.17 -1.12 0.029 
Mock treaed ovarian cancer 
cell line 
Milani et al., 2011 
  
 
Dexamethasone study 
4 
-0.22 -1.17 0.030 Vehicle treated HOb514 cells Guix et al., 2008 
  
 
Hydrochloric acid 0.12 1.09 0.037 
Breast epithelial cells exposed 
to acidosis 
Chen et al., 2010 
  
 
Calcitriol 
(intermediate) study 
2 
-0.09 -1.07 0.040 Untread breast cancer cells 
Wermuth et al., 
2010 
  
 
Cyclohexemide 0.42 1.34 0.018 
Vehicle (DMSO) treated 
MCF-7 cells 
Johnson et al., 
2006 
  
 
PMA study 3 
(shRNA cycT1) 
-0.06 -1.04 0.017 
Mock treated transduced 
MONO-MAC-6 (shRNA 
Osaba et al., 2008 
(b) 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
contr.) 
  
 
R547 (6 h) study  0.56 1.47 0.001 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24 h) study 3 0.44 1.38 0.033 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (2 h) study 3 0.17 1.13 0.020 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (6 h) study 3 0.68 1.65 0.046 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (6 h) study 5 0.30 1.23 0.010 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (1 h) study 6 0.14 1.10 0.038 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R568 (intermediate) 
study 2 
-0.19 -1.14 0.002 Coronary smooth muscle cells 
Stockwin et al., 
2009 
  
 
Rottlerin  0.35 1.28 0.047 Normal dermal fibroblasts 
Chen and Chi, 
2008 
  
 
Rottlerin (systemic 
sclerosis) 
-0.51 -1.43 0.024 Normal dermal fibroblasts 
Chen and Chi, 
2008 
  
 
Sapphyrin PCI-5020  0.83 1.77 0.001 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Sapphyrin PCI-5020 
study 2 
0.79 1.73 0.005 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Sapphyrin PCI-5002  -0.13 -1.10 0.011 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
zalypsis study 2 0.29 1.22 0.036 Untreated OPM1 cells 
Sarasin-Filipowicz 
et al., 2008 
  Disease             
  
 
Idiopathic dilated 
cardiomyopathy 
0.16 1.11 0.004 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
Viral cardiomyopathy 0.19 1.14 0.031 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
Grwoth factors and 
cytokines 
            
  
 
G-CSF 0.30 1.23 0.018 Untreated leukocytes Buzzeo et al., 2007 
  
 
IFN-g study 2 0.25 1.19 0.016 Untreated OPM1 cells 
Sarasin-Filipowicz 
et al., 2008 
  
 
IL-1b 0.22 1.16 0.002 Untreated OPM1 cells 
Sarasin-Filipowicz 
et al., 2008 
  
 
IL-22 0.23 1.17 0.013 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
IL-24 0.20 1.15 0.003 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
SDF  -0.19 -1.14 0.004 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
SDF study 2 0.36 1.29 0.033 Untreated MDA Mb231 cells Nickols et al., 2007 
  Hormones             
  
 
17-betaestradiol (late) 
study 10 
-0.24 -1.18 0.021 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17-betaestradiol 
study 11 
-0.05 -1.04 0.021 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
estrogen (late) -0.33 -1.25 0.033 MCF-7 cells Carroll et al., 2006 
BCRP               
  Chemicals             
  
 
Apple 
procyanidin/TNFa/D
MSO 
-0.30 -1.23 0.044 HUVEC 
García-Conesa et 
al., 2009 
  
 
ARC -0.53 -1.44 0.025 MCF-7 
Szatmari et al., 
2006 
  
 
BPDE (late) study 2 -0.28 -1.22 0.036 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
Rosiglitazone/IL-
4/GM-CSF 
2.88 6.77 0.009 
Vehicle (DMSO/EtOH) IL-4/ 
GM-CSF treated cells 
Tuomisto et al., 
2008 
  
 
Rosiglitazone/AGN1
93109/IL-4/GM-CSF 
2.63 5.78 0.041 
Vehicle (DMSO/EtOH) IL-4/ 
GM-CSF treated cells 
Tuomisto et al., 
2008 
  
 
Lactic acid -0.74 -1.67 0.001 
Untreated breast epithelial 
cells 
Donnellan and 
Hardie, 2007 
  
 
5-aza-2'-
deoxycitidine/TSA 
study 4 
1.82 3.52 0.000 
Mock treated bronchial 
epithelial cells 
Milani et al., 2011 
  
 
5-aza-2'-
deoxycitidine/TSA 
study 5 
1.36 2.56 0.000 
Mock treated bronchial 
epithelial cells 
Milani et al., 2011 
  
 
Elesclomol/paclitaxel 0.73 1.65 0.049 
Vehicle (DMSO) treated Hs 
294 T cells 
Lin et al., 2007 
  
 
Gefitinib 2.25 4.76 0.000 Wild type A431 cells Guix et al., 2008 
  
 
Dexamethasone study 
4 
-0.29 -1.22 0.000 Vehicle treated HOb514 cells Guix et al., 2008 
  
 
Mifepristone/dexame
thasone study 4 
0.24 1.18 0.001 A549 cells Olsen et al., 2009 
  
 
Simvastatin (early) 0.26 1.19 0.027 HPBM 
van der Meer et al., 
2010 
  
 
Tibolone 0.76 1.63 0.004 
Untreated endometrium 
sample 
Hanifi-
Moghaddam et al., 
2007 
  
 
Epoxomicin (early) -0.24 -1.18 0.013 HEK293 Chang et al., 2011 
  
 
Epoxomicin (late) -0.85 -1.81 0.000 HEK293 Chang et al., 2011 
  
 
Cyclohexemide 0.51 1.43 0.000 
Vehicle (DMSO) treated 
MCF-7 cells 
Johnson et al., 
2006 
  
 
PMA study 2  3.65 13.33 0.005 
Mock treated, transduced  
MONO-MAC-6 cells 
Osaba et al., 2008 
(b) 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
PMA study 2 
(shRNA contr.) 
4.50 23.92 0.003 
Mock treated, transduced  
MONO-MAC-6 cells 
Osaba et al., 2008 
(b) 
  
 
PMA study 2 
(shRNA cycT1) 
3.62 15.84 0.049 
Mock treated transduced 
MONO-MAC-6 (shRNA 
contr.) 
Osaba et al., 2008 
(b) 
  
 
PMA study 4/PMA 
study 5 
6.22 63.86 0.000 
Vehicle (DMSO) tretaed 
ASPC-1 cells 
Murphy, 2010 
  
 
R547 (2 h) 0.43 1.34 0.011 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (6 h) 0.85 1.79 0.000 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (6 h) study 2 0.38 1.30 0.022 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24 h) study 3 -0.59 -1.51 0.002 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (2 h) study 3 0.25 1.19 0.048 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (6 h) study 3 0.69 1.61 0.002 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24 h) study 5 -0.28 -1.21 0.013 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24 h) study 5 -0.28 -1.21 0.010 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24 h) study 6 -0.25 -1.19 0.005 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
Sapphyrin PCI-
2002/ZnOAc2 
-0.32 -1.25 0.019 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  Disease             
  
 
Dilated 
cardiomyopathy 
0.93 1.66 0.006 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
(after VAD) 
  
 
Ischemic 
cardiomyopathy 
0.41 1.26 0.038 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Myocardial infarction 
(7 d) /unstable angina 
(7 d) 
-0.62 -1.65 0.036 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Ulcerative colitis 
(Iflamm.) study 4 
-2.01 -8.85 0.034 
Colonic mucosal endoscopic 
pinch biopsies 
Sa et al., 2007 
  
 
Ulcerative colitis 
(Iflamm.) study 4 
-2.74 -8.62 0.004 
Colonic mucosal endoscopic 
pinch biopsies 
Sa et al., 2007 
  
Growth factors and 
cytokines 
            
  
 
Angiopoietin-1 
(sparse)/angiopoietin-
1 (conf) 
-3.65 -12.56 0.000 
Sparse human umbelical vein 
cells 
Fukuhara et al., 
2008 
  
 
IL-1b 0.31 1.24 0.029 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
SDF  study 4 -1.09 -2.16 0.007 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
TGF-β (intermediate) 
study 5 
-3.20 -7.97 0.013 Untreated A549 cells 
Shalhoub et al., 
2010 
  
 
TGF-β (late) study 5 -3.79 -13.17 0.027 Untreated A549 cells 
Shalhoub et al., 
2010 
  
 
TGF-β3 
(intermediate)/BPM-
2 (intermediate) 
study 2 
-0.12 -1.08 0.022 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
  
 
TNF-α/Il-1b/IL-
6/PGE2 
-3.83 -14.01 0.000 
Normal lymphatic endotelial 
cells biopsies 
Kirshner et al., 
2008 
  Hormones             
  
 
17beta- 0.56 1.47 0.000 Vehicle treated MCF-7 cells Johnson et al., 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
estradiol/cyclohexem
ide 
2006 
  
 
17beta-estradiol 
(early) study 10 
-0.38 -1.30 0.000 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
(intermediate) study 
10 
-0.24 -1.18 0.000 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol (late) 
study 10 
-0.19 -1.14 0.021 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
study 11 
0.31 1.24 0.003 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
study 12 
0.97 1.96 0.009 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
study 8 
1.32 2.53 0.000 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
study 8 
-0.23 -1.17 0.036 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
Dihydrotestosterone -0.50 -1.41 0.023 MCF-7 cells Carroll et al., 2006 
  
 
Estradiol 1.06 1.98 0.000 
Untreated endometrium 
sample 
Meja et al., 2008 
  
 
Estradiol (late) -0.31 -1.24 0.001 
Untreated endometrium 
sample 
Meja et al., 2008 
MCT1               
  Chemicals             
  
 
Apple procyanidin 0.65 1.56 0.001 HUVEC 
García-Conesa et 
al., 2009 
  
 
BPDE (early) study 2 0.85 1.80 0.000 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
  
 
BPDE (intermediate) 
study 2 
-0.34 -1.27 0.025 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2010 
Appendix II- Transcriptional modulation of transporters  
 
XXV 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
cadmium (ealry) -0.82 -1.77 0.005 
Untreated, 72h starved NPrEC 
cells 
Bakshi et al., 2008 
  
 
Rosiglitazone/IL-
4/GM-CSF 
-0.41 -1.33 0.029 
Vehicle (DMSO/EtOH) IL-4/ 
GM-CSF treated cells 
Tuomisto et al., 
2008 
  
 
Lactic acid 0.30 1.23 0.013 
Untreated breast epithelial 
cells 
Donnellan and 
Hardie, 2007 
  
 
Lactic acid/hypoxia 0.42 1.34 0.023 
Untreated breast epithelial 
cells 
Donnellan and 
Hardie, 2007 
  
 
5-aza-2'-
deoxycitidine/TSA 
study 4 
0.45 1.36 0.008 
Mock treated bronchial 
epithelial cells 
Milani et al., 2011 
  
 
5-azacytidine 0.64 1.56 0.024 
MEM grown bone marrow-
derived mesenchymal cells 
Mrugala et al., 
2006 
  
 
5-azacytidine/tumor 
cond. medium 
0.31 1.24 0.021 
MEM grown bone marrow-
derived mesenchymal cells 
Mrugala et al., 
2006 
  
 
Dexamethasone study 
3 (late) 
-0.14 -1.10 0.008 Vehicle treated HOb514 cells Guix et al., 2008 
  
 
Mifepristone/dexame
thasone study 4 
-0.23 -1.17 0.040 A549 cells Olsen et al., 2009 
  
 
Deferoxamine 0.68 1.60 0.009 
Untreated U251 astroglioma 
cells 
Bourdeau et al., 
2007 
  
 
Peginterferon study 4 -0.30 -1.23 0.004 PBMC cells Sartor et al., 2009 
  
 
Hydrochloric acid -0.27 -1.20 0.005 
Breast epithelial cells exposed 
to acidosis 
Chen et al., 2010 
  
 
Tibolone 0.39 1.34 0.022 
Untreated endometrium 
sample 
Hanifi-
Moghaddam et al., 
2007 
  
 
Echinomycin/deferox
amine 
-1.56 -2.95 0.000 
Astroglia cells stimulated with 
deferoxamine 
Bourdeau et al., 
2007 
  
 
Elesclomol 0.23 1.17 0.017 Vehicle (DMSO) treated Hs Lin et al., 2007 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
294 T cells 
  
 
Epoximycin (early) -0.20 -1.15 0.005 HEK293 Chang et al., 2011 
  
 
Epoximycin (late) 0.21 1.16 0.015 HEK293 Chang et al., 2011 
  
 
Cyclohexemide 0.17 1.13 0.042 
Vehicle (DMSO) treated 
MCF-7 cells 
Johnson et al., 
2006 
  
 
GW7647 (24 h) 0.18 1.13 0.001 
Vehicle (DMSO) treated 
HepG2 cells 
Wang (Z) et al., 
2007 
  
 
GW7647 (6 h) 0.16 1.12 0.016 
Vehicle (DMSO) treated 
HepG2 cells 
Wang (Z) et al., 
2007 
  
 
PMA study 2 
(shRNA cycT1) 
-0.49 -1.41 0.002 
Mock treated, transduced  
MONO-MAC-6 cells 
Osaba et al., 2008 
(b) 
  
 
PMA study 3 
(shRNA contr.) 
-0.96 -1.94 0.020 
Vehicle (DMSO) tretaed 
ASPC-1 cells 
Murphy, 2010 
  
 
R547 (2 h) 0.30 1.23 0.025 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 2 (24 h) -0.33 -1.27 0.024 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 3 (24 h) -0.67 -1.61 0.003 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 3 (2 h) 0.33 1.26 0.015 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 4 (6 h) -0.41 -1.33 0.029 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 5 (6 h) -0.35 -1.27 0.042 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 6 (1 h) -0.38 -1.30 0.045 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 6 (4 h) -0.29 -1.22 0.001 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 6 (6 h) -0.38 -1.30 0.028 Vehicle (DMSO) treated Mariko, 2006 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
DU145 cells 
  
 
R568 (intermediate) -0.20 -1.15 0.033 Coronary smooth muscle cells   
  
 
Rotenone -0.32 -1.25 0.014   Greene, 2006 
  
 
Zalypsis study 2 -1.41 -2.64 0.017 Untreated OPM1 cells 
Sarasin-Filipowicz 
et al., 2008 
  Disease             
  
 
Arterial fibrillation 
study 2 
0.55 1.45 0.013 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Ulcerative colitis 
(Inflamm.) study 4 
-1.27 -3.41 0.012 
Colonic mucosal endoscopic 
pinch biopsies 
Sa et al., 2007 
  
 
Ulcerative colitis 
(Inflamm.) study 4 
-1.93 -4.36 0.000 
Colonic mucosal endoscopic 
pinch biopsies 
Sa et al., 2007 
  
Growth factors and 
cytokines 
            
  
 
IFN-a2b -0.43 -1.36 0.049 Immature dendritic cells 
Dhodapkar et al., 
2007 
  
 
Il-22 0.45 1.37 0.003 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
IL-24 0.27 1.21 0.027 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
SDF study 2 0.29 1.22 0.042 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
SDF study 3 (late) 0.32 1.24 0.010 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
TGF-β (late) study 5 0.71 1.64 0.047 Untreated A549 cells 
Shalhoub et al., 
2010 
  
 
TGF-β3 
(early)/BPM-2 
(intermediate) study 
2 
0.37 1.30 0.048 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
  
 
TGF-β3 
(intermediate)  
0.44 1.38 0.048 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
TNF-α/Il-1b/IL-
6/PGE2 
-0.72 -1.68 0.003 
Normal lymphatic endotelial 
cells biopsies 
Kirshner et al., 
2008 
  Hormones             
  
 
17beta-estradiol 
(early) study 10 
0.31 1.24 0.016 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
(intermediate) study 
10 
0.60 1.50 0.046 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol (late) 
study 10 
0.41 1.33 0.015 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
study 12 
0.97 1.97 0.013 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
Dihydrotestosterone  0.08 1.06 0.017 MCF-7 cells Carroll et al., 2006 
  
 
Dihydrotestosterone 
(early) study 2 
-0.20 -1.15 0.016 MCF-7 cells Carroll et al., 2006 
  
 
Dihydrotestosterone 
(late) study 2 
-0.24 -1.18 0.028 MCF-7 cells Carroll et al., 2006 
  
 
Estradiol 0.71 1.65 0.000 
Untreated endometrium 
sample 
Meja et al., 2008 
  
 
Estradiol/medroxypro
gesterone acetate 
0.43 1.34 0.004 Endometrium samples 
Hanifi-
Moghaddam et al., 
2007 
MCT7               
  Chemicals and Drugs             
  
 
Cadmium (early) 0.51 1.42 0.000 
Untreated, 72h starved NPrEC 
cells 
Bakshi et al., 2008 
  
 
Lactic acid  0.51 1.43 0.010 
Untreated breast epithelial 
cells 
Donnellan and 
Hardie, 2007 
  
 
Lactic acid/hypoxia 0.49 1.40 0.004 
Untreated breast epithelial 
cells 
Donnellan and 
Hardie, 2007 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
5-aza-2'-
deoxycitidine/TSA 
study 4 
0.30 1.23 0.004 
Mock treated bronchial 
epithelial cells 
Milani et al., 2011 
  
 
5-azacytidine -0.82 -1.77 0.000 
MEM grown bone marrow-
derived mesenchymal cells 
Mrugala et al., 
2009 
  
 
Gefitinib -0.70 -1.63 0.000 Wild type A431 cells Guix et al., 2008 
  
 
Calcitriol 
(intermediate) 
0.28 1.23 0.009 Untread breast cancer cells 
Wermuth et al., 
2010 
  
 
Calcitriol (late) 0.15 1.11 0.020 Untread breast cancer cells 
Wermuth et al., 
2010 
  
 
Paricalcitol 
(intermediate) 
0.20 1.16 0.018 Coronary smooth muscle cells 
Stockwin et al., 
2009 
  
 
Vitamin D3 -0.20 -1.15 0.003 
Vehicle (EtOH) treated 
bronchial smooth muscle cells 
Bossé et al., 2007 
  
 
Echinomycin/deferox
amine 
1.20 2.29 0.000 
Astroglia cells stimulated with 
deferoxamine 
Bourdeau et al., 
2007 
  
 
Elesclomol study 2 -0.42 -1.34 0.031 
Vehicle (DMSO) treated Hs 
294 T cells 
Lin et al., 2007 
  
 
Epoxomicin (late) -0.30 -1.23 0.004 HEK293 Chang et al., 2011 
  
 
Cyclohexemide -0.57 -1.48 0.003 
Vehicle (DMSO) treated 
MCF-7 cells 
Johnson et al., 
2006 
  
 
Triadimefon (high) -0.80 -1.75 0.019 DMSO treated hepatocytes 
Goetz and Dix, 
2008 
  
 
PMA study 4/PMA 
study 5 
-0.60 -1.52 0.019 
Vehicle (DMSO) tretaed 
ASPC-1 cells 
Murphy, 2010 
  
 
R547 (2 h) 0.33 1.25 0.037 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (6 h) 0.79 1.73 0.000 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 (24 h) study 3 0.66 1.58 0.000 Vehicle (DMSO) treated Fridgway and 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
DU145 cells Conlon, 2011 
  
 
R547 (6 h) study 3 0.67 1.59 0.002 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  Disease             
  
 
Dilated 
cardiomyopathy 
(after VAD) 
0.41 1.35 0.024 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Idiopathic dilated 
cardiomyopathy 
0.26 1.20 0.000 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Hypertrophic 
cardiomyopathy 
0.35 1.27 0.001 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Viral cardiomyopathy 0.26 1.19 0.005 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Ischemic 
cardiomyopathy 
0.37 1.30 0.000 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
Growth factors and 
cytokines 
            
  
 
BMP-2 
(intermediate) study 
2 
-1.13 -2.10 0.003 HOb514 
Muzikar et al., 
2009 
  
 
BMP-2 (late) study 2 -0.90 -1.85 0.010 HOb514 
Muzikar et al., 
2009 
  
 
G-CSF 0.37 1.30 0.025 Untreated leukocytes Buzzeo et al., 2007 
  
 
IL-1b 0.48 1.39 0.011 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
IL-20 -0.50 -1.41 0.005 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
Il-22 -0.47 -1.39 0.003 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
IL-24 -0.37 -1.29 0.019 Untreated neonatal epidermal Sarasin-Filipowicz 
Appendix II- Transcriptional modulation of transporters  
 
XXXI 
 
Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
keratinocytes et al., 2008 
  
 
KGF -0.98 -1.98 0.001 
Untreated neonatal epidermal 
keratinocytes 
Sarasin-Filipowicz 
et al., 2008 
  
 
SDF (late) study 3 0.36 1.30 0.047 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
SDF study 4 -0.90 -1.84 0.000 Untreated MDA Mb231 cells Nickols et al., 2007 
  
 
TGF-β (late) study 5 3.87 14.63 0.000 Untreated A549 cells 
Shalhoub et al., 
2010 
  
 
TGF-β1 (early) 0.41 1.32 0.033 Untreated A549 cells 
Shalhoub et al., 
2010 
  
 
TGF-β3 
(early)/BPM-2 
(intermediate) study 
2 
0.66 1.51 0.044 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
  
 
TGF-β3 
(intermediate)  
-0.47 -1.39 0.028 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
  Hormones             
  
 
17beta-
estradiol/cycloheximi
de 
-0.64 -1.55 0.000 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
(early) study 10 
-0.17 -1.12 0.012 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
(intermediate) study 
10 
-0.41 -1.33 0.006 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol (late) 
study 10 
-0.71 -1.63 0.002 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
study 8 
-0.37 -1.30 0.004 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
  
 
17beta-estradiol 
study 8 
-0.29 -1.22 0.043 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
Dihydrotestosterone -0.26 -1.20 0.013 MCF-7 cells Carroll et al., 2006 
  
 
Estrogen (early) -0.28 -1.21 0.015 MCF-7 cells Carroll et al., 2006 
  
 
Estrogen 
(intermediate) 
-0.26 -1.20 0.002 MCF-7 cells Carroll et al., 2006 
  
 
Estrogen (late) -0.44 -1.35 0.001 MCF-7 cells Carroll et al., 2006 
SMCT1               
  Chemicals and Drugs             
  
 
Apple 
procyanidin/TNFa/D
MSO 
0.23 1.18 0.008 
Normal lymphatic endotelial 
cells biopsies 
Kirshner et al., 
2008 
  
 
ARC -0.33 -1.25 0.000 MCF-7 
Szatmari et al., 
2006 
  
 
beta-
glycerophosphate 
(late) study 2 
-0.29 -1.22 0.048 
Diff. Medium exposed bone 
marrow stomal cells 
Johnson et al., 
2006 
  
 
BPDE (intermediate) 
study 2 
0.31 1.24 0.044 
Vehicle (DMSO) treated 
amnion epithelial FL cells 
Lu et al., 2009 
  
 
5-aza-2'-
deoxycitidine/TSA 
study 4 
-0.28 -1.22 0.024 
Mock treated bronchial 
epithelial cells 
Milani et al., 2011 
  
 
5-azacytidine -0.18 -1.13 0.006 
MEM grown bone marrow-
derived mesenchymal cells 
Mrugala et al., 
2009 
  
 
5-azacytidine study 5 0.16 1.12 0.036 
MEM grown bone marrow-
derived mesenchymal cells 
Mrugala et al., 
2009 
  
 
Actinomycin D 0.65 1.60 0.024 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  
 
Rituximab/methylpre
dnisolone 
-0.24 -1.17 0.019 synovium samples 
Gutierrez-Roelens 
et al., 2011 
  
 
Dexamethasone 
9late) study 3 
0.20 1.15 0.021 Vehicle treated HOb514 cells Guix et al., 2008 
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
Echinomycin/deferox
amine 
0.49 1.42 0.049 
Astroglia cells stimulated with 
deferoxamine 
Bourdeau et al., 
2007 
  
 
Epoxomicin (late) 0.30 1.23 0.006 HEK293 Chang et al., 2011 
  
 
PMA -0.24 -1.18 0.020 
Vehicle (DMSO) tretaed 
ASPC-1 cells 
Murphy, 2010 
  
 
PMA study 4/Pma 
study 5 
0.24 1.18 0.026 
Vehicle (DMSO) tretaed 
ASPC-1 cells 
Murphy, 2010 
  
 
PMA (6 h) study 4  0.38 1.30 0.001 
Vehicle (DMSO) tretaed 
ASPC-1 cells 
Murphy, 2010 
  
 
R547 (24 h) 0.35 1.28 0.025 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
R547 study 6 -0.19 -1.14 0.049 
Vehicle (DMSO) treated 
DU145 cells 
Fridgway and 
Conlon, 2011 
  
 
Sangivamycin -0.43 -1.35 0.012 MCF-7 cells Rosinski, 2009 
  
 
Sapphyrin PCI-2050 0.16 1.12 0.004 Mannitol treated A549 cells 
Wang (Q) et al., 
2007 
  Disease             
  
 
Dilated 
cardiomyopathy 
(before VAD) 
-0.26 -1.21 0.047 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
 
Myocardial infarction 
(7 d)/unstable angina 
(7 d) 
-0.17 -1.13 0.029 
Myocardial sample (left 
ventricle biopsy) 
Schinke et al., 2004 
  
Growth factors and 
cytokines 
            
  
 
BMP-2 (late) 0.24 1.18 0.030 
Untreated mesenchymal stem 
cells 
Mrugala et al., 
2009 
  
 
TNF-α/Il-1b/IL-
6/PGE2 
0.27 1.21 0.041 
Normal lymphatic endotelial 
cells biopsies 
Kirshner et al., 
2008 
  Hormones             
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Transporter Class of modulator Treatment Log(2) ratio 
Fold 
change 
p 
value 
Sample Reference 
  
 
17beta-estradiol 
study 11 
0.18 1.13 0.031 Vehicle treated MCF-7 cells 
Johnson et al., 
2006 
    Estrogen (late) -0.18 -1.14 0.046 MCF-7 cells Carroll et al., 2006 
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